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ABSTRACT 
 
 
The goal of this dissertation work was to (1) determine the distribution of several 
tetrahydroisoquinoline (TIQ) derivatives in rodent, normal human and Parkinson disease 
(PD) brain, (2) quantify the levels of these TIQ derivatives in common food sources in an 
effort to link specific food intake patterns with the development of PD and (3) examine 
the neurotoxicity of select TIQ derivatives in human dopaminergic cell culture.  The TIQs 
are a family of monoamine alkaloids that share structural homology with 1-methyl-4-
phenyl-1,2,3,6-tetrahyrdropyridine (MPTP), can be formed from dopamine or its oxidized 
metabolites and may be involved in the pathogenesis of monoaminergic cell death. 
 
In our studies, we utilize enantiomeric-selective high-performance liquid 
chromatography with electrochemical detection (HPLC-EC) and liquid chromatography 
with tandem mass spectroscopy (LC-MS/MS) to determine the concentrations of TIQ 
derivatives in brain, as well as in common dietary plants in the United States.  The 
dopaminergic SH-SY5Y human neuroblastoma cell line was utilized to document the 
neurotoxicity of N-methylated salsolinol derivatives.    
 
Several TIQ derivatives were detected in all regions subjected to analysis.  In 
general, salsolinols were present at higher concentrations than TIQ and its benzyl and 
methyl derivatives, especially in human brain.  Moreover, salsolinols were concentrated 
in areas with increased dopamine synthesis and turnover such as the ventral midbrain 
and striatum, respectively.  Significantly lower levels of (R)salsolinol, (S)salsolinol, N-
methyl-(R)salsolinol and N-methyl-(S)salsolinol were found in the caudate nuclei of PD 
in comparison with normal human brain.  N-methyl-norsalsolinol was detected in all 
regions of rodent and human brain subjected to analysis.  In comparison to normal 
human controls, N-methyl-norsalsolinol levels were significantly lower in the substantia 
nigra and caudate nuclei from PD patients.  N-methyl-norsalsolinol-immunoreactivity co-
localized with a general neuronal marker and a monoaminergic cell marker.  N-methyl-
norsalsolinol-immunoreactivity was not observed in glia.  
 
Our analysis of common foods revealed high concentrations of TIQ derivatives in 
banana, cherry, peach, grapefruit, avocado, button mushroom, leaf lettuce and celery.  
Enantiomeric salsolinol derivatives were detected as racemic mixtures, without evidence 
of stereoselective synthesis.  Utilizing a lifetime food-item intake questionnaire, we 
identified trends for increased intake of several plants products in PD patients.  Members 
of the rue (Rutaceae), banana (Musaceae), gourd (Cucurbitaceae), carrot (Apiaceae) 
and nightshade (Solanaceae) families were found to be highly consumed in both normal 
human and PD groups, and to concentrate several potentially neurotoxic TIQ 
derivatives. 
 
We correlated indices of cellular energy production and cell viability in 
dopaminergic SH-SY5Y cells after exposure to N-methyl-norsalsolinol and N-methyl-
(R/S)salsolinol.  Both toxins induce dose-dependent decreases in cell survival with LC50 
values of 0.305 mM and 0.377 mM after 24 hrs, respectively.  These results suggest that 
cell death induced by these N-methylated salsolinols is due to impairment of cellular 
energy supply, caused in particular by inhibition of mitochondrial complex I.  Their 
concentration in dopaminergic regions of human brain and relatively potent cytotoxicity 
among TIQs makes these compounds strong candidates for both an endogenous and 
exogenous link to cell death in PD.   
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CHAPTER 1. INTRODUCTION 
 
 
1.1 PARKINSON DISEASE 
 
In the famous 1817 monograph “An Essay on the Shaking Palsy”, James 
Parkinson first described the clinical condition that now bears his name (Parkinson 
2002).  His description was based on an account of six subjects, only three of whom he 
actually examined.  The remaining three individuals were observed in public.  
Remarkably accurate in his clinical descriptions, he single-handedly brought to life all of 
the cardinal features of the disease.  Considering that few of his successors had 
improved upon this initial description, in 1872 Jean Martin Charcot dubbed the illness 
Parkinson disease (PD) (Charcot 1872-1873).  Today, after almost 200 years of 
progress in understanding the pathophysiology of idiopathic PD, it remains a purely 
clinical diagnosis.  In the current era of rapidly advancing medical technology, it is a 
humbling experience to the modern clinician that no ancillary test can prove the 
diagnosis of PD beyond the acuity of the neurologist’s trained eye. 
 
 By definition, the presence of two out of three cardinal motor signs of 
parkinsonism (tremor, rigidity and bradykinesia) together with a consistent response to 
an adequate dose of levodopa are considered by most experts in the field to be essential 
for the diagnosis of PD to be made (Gibb & Lees 1988).  Importantly, these criteria are 
also needed to distinguish true PD from other parkinsonian syndromes (e.g., multiple 
system atrophy, progressive supranuclear palsy, corticobasal degeneration). 
 
 
1.1.1 Clinical Features 
 
Since the introduction of levodopa, the L-3,4-dihydroxyphenylalanine precursor of 
dopamine, in the1960s, the clinical picture and natural history of PD has changed 
drastically.  The many problems facing the untreated PD patient before the advent of 
levodopa therapy have now been replaced with the serious complications of long-term 
levodopa treatment, such as choreiform and dystonic involuntary movements, motor 
fluctuations (the on-off phenomenon), orthostatic hypotension and confusional states 
with visual hallucinations.  However, as was the case before the arrival of levodopa 
therapy, there remains a minority of patients with PD who will not respond to 
pharmacotherapy.  With this in mind, it is common to distinguish between the primary 
(tremor, rigidity and bradykinesia) and secondary (dementia, depression, axiety, 
visuospatial deficits, blurred vision, dysarthria, dysphagia, impaired gastrointestinal 
motility, constipation and paresthesias) manifestations of PD. 
 
 
1.1.1.1 Tremor 
 
The tremor of PD results from an oscillation of agonist and antagonist muscles 
and is arguably the most visible signature of the disease.  Usually noted in the early 
stages of the disease, tremor affects approximately 75 percent of PD patients (Hoehn & 
Yahr 1967).  Tremor often subsides as a prominent sign late in the course of PD, as 
bradykinesia and postural instability become dominant features.  The usual frequency of 
PD resting tremor is 3 to 5 Hz.  Physiologic tremor, in contrast, typically has a frequency 
of 8 to 10 Hz (Findley et al 1981).  Characteristically, the tremor is noticed at rest and 
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diminishes with purposeful movement.  The rate of progression of tremor is highly 
variable, much like signs and symptoms of PD.  It is most pronounced in the distal 
extremities, but at times may involve an entire limb.  With advancing disease, the tremor 
can spread to involve the lips, jaw, chin and tongue. 
 
The cause of tremor in the setting of PD remains unknown.  Intracranial 
recordings in primates and human patients undergoing stereotactic neurosurgical 
procedures show that the ventral intermediate nucleus (VIM) of the thalamus contains 
intrinsic pacemaker neurons which fire at the same frequency as parkinsonian tremor 
(Ohye et al 1974; Ward et al 1948).  Moreover, lesioning of a precisely selected portion 
of the VIM can abolish tremor, as can lesioning of the internal segment of the globus 
pallidus (GPi) (Benabid et al 1996; Taha et al 1996).  Although the thalamus is likely the 
central generator of tremor in PD, it remains unclear as to how neuronal degeneration in 
the substantia nigra pars compacta (SNpc), the focal point of PD pathology, and the 
resultant depletion of dopamine influences other neurons in a particular nucleus of the 
thalamus to generate tremor.  This conundrum is underscored by the observation that 
ablation of the SNpc and its striatal connections in experimental animals does not induce 
tremor. 
 
 
1.1.1.2 Rigidity 
 
Rigidity is defined as resistance to passive movement that occurs in both flexors 
and extensors throughout full range of motion.  In contrast, spasticity is increased 
muscle tone present at initiation of movement which then quickly subsides (“clasped 
knife” phenomenon).  Parkinsonian rigidity displays the classic “cogwheeling” quality, 
caused by the overlay of resting tremor on increased muscle tone even though the 
tremor may not be visible (Lance et al 1963).  Cogwheeling is more apparent in the 
upper extremities, probably because tremor is also more prevalent in the arms as 
compared to the legs.  Rigidity is present in the majority of PD patients, exhibiting great 
variation in severity and laterality.  There is, however, a strong correlation between the 
severity of rigidity and the progression of disease, although the contribution of rigidity by 
itself to overall disability remains unclear (Selby 1984). 
 
Although the pathophysiology of rigidity in PD is obscure, there is evidence that 
an abnormality of muscle spindle feedback to the spinal cord may contribute to 
symptomatology (Guekht et al 2005).  However, primary muscle spindle afferent activity 
is normal in PD and there is some evidence to suggest hyperactivity of spinal 
interneurons or long loop reflex pathways with feedback to sensorimotor cortex in 
muscle rigidity (Cody et al 1986; Tatton et al 1984).  In the brain, the GPi may exert 
influence on rigidity, as surgical lesioning in the posteroventrolateral segment abolishes 
parkinsonian rigidity in contralateral limbs (Laitinen et al 1992). 
 
 
1.1.1.3 Bradykinesia 
 
Bradykinesia is present in the majority of PD patients at initial presentation, even 
if rigidity and tremor are not apparent.  Bradykinesia, defined as a slowness in 
movement or difficulty initiating movement, accounts for typical parkinsonian signs such 
as decreased dexterity and the inability to perform rapid alternating movements.  As the 
disease progresses, bradykinesia involving larger muscle groups is responsible for 
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difficulty standing from a seated position, walking and turning in bed.  Secondary 
symptoms such as masked facies (decreased range of facial expression), sialorrhea due 
to decreased frequency of swallowing and overall slowing of gastrointestinal motility are 
also attributed to bradykinesia.  Dopamine depletion in the basal ganglionic-frontal 
cortical circuitry mediating motor programming and planning is the fundamental cause of 
bradykinesia (Marsden 1982).  This is supported by the often dramatic response of 
bradykinesia to levodopa therapy in PD patients.  It is believed that motor programming, 
(a cognitive function) is normal in PD, while the execution of planned motor tasks (also 
cognitive) is disrupted (Day et al 1984).  This hypothesis is supported by the results of 
neuropsychological testing in PD patients revealing the loss of frontal executive ability, 
along with positron emission tomography imaging showing decreased activation of 
frontal premotor cortex during cognitive tasks (Jenkins et al 1992). 
 
 
1.1.1.4 Parkinsonian Gait 
 
The classic gait of PD, described as narrowly based, small-stepped and shuffling 
with a stooped-forward appearance with the arms held close to the body, was initially 
depicted in detail by James Parkinson.  Patients may transiently hesitate in initiating the 
first steps, but move forward in steady fashion until a doorway or other obstacle causes 
them to slow, stop and freeze again until attempting to resume regular walking speed.  
Parkinson also describes the phenomenon of festination, or the tendency for the upper 
body to travel faster than the shuffling lower body, often resulting in a fall or collision.  A 
complex motor activity, gait requires input from multiple levels of the nervous system, 
including the basal ganglia and spinal cord, as well as multiple functions such as 
proprioception, vision, coordination, muscle tone and vestibular equilibrium (Marsden 
1982; Nutt et al 1993). 
 
In the early stages of illness, the majority of PD patients have little to no difficulty 
with walking.  In contrast, early-onset gait disorder associated with postural instability 
should arouse the suspicion of a parkinsonian sydrome other than PD, such as 
progressive supranuclear palsy or multisystem atrophy.  In advanced PD, postural 
instability develops due to a loss of basal ganglia-mediated postural righting reflexes.  
Minor pertubations of balance can cause uncontrolled forward or backward movement, 
resulting in frequent falls and, at times, serious injury (Nutt et al 1993).  It remains 
unclear why visual, vestibular and proprioceptive corrective reflexes fail to compensate 
for the postural instability in late PD.  The worsening of this postural instability with 
advancing disease, even as levodopa therapy controls other symptoms, strongly 
suggests that non-dopaminergic systems and circuits outside of the basal ganglia may 
play a principal role. 
 
 
1.1.1.5 Secondary Manifestations 
 
Depression has long been recognized as a frequent and serious disorder in PD 
patients.  The reported incidence of significant depressive symptoms in PD ranges from 
30-40% (Reijnders et al 2008).  Key characteristics of depression in PD are decreased 
mood and anhedonia.  Other features of depression can be present in varying 
combinations but many of these, such as decreased appetite or sleep, weight change, 
psychomotor retardation, reduced memory and loss of energy can overlap with the 
symptoms of PD, making diagnosis of depression difficult.  However, feelings of guilt or 
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worthlessness and suicidal ideation may be less common in PD patients (Gotham et al 
1986).  The concept that depression should be viewed as an integral component of 
disease rather than a purely psychological reaction is supported by the observation that 
in 15-25% of cases, unexplained depression preceded the onset of motor symptoms of 
PD, often by as long as several years (Mayeux et al 1984b).   
 
Cognitive dysfunction and dementia have long been recognized as causes of 
morbidity and disability in PD patients.  Defined as the loss of cognitive and intellectual 
functions without impairment of perception or consciousness, an estimated 20% of PD 
patients suffer from dementia (Brown & Marsden 1988).  In 1974 the term “subcortical 
dementia” was introduced, with typical features of slowness of information processing, 
altered personality with apathy, forgetfulness and a decreased ability to retrieve acquired 
knowledge (Albert et al 1974).  By definition, subcortical dementia lacks the cortical 
features of aphasia, apraxia and agnosia typically found in Alzheimer disease (AD), the 
classic prototype of cortical dementia.  Recently, overlap between cortical and 
subcortical dementia has been emphasized, as has the utility of using 
neuropsychological data to classify the cognitive disorders associated with PD and 
parkinsonian syndromes (Pillon et al 1996).  Deficits in visuospatial discrimination, 
frontal lobe executive function and memory retrieval are typical of the subcortical 
dementias in general and PD in particular (Hamill et al 1988).  However, most data 
illustrate that the clinical distinction between cortical and subcortical dementia is at best 
arbitrary and the gold standard for accurate anatomical diagnosis remains histo- and 
immunopathology (Hansen & Samuel 1997). 
 
At least some degree of autonomic nervous system dysfunction is present in the 
majority of PD patients.  Although in most the degree of impairment is mild, it can be the 
cause of significant functional disability.  Low-normal blood pressure is very common in 
PD due to degeneration of sympathetic neurons of the hypothalamus.  Dopaminergic 
agonists used in the treatment of PD have the potential to lower blood pressure further, 
often leading to orthostatic dizziness and syncope.  Urinary urgency and urge 
incontinence occur in PD with degeneration of descending frontal cortical inhibitory 
pathways to the bladder, secondarily reducing its capacity and leading to spasticity 
(Berger et al 1987).  Autonomic dysfunction of the gastrointestinal (GI) tract is almost 
universal in PD.  Although an exact mechanism is unknown, degeneration of the 
myenteric plexus with α-synuclein immunoreactive Lewy body (LB) inclusions has been 
documented in patients at autopsy (Braak et al 2006; Qualman et al 1984).  Slowed 
motility of the GI tract may also lead to excessive salivation and poor anal contraction 
(Edwards et al 1992).  Sialorrhea results from infrequent glutition, however, rather than 
overproduction.  Likewise, segmental esophageal spasm is a result of poor motility and 
most patients experiencing dysphagia swallow soft foods and liquids without difficulty 
(Gibberd et al 1974).  Slow gastric and small bowel motility translates into subjective 
feelings of postprandial fullness and bloating, sometimes to the point of pseudo-
obstruction.  Constipation can be a pervasive source of discontent in PD patients and is 
usually relieved only with a carefully designed regimen of dietary measures, stool 
softeners and laxatives.  Obstipation and fecal impaction are common outcomes when 
constipation is neglected or not aggressively managed (Jost 2010). 
 
In addition to dysfunction of the motor system, up to 50% of PD patients report 
sensory disturbances of some form (Snider et al 1976).  For instance, paresthesias or 
burning pain in the limbs may precede the appearance of the more clinically 
recognizable signs of disease by months or even years and are rarely associated with 
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objective findings on neurological exam (Quinn et al 1986).  Restlessness of the legs or 
body and other more bizarre sensations also may be common manifestations of the 
“wearing-off” effect of levodopa therapy (Nutt & Carter 1984).  The loss of olfactory 
sense is a frequent and poorly understood defect in PD, often demonstrable at or even 
before the onset of motor symptoms (Doty et al 1992).  A similar finding is commonly 
seen in the early stages of AD which may suggest a commonality in neurodegenerative 
pathogenesis. 
 
Disruption of the normal sleep cycle is almost universal in advanced PD.  The 
most common pattern, especially late in the course of disease, is fitful sleep at night and 
excessive napping during the day.  Excessive daytime sleeping becomes even more 
problematic for the patient when it occupies so much of the day that worthwhile physical 
and social activities are thwarted.  Disrupted sleep has many causes, including poor bed 
mobility due to rigidity and bradykinesia, nocturnal urinary urgency and frequency, and 
vivid dreaming and early morning awakening secondary to depression (Askenasy 1981).  
Patients with significant cognitive loss or dementia tend to sleep excessively, day and 
night.  However, alarming periods of agitation and even belligerent behavior can erupt 
after sundown or at unpredictable times during the night. 
 
Hypophonia, the loss of voice volume, is the most common manifestation of 
parkinsonian speech impairment.  Slowed movement and incoordination of the muscles 
of speech production, within the lips, tongue and pharynx, muffle the normally sharp 
articulation of speech.  As bradykinesia worsens, voice volume may decline further and 
speech output takes on a festinating quality as the repetitive movements of the involved 
oropharyngeal muscles cause words to run together.  As with any sustained, repetitive 
movement in PD, amplitude steadily decreases in direct relation to the duration of the 
activity.  Therefore, relatively forceful enunciation at the beginning of speech production 
is rapidly followed by gradual loss of volume and speech quality.  As may be expected, 
vocal cord rigidity is a common laryngoscopic finding in PD patients, contributing to 
hoarseness, changes in pitch and other abnormalities of prosody (Vincken et al 1984). 
 
 
1.1.2 Natural History 
 
Longitudinal studies of the natural history of PD reveal a long course of illness, 
remarkably variable and unpredictable, with most patients experiencing all of the classic 
features in the earliest stages.  Clinical disability is by nature progressive due to the 
increasing loss of nigral neurons over time.  However, factors determining the tempo of 
cell death in the individual are currently unknown (Hughes et al 1993).  Because the 
pace of pathologic progression is slow in the majority of patients, those with levodopa 
responsive parkinsonism may function independently if not normally for many years after 
initial symptoms appear.  However, some deteriorate more rapidly and lose all 
independence within a few years due to medically intractable bradykinesia, postural 
instability and cognitive impairment.  Furthermore, some patients in whom tremor is an 
early and dominant symptom remain unencumbered by other symptoms of PD before 
signs of true progression occur.  In contrast, early onset postural instability and gait 
disorder (PIGD) usually predicts an accelerated decline in function and is a predictor that 
a non-LB Parkinsonian syndrome may underlie the cause of disability, especially if the 
response to levodopa is weak.  Although PD is typically a disorder of middle and older 
age, those of younger age (less than 40 years) can be affected but often experience a 
more benign course with a better response to levodopa than the elderly despite the 
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dyskinesias and motor fluctuations that younger patients may encounter with chronic 
levodopa therapy. 
 
The impact of levodopa on the natural history of PD has been mixed.  Although 
the benefit of levodopa to the patient cannot be overestimated, the practical and 
hypothetical problems associaed with long-term treatment have not been trivial.  
Morbidity and mortality have dropped substantially since the pre-levodopa era, when 
drug therapy consisted of relatively ineffectual agents with low therapeutic margins 
(Diamond & Markham 1976).  However, data accumulated over the last 30 years have 
shown that despite the vastly improved quality of life for the average PD patient, 
progression of disability is no less variable than before.  Furthermore, although mortality 
has been reduced in the levodopa era compared with the years before, death rates 
remain higher in PD patients versus age-matched controls (Morens et al 1996). 
 
Long term levodopa use has been associated with a variety of adverse cognitive 
and motor consequences.  The early period of a sustained and excellant response to 
levodopa usually gives way unpredictably after several years to motor fluctuations, 
characterized by a distinct feeling of activation (“turning on”) 20-30 minutes after taking 
the drug, followed by a wearing off of effectiveness 3-6 hours later and a return of 
bradykinesia.  The usual dosing schedule of three to four times a day that once worked 
well to provide a smooth and unvarying response must be replaced by more frequent 
dosing to accommodate the emergence of the short-duration response.  The cause of 
these “on” and “off” cycles is presumed to be the result of an incompletely understood 
combination of diminished capacity of the nigrostriatal neurons to store and tonically 
release dopamine derived from exogenous levodopa and of downregulation of 
postsynaptic striatal dopaminergic receptors (Hurtig 1997).  Dyskinesias or abnormal 
involuntary movements of the extremities gradually appear during the evolution of motor 
fluctuations, occurring most commonly during the pharmacokinetic peak of each dose of 
levodopa (Nutt 1990).  As parkinsonian disability increases with progressive loss of 
nigral neurons, so does the severity of on-off fluctuations and dyskinesias.  Treatment of 
fluctuations with a combination of dopamine agonists and levodopa can potentially 
modulate fluctuations by allowing a reduction in levodopa dose without a loss of benefit.  
The use of a controlled-release combination of levodopa and carbidopa (a peripheral 
dopa decarboxylase inhibitor) can dampen the intensity of dyskinesias and lengthen the 
duration of motor response. 
 
Dyskinesias usually have distinctively choreoathetotic features, but may also 
contain elements of dystonic posturing, rapid myoclonic jerking or both (Luquin et al 
1992; Nutt 1990).  Dyskinesias occur most commonly at the peak of the dose-response 
cycle, but levodopa’s short half-life (90 min) limits the duration of any dyskinetic reaction 
unless dosing is so frequent that blood levels become markedly elevated.  Dyskinesias 
can also take the form of dystonic posturing of the extremities, occuring during the 
wearing-off phase.  Dystonic posturing on the side of greater Parkinsonian impairment is 
a common early-morning off reaction in some patients after doing without levodopa 
overnight.  This usually resolves after the first dose of levodopa of the day.  In contrast 
with choreoathetotic involuntary movements, dystonic posturing of the hands, feet and 
neck can occur as an integral symptom of untreated parkinsonism (Muenter et al 1977). 
 
 Parkinsonism is a chronic and progressive disease with decreased life 
expectancy despite modern treatment.  Hoehn and Yahr first reported a standardized 
mortality ratio (the ratio of observed deaths to expected deaths) of 2.9 in patients with 
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PD (Hoehn & Yahr 1967).  Standardized mortality ratios from more recent PD studies 
have ranged from 1.3 to 4.1 (Herlofson et al 2004; Marras et al 2005).  In a study of PD 
patients in the midwestern United States, median survival of patients from diagnosis was 
10.3 years, while in the Sydney Multicenter Study median time from motor onset to 
death was 12.2 years (Elbaz et al 2003; Hely et al 2005).  In these studies, disease 
severity, dementia and age were independent risk factors for increased mortality in PD.  
However, the cause of death in PD patients is often related to fatal infections as a result 
of immobility (Beyer et al 2001). 
 
 
1.1.3 Epidemiology 
 
The term “Parkinsonian syndrome” (PS) refers to a condition in which at least two 
of the three major clinical manifestations associated with PD are found (Rajput et al 
1991).  Therefore, this condition includes several different entities.  In some cases the 
cause is recognizable: postencephalitic parkinsonism, posttraumatic parkinsonism, 
neuroleptic drug-induced parkinsonism, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) toxicity, manganese toxicity and cyanide poisoning (Calne et al 1994; Casson et 
al 1984; Duvoisin & Yahr 1965; Langston et al 1983; Uitti et al 1985).  However, in the 
majority of cases the cause is often unknown.  The most common form of parkinsonism 
is idiopathic PD (Duvoisin & Golbe 1989).  PS is also a feature of several other 
degenerative diseases, such as progressive supranuclear palsy, mutiple system atrophy, 
Creutzfeld-Jakob disease and corticobasal degeneration. 
 
Because a clinical assessment may not accurately distinguish between different 
PS variants, studies that include only the diagnosis of PD likely include a significant 
proportion of other PS variants.  Community epidemiologic prevalence surveys are 
usually based on a single neurological assessment and may include false-positive 
diagnoses of PD as high as 35%, as reported in autopsy verification of initial PD 
diagnosis by neurologists (Bharucha et al 1988; Morgante et al 1992; Schoenberg et al 
1985).  To reduce such error, Hughes and colleagues proposed a different set of 
diagnostic criteria: asymmetrical symptom onset and no evidence of another disorder or 
possible etiology (Hughes et al 1992).  When applying these criteria to their own 
autopsied series, they found that 7% of the non-PD cases were misdiagnosed as PD 
and 32 percent of PD cases did not fit their criteria.  In addition, further autopsy studies 
have shown that approximately 4% of PD cases have a symmetrical onset of symptoms 
(Rajput et al 1993).  Therefore, the proposed criteria of Hughes et al may not suitable for 
descriptive epidemiology.  In turn, studies that include a liberal definition of PS diagnosis 
are liable to include non-PS cases and the distinction between normal aging and early 
PS may be difficult.   
 
 
1.1.3.1 Incidence 
 
Incidence calculations are thought to be a more precise estimate of the 
frequency of disase as they are not influenced by mortality.  Published age-standardized 
incidence rates for parkinsonism range from 9 to 20 per 100,000 population in the United 
States (US) and European countries (Twelves et al 2003).  Some studies may include all 
PS, while others are restricted to PD cases.  The lowest incidence in the western world 
is 4.9 per 100,000, reported from Sardinia between 1961 and 1971 (Rosati et al 1980).  
A report from the Netherlands noted an incidence rate of 11 per 100,000 for men and 12 
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per 100,000 for women (Hofman et al 1989).  In Japan, Harada and colleagues reported 
annual incidence of 10.2 per 100,000 population (Harada et al 1983).   
 
All literature reports have noted a progressive increase in the incidence of PD 
with age (Mayeux et al 1995; Rajput & Birdi 1997).  Onset before age 30 is very rare and 
onset before age 40 accounts for 4 to 10% of all cases of PS (Rajput 1992).  After age 
50, age-specific incidence rises dramatically.  Data from the Mayo Clinic in Rochester, 
MN, between the years of 1935 and 1979 show that between the ages of 40 and 49 the 
incidence of PD was 5 per 100,000; this value increased 35-fold to 174 per 100,000 in 
the 70 to 79-year-old age group (Rajput et al 1984). 
 
Gender differences in the development of PD have been described in numerous 
studies, most of which report higher incidence rates in males, especially in the oldest 
age groups (Bharucha et al 1988; Diamond et al 1990; Kessler 1972; Schoenberg et al 
1985; Taylor et al 2007; Vanacore et al 1992).  However, several studies have found no 
difference in the incidence of PD between men and women less than 60 years of age.  
Neuroprotective properties of female steroid hormones and gender differences in 
exposure to environmental or occupational risk factors have been discussed as 
underlying causes (Shulman 2007; Taylor et al 2007).  In a meta-analysis of 17 
incidence studies, the overall age-adjusted male to female ratio for incident PD was 1.46 
(Shulman 2007; Taylor et al 2007).  However, there is some data to suggest that gender 
incidence may differ by ethnicity, with a higher incidence of male PD in western 
populations.   
 
 
1.1.3.2 Prevalence 
 
The prevalence rate of PD can be determined by several different methods, the 
most reliable of which is that based on the door-to-door community survey (Bharucha et 
al 1988; Morgante et al 1992; Schoenberg et al 1985).  It is estimated that 35 to 42% of 
PD cases in the community are undiagnosed, thus community surveys yield higher and 
presumably more accurate rates than other methods (Morgante et al 1992; Schoenberg 
et al 1985).  PD is found in all ethnic groups, with geographical differences in 
prevalence.  Early-onset sporadic PD is rare, with about 4% of patients developing 
clinical signs of disease before age 50 (Van Den Eeden et al 2003).  Approximately 1 to 
2% of the population over age 65 suffers from PD.  This figure increases to 3 to 5% in 
those age 85 or older (Fahn 2003).  As PD is primarily an illness of later life, it is more 
common in developed countries where life expectancy is longer.  Door-to-door surveys 
report prevalence rates of PD ranging from 57 per 100,000 in China to 371.5 per 
100,000 in Sicily (Li et al 1985; Morgante et al 1992).  Most communtiy-based 
prevalence studies across Europe found prevalence rates between 100 and 200 per 
100,000 inhabitants (von Campenhausen et al 2005).  A prevalence of 328 per 100,000 
was reported in a community from Bombay, India, and 347 per 100,000 in Copiah 
County, Mississippi (Bharucha et al 1988; Schoenberg et al 1985).  Overall, the 
estimated prevalence rate of PD in the United States and Canada is approximately 300 
per 100,000 (Duvoisin & Golbe 1989).   
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1.1.3.3 Geographic Environments 
 
 The variation in prevalence rate of PD across geographic enviornments is 
notable and warrants further discussion.  The lowest reported prevalence rate, 57 per 
100,000, is found in China, followed by Sardina (65.6 per 100,000), Nigeria (67 per 
100,000), and Japan (80.6 per 100,000) (Harada et al 1983; Li et al 1985; Rosati et al 
1980; Schoenberg et al 1988).  The highest prevalence rate reported, 371.5 per 
100,000, is found in Sicily (Morgante et al 1992).  Different prevalence rates have also 
been reported in populations of the same race.  Northampton, England, has a 
prevalence rate of 108 per 100,000, and that of Aberdeen, Scotland is 164.2 per 
100,000 (Schoenberg 1987).  Such differences can be in part attributed to variations in 
methods.  However, two studies by Schoenberg and colleagues used identical methods 
and found markedly different prevalence rates in populations of the same race 
(Schoenberg et al 1985; Schoenberg et al 1988).  Although African-Americans and 
Caucasians in the US had similar prevalence rates, the rates for US African-Americans 
was fivefold higher than that of Africans in Nigeria (Schoenberg et al 1988).  This finding 
indicates a genuine difference based on geography. 
 
 Differences in the incidence of PD based on population density were first 
reported in Saskatchewan, Canada, and it was concluded that those born and raised in 
rural Saskatchewan had an increased risk of developing early-onset PD (Rajput et al 
1986).  In this study, a rural community was defined as one which utilized well water as a 
drinking source.  Interestingly, 19 out of 21 patients in this study utilized well water 
exclusively for the first 15 years of life.  Along similar lines of rural living, Barbeau and 
colleagues reported a higher PD concentration in communities that concentrated on 
market gardening (Barbeau et al 1987).  In addition, several other North American and 
European reports noted a higher PD risk associated with prior rural residence (Hertzman 
et al 1990; Hubble et al 1993; Koller et al 1990; Ludin & Ludin 1989; Tanner et al 1987).  
For instance, Butterfield and colleagues noted that rural residency in Oregon at the time 
of diagnosis, as well as nut and seed eating 10 years prior to dagnosis was more 
common in PD cases than in age-matched controls (Butterfield et al 1993).  Although an 
increased risk of PD has been associated with exposure to fertilizers, pesticides, 
insecticides, paints, wood preservatives and fungicides, no specific chemical or 
chemicals have been attributed to date (Barbeau et al 1987; Hertzman et al 1990; Koller 
et al 1990; Seidler et al 1996; Semchuk et al 1991; 1992; Svenson 1991; Svenson et al 
1993; Tanner et al 1989).                   
 
 
1.1.3.4 Genetic Risk Factors 
 
In recent years, genetic risk factors have become increasingly important in the 
search for possible causes of PD.  Family members of affected patients are at three- to 
four-fold increased risk of developing PD compared to the general population (Autere et 
al 2000; Kurz et al 2003).  The first finding strengthening the involvement of genetic risk 
factors in PD was the identificaiton of the PARK1 locus on chromosome 4q21, linking to 
familial forms of the disease (Polymeropoulos et al 1996).  The finding of a chromosomal 
region linked to PD was later confirmed by identification of the point mutation A53T in 
the SNCA (-synuclein) gene in Italian and Greek families with autosomal dominant 
inheritance (Polymeropoulos et al 1997).  During the last two decades, other gene loci 
were found to be associated with autosomal dominantly (-synuclein [PARK4] and 
ubiquitin carboxyl-terminal esterase L1 [PARK5]) or recessively (parkin [PARK2], PTEN 
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induced putative kinase 1 [PINK1 or PARK6], DJ-1 [PARK7] and ATPase 13A2 
[PARK9]) inherited parkinsonism (Gasser et al 1998; Hampshire et al 2001; Kitada et al 
1998; Leroy et al 1998; Paisan-Ruiz et al 2004; Singleton et al 2003; Valente et al 2004; 
Valente et al 2001; van Duijn et al 2001).  To date, most of the known gene mutations 
cause juvenile or early onset of the disease, while others such as the most recently 
identified leucine-rich repeat kinase 2 (LRRK2 or PARK8) mutation and several 
mutations in glucocerebrosidase (GBA) appear to cause parkinsonism resembling 
sporadic PD with respect to both clinical and demographical features (Aasly et al 2005; 
Funayama et al 2002; Sidransky et al 2009).  The discovery of these genetic mutations 
and the increased understanding in dysfunction of their aberrantly encoded proteins has 
provided important and novel insights into the molecular pathogenesis of the disease.  
There is now strong evidence that impairment of the ubiquitin-proteasome system, 
mitochondrial dysfunction and decreased oxidative stress tolerance are key mechanisms 
in PD pathogenesis (Eriksen et al 2005; Gandhi & Wood 2005).  However, the exact 
mechanisms are not completely understood and monogenetic causes only account for a 
small proportion (<10%) of all PD cases, while the vast majority of PD cases appear to 
be sporadic.  In these, occupational, lifestyle and environmental factors, possibly in 
interaction with each other or with susceptibility genes, may play a part. 
 
 
1.1.4 Cellular and Molecular Pathology 
 
The hallmark neuropathologic features of PD that are essential for the diagnosis 
of definite PD at postmortem brain examination include the extensive loss of 
dopaminergic neurons in the SNpc, the presence of intracytoplasmic inclusions (LBs) in 
the remaining dopaminergic neurons, variable amounts of extracellular melanin released 
from degenerated neurons and gliosis (Fearnley & Lees 1991; Forno 1996; McGeer et al 
1988).  The primary neurochemical defect in PD is the loss of dopaminergic projections 
to the striatum as a result of the massive degeneration of the neuromelanin-containing 
dopaminergic neurons of the SNpc (Bernheimer et al 1973; Kish et al 1988).  In addition 
to dopaminergic neurons in the SNpc, other populations of neuromelanin and non-
neuromelanin containing neurons in the brainstem and basal forebrain degenerate and 
accumulate LBs that are similar to those seen in the SNpc (Forno 1996).  Moreover, the 
loss of these populations of neurons leads to neurotransmitter deficits, but to a lesser 
extent than that which accompanies the degeneration of dopaminergic SNpc neurons.  
For example, norepinephrine, serotonin and acetylcholine are variably decreased in PD 
owing to the loss of neurons in the locus ceruleus, raphe nucleus and nucleus basalis of 
Maynert, respectively, and many of the secondary clinical features of PD have been 
ascribed to these neurotransmitter deficits (D'Amato et al 1987; Mayeux et al 1984a; 
Whitehouse 1987).   
 
The LB is considered the signature histopathologic hallmark of PD (Forno 1996; 
Pollanen et al 1993).  LBs were originally described in the cholinergic neurons of the 
substantia innominata by Friederich Lewy in 1912 and have subsequently been noted in 
the dopaminergic neurons of the SNpc in virtually all PD cases in association with 
neuronal loss and gliosis (Forno 1996; Hughes et al 1993).  Furthermore, LBs are also 
seen in all other populations of neurons that degenerate in the PD brain and may be 
found in the cerebral cortex as well as in brainstem nuclei (Forno 1996; Galvin et al 
1999). 
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The morphology of the LB in PD is well established at the light- and electron-
microscopic levels.  The majority of LBs in SNpc neurons exhibit a loose, radiating array 
of filaments in the periphery of the LB, surrounding a matted meshwork of filaments in 
the center or core (Forno 1996; Hill et al 1991; Pollanen et al 1993; Schmidt et al 1991).  
Although most LBs are spherical inclusions in the cell body of neurons, they may also 
assume an irregular geometry and extend into the proximal segments of neuronal 
processes.  Most cellular organelles are excluded from LBs, which are often displaced or 
deformed along with the nucleus.  The predominant structural elements in LBs are 
filaments 7 to 25 nm in diameter (Hill et al 1991; Schmidt et al 1991).  In contrast to 
SNpc LBs, cortical LBs have a less stereotyped morphology that lacks a clearly 
definable central core and a distinct peripheral corona, which may account for the 
inconspicuous appearance by hematoxylin and eosin staining (Forno 1996; Galvin et al 
1999; Okazaki et al 1961; Pollanen et al 1993; Schmidt et al 1991). 
 
Much of the information currently known about the components of LBs has been 
obtained using immunohistochemical techniques.  These studies have demonstrated 
that the major antigenic components of LBs are the presynaptic protein α-synuclein, 
neurofilament proteins and ubiquitin, a protein involved in the non-lysosomal intracellular 
degradation of cellular products (Baba et al 1998; Forno et al 1986; Galvin et al 1997; 
Goldman & Yen 1986; Goldman et al 1983; Irizarry et al 1998; Kuzuhara et al 1988; 
Lowe et al 1988; Lowe et al 1990; Spillantini et al 1998; Spillantini et al 1997).  However, 
a number of other cytoskeletal and non-cytoskeletal proteins have also been identified 
within LBs.  It has been suggested that the antigenic components of LBs can be divided 
into four groups: (1) structural elements of LB filaments; (2) proteins that reflect a cellular 
response to LB formation; (3) enzymes such as kinases and phosphatases, which may 
modulate LB filaments; and (4) other cytosolic proteins that presumably become trapped 
in LBs during formation of these inclusions (Pollanen et al 1993). 
 
Although a large number of molecules have been identified in LBs, the most 
prominent is α-synuclein.  α-synuclein was first cloned from the Torpedo californium and 
later identified in humans as the non-Aβ component of AD amyloid (NAC) precursor 
(NACP) (Maroteaux et al 1988; Ueda et al 1993).  Attention focused on α-synuclein 
when Polymeropoulos and colleagues reported that in a kindred with familial PD, a 
mutation, A53T, was associated with disease (Polymeropoulos et al 1996; 
Polymeropoulos et al 1997).  A number of groups then quickly reported α-synuclein as a 
major component of LBs (Baba et al 1998; Irizarry et al 1998; Spillantini et al 1997; 
Takeda et al 1998; Wakabayashi et al 1997).  α-synuclein is a member of a highly 
conserved family of proteins consisting of α-, β-, and -synuclein.  The protein consists of 
140 amino acids and the α-synuclein gene contains seven exons, five of which are 
protein coding (Clayton & George 1998; Norris et al 2004). The N-terminal 89 amino 
acids are composed almost entirely of six variants of a degenerate 11-amino acid 
consensus motif with slight variations.  The 11-mer repeats comprise an apolipoprotein-
like-class-A2 helix, which mediates binding to vesicles of phospholipids.  In neutral 
solution, α-synuclein is unfolded, but binding to lipid shifts the protein secondary 
structure from ≈3% to >70% α-helix.  The central region contains two of the 11-mer 
repeats and the hydrophobic NAC portion between residues 61 and 95.  The NAC region 
of α-synuclein appears to be crucial to fibrillation, because α-synuclein lacking the 
domain and β-synuclein, which lacks 11 amino acids in the NAC region, have reduced 
susceptibility to form fibrils.  The C terminus is less conserved than the N terminus and 
contains a preponderance of acidic residues. 
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The function(s) of α-synuclein is not fully understood, but studies of α-synuclein 
knockout (KO) mice have been informative.  Abeliovich and colleagues reported that α-
synuclein KO mice were viable and fertile and had normal brain architecture, particularly 
of the nigrostriatal dopaminergic system, indicating that α-synuclein is not necessary for 
its normal development (Abeliovich et al 2000).  The dopamine content in the striatum, 
but not the midbrain, was reduced.  Open field activity was normal, but amphetamine-
induced locomotion was reduced.  Simple electrical stimulation of the nigrostriatal 
dopaminergic system produced a normal pattern of dopamine discharge and reuptake.  
Paired-pulse stimulation had accelerated recovery of release of dopamine after an initial 
stimulus, suggesting an inhibitory role for α-synuclein in the activity-dependent 
modulation of nigrostriatal dopamine transmission.  Chandra and colleagues used single 
and double α- and β-synuclein KO mice and reported that the synucleins are not crucial 
to neurotransmitter release but may be involved in long-term regulation and/or 
maintenance of presynaptic function (Chandra et al 2004).  Cabin and colleagues carried 
out similar studies in α-synuclein KO mice and noted a reduction in the pool of undocked 
vesicles in the hippocampus and that prolonged stimulation in slices, which would rely 
on the reserve vesicle pool, was impaired (Cabin et al 2002).  In cultured hippocampal 
cells, long-lasting potentiation of synaptic transmission between cells was accompanied 
by an increase in the number of α-synuclein clusters.  In cultures derived from α-
synuclein KO mice this potentiation was not observed (Liu et al 2004).  It was thus 
concluded that α-synuclein is required for the genesis, localization and/or maintenance 
of at least some of the vesicles that make up the reserve or resting pools of presynaptic 
vesicles, and the data appear to be consistent with this conclusion (Cabin et al 2002).  
The mechanism by which α-synuclein modulates neurotransmitter release is uncertain, 
but it may be via inhibition of phospholipase D2, with effects on levels of diacyl glycerol 
and phosphatidic acid and their effects on the size and recovery rate of the readily 
releasable pool of synaptic vesicles and membrane trafficking (Abeliovich et al 2000).  
Of particular interest, the α-synuclein KO mice have shed light on certain pathogenic 
mechanisms important in PD.  Four lines of α-synuclein KO mice have demonstrated 
resistance to the neurotoxin MPTP, and the protective effect appeared to be upstream of 
the mitochondria (Dauer et al 2002). 
 
Attention was drawn to the ubiquitin-proteasome system (UPS) by the 
discoveries that a common form of autosomal recessive PD is due to mutations in the 
Parkin gene, which encodes for an E3 ligase (Kitada et al 1998; Shimura et al 2000).  
Another member of the UPS, ubiquitin C-terminal hydroxylase L1, was reported to have 
a missense polymorphism in two siblings with PD (Leroy et al 1998).  However, the role 
of the UPS and Parkin in the degradation of α-synuclein is not fully understood.  Bennett 
and colleagues reported that α-synuclein was degraded by the UPS, but other groups 
have reported that inhibition of proteasomes did not increase levels of α-synuclein, 
suggesting alternate pathways for degradation (Ancolio et al 2000; Bennett et al 1999; 
Rideout et al 2001).  In vitro α-synuclein can be degraded by the 20S proteasome 
through a ubiquitin-independent mechanism (Tofaris et al 2001).  Infusion of the 
proteasome inhibitor lactacystin into the SN and lactacystin and epoxomycin (a naturally 
occurring inhibitor) into the striatum created models of PD in the rat (Fornai et al 2003; 
McNaught et al 2002).  McNaught and colleagues extended this data by systemically 
administering epoxomicin to rats and found that the animals developed behavior and 
pathology with α-synuclein inclusions reminiscent of PD (McNaught et al 2004).  
However, mutant forms of α-synuclein and protein aggregates have been shown to 
reduce proteasomal activity (Bence et al 2001; Petrucelli et al 2002; Stefanis et al 2001; 
Tanaka et al 2001).  The finding that Parkin KO mice have a normal level of α-synuclein 
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raised the possibility that it is not a normal substrate for Parkin and that other 
degradation systems are involved (Goldberg et al 2003).  Inhibition of both the 
proteasome and autophagy increased the levels of α-synuclein in PC12 cells with α-
synuclein in autophagic vacuoles and lysosomes (Webb et al 2003).  In cultured cortical 
neurons, proteasome inhibition led to activation of macroautophagy and the lysosomal 
pathway (Rideout et al 2004).  In cultured neuronal cells, α-synuclein oligomers, but not 
mature fibrillar inclusions, were cleared by the lysosomal pathway (Lee et al 2004a).  
Cuervo and colleagues reported that wild type (WT) α-synuclein was internalized and 
degraded in lysosomes by chaperone-mediated autophagy, and A30P and A53T forms 
of α-synuclein blocked lysosomal uptake and degradation of α-synuclein by chaperone-
mediated autophagy (Cuervo et al 2004).  Of note, four groups have reported an 
increased prevalence of heterozygous carriers of mutant forms of GBA, the lysosomal 
enzyme involved in Gaucher's disease, in Parkinsonian patients, and one series 
described cortical and/or hippocampal LBs (Aharon-Peretz et al 2004; Clark et al 2005; 
Goker-Alpan et al 2004; Lwin et al 2004; Sato et al 2005).  Subclinical lysosomal 
dysfunction in cases with mutant GBA has thus been hypothesized to lead to impaired 
clearance of α-synuclein (Goker-Alpan et al 2004).  This data indicates that α-synuclein 
can be degraded by both the proteasome (through ubiquitin-dependent and -
independent processes) and autophagy. 
 
A number of groups have demonstrated that α-synuclein can aggregate to form 
protofibrils and amyloid-like fibrillar structures (Conway et al 1998; Giasson et al 1999; 
Hashimoto et al 1998).  In solution, the mutations A53T and A30P increased the rate of 
α-synuclein oligomerization and formation of β-sheets (Narhi et al 1999; Uversky & Fink 
2002).  The rate of formation of mature fibrils was increased by A53T and reduced by 
A30P (Conway et al 2000).  Overexpression of α-synuclein in a number of cell lines 
resulted in the formation of aggregates (Hsu et al 2000; Stefanis et al 2001; Stefanova et 
al 2001).  Masliah and colleagues overexpressed WT α-synuclein in mice and found 
amorphous and granular (but not fibrillar) aggregates of α-synuclein in various brain 
regions in which LBs are found (Masliah et al 2000).  The mice exhibited injury to the 
nigrostriatal dopaminergic system and motor deficits.  Adenoviral vector-selective 
overexpression of WT and A53T α-synuclein in the SN in nonhuman primates caused α-
synuclein inclusions and degeneration of dopaminergic neurons (Kirik et al 2003).  
Overexpression of WT and mutant α-synuclein in Drosophila resulted in intraneuronal α-
synuclein inclusions, loss of dopaminergic neurons and motor deficits (Feany & Bender 
2000).  Overexpression of mutant and WT α-synuclein in Caenorhabditis elegans 
resulted in dopaminergic cell loss as well (Lakso et al 2003).  The concentration 
dependence of aggregation may be relevant to PD, because triplication of the α-
synuclein gene is associated with familial PD (Singleton et al 2003). 
 
Evidence of excessive oxidation is found in the brains of PD patients (Alam et al 
1997a; Alam et al 1997b; Dexter et al 1989). Hashimoto and colleagues demonstrated 
that treatment of α-synuclein with H2O2 and ferrous iron in solution led to the formation of 
insoluble aggregates of α-synuclein (Hashimoto et al 1999).  Treatment of 
neuroblastoma cells overexpressing A53T, A30P and WT α-synuclein with iron resulted 
in the formation of α-synuclein aggregates, and the mutants were found to be more 
susceptible (Ostrerova-Golts et al 2000).  Furthermore, increased amounts of iron have 
been found in the SN of PD brains (Dexter et al 1991).  Considerable evidence exists 
that mitochondrial dysfunction and oxidative stress are involved in the pathogenesis of 
PD.  Chronic treatment of rats with rotenone, a known complex I mitochondrial inhibitor, 
resulted in injury to the nigrostriatal dopaminergic system and formation of α-synuclein 
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aggregates and continuous exposure of mice to MPTP resulted in a PD phenotype and 
formation of LB-like inclusions (Betarbet et al 2000; Fornai et al 2005).  α-synuclein 
inclusions in brains of PD patients have also been shown to contain oxidized α-synuclein 
(Duda et al 2002). 
 
The observation that up to 50% of AD cases also contain LBs suggests there 
might be a commonality in the processes that form LBs and the senile plaques and 
neurofibrillary tangles (NFTs), the pathological hallmarks of AD (Hansen et al 1990; 
Kotzbauer et al 2004; Lee et al 2004b).  Cases of familial AD can have LBs, and patients 
with the A53T mutation in the gene for α-synuclein have tau, as well as α-synuclein, 
inclusions (Kotzbauer et al 2004; Lippa et al 1998).  Tau proteins interact with tubulin to 
stabilize microtubules and promote tubulin assembly.  Six tau isoforms exist in brain 
tissue and they are distinguished by their number of binding domains.  Giasson and 
colleagues reported that α-synuclein could initiate polymerization of tau in vitro, and that 
tau significantly increased the assembly of α-synuclein into fibrils (Giasson et al 2003).  
However, both tau and α-synuclein preferentially form homopolymers rather than 
heteropolymers, suggesting that each may participate in an initiation phase of formation 
of fibrils, but that enlargement into larger fibrils is specific for each protein and that these 
and other amyloidgenic proteins can induce both α-synuclein and tau pathology (Geddes 
2005; Lee et al 2004b).  In AD, neurons tend show a predilection to form NFTs or LBs, 
and tau and α-synuclein tend to segregate into separate filaments (Geddes 2005).  This 
commonality might also be due to processes that underlie the formation of tau and α-
synuclein inclusions. 
 
It is plausible that excessive amounts of α-synuclein oligomers might overwhelm 
the mechanisms responsible for clearance of aberrant proteins, thereby interfering with 
the normal physiology of the cell and eventually leading to cell injury and death.  
Impairment of proteasome function can obviously be the primary event (as occurs in 
patients who have mutations in the Parkin gene but lack LBs), but investigators have 
also shown that mutant forms of α-synuclein and protein aggregates can reduce 
proteasomal activity (Bence et al 2001; Petrucelli et al 2002; Stefanis et al 2001; Tanaka 
et al 2001).  The inability to normally degrade misfolded and damaged proteins would 
lead to increasing dysfunction and death of cells.  As discussed above, there is evidence 
of proteasomal dysfunction in PD and animal models in which proteasome inhibitors 
have been reported to create the behavioral and pathological features of PD.  
Interestingly, Parkin KO mice exhibited mitochondrial dysfunction and oxidative damage 
(Palacino et al 2004).  Mitochondrial dysfunction has been established to occur in PD 
and overexpression of α-synuclein has been reported to impair mitochondrial function 
(Hsu et al 2000). 
 
Specific mechanisms through which α-synuclein aggregates injure neurons have 
not been identified.  Our current understanding of the pathogenic mechanisms in PD 
involves three pathways: protein aggregation; impaired protein degradation (i.e., 
dysfunction of the proteasome and lysosome systems); and mitochondrial 
dysfunction/oxidative stress (Betarbet et al 2000; Cuervo et al 2004; Dawson & Dawson 
2003; Eriksen et al 2003; Ross & Pickart 2004; Shults 2004; Snyder & Wolozin 2004).  
Other processes, such as inflammation, may also contribute to the death of cells (Hald & 
Lotharius 2005; Teismann & Schulz 2004).  These three processes likely overlap and 
interact (Dawson & Dawson 2003; Eriksen et al 2003; Greenamyre & Hastings 2004).  
For example, overexpression and aggregation of α-synuclein can lead to mitochondrial 
dysfunction, and inhibition of mitochondrial function with MPTP and rotenone leads to 
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aggregation of α-synuclein (Betarbet et al 2000; Fornai et al 2005; Hsu et al 2000).  
Impairment of the proteasomal system in Parkin KO mice and in PC12 cells leads to 
mitochondrial dysfunction and mitochondrial dysfunction results in impairment of 
proteasomal function (Hoglinger et al 2003; Lee et al 2005; Palacino et al 2004).  
Inhibition of the proteasomal system results in formation of α-synuclein aggregates and 
aggregates of α-synuclein can impair proteasomal function (Bence et al 2001; Fornai et 
al 2003; McNaught et al 2002; McNaught et al 2004).   Malfunction of mitochondria or 
the proteasome and lysosome systems would result in the accumulation of proteins, 
many abnormal, and obviously would interfere with function of the cell.  However, 
specific mechanisms through which these aggregates of proteins are injurious to cells 
have been surprisingly unexplored.  The processes involved in the formation of LBs 
suggest a mechanism through which these processes may interact, lead to α-synuclein 
aggregation, and result in mitochondrial dysfunction and potentially release of 
proapoptotic molecules.  It may not be coincidence that mitochondria are a conspicuous 
component of LB (Gai et al 2000; Hayashida et al 1993; Roy & Wolman 1969).  
Mitochondria, which both produces ATP for the cell and are central to apoptosis, are 
composed of an outer membrane, an intermembrane space and an inner membrane and 
matrix (Shults 2004; Wallace 2005).  The electron transport chain (ETC), which is 
composed of five complexes, is located on the inner mitochondrial membrane, and 
energy released by passage of electrons down the ETC is used by complexes I, III, and 
IV to transport protons from the matrix to the intermembrane space.  The transport of 
protons creates a proton and electrochemical gradient across the inner membrane, and 
the energy stored in the electrochemical proton gradient is used to drive complex V to 
form ATP.  In addition to its role in the bioenergetics of the cell, or perhaps because of 
its central position in the energetics of the cell, the mitochondrion has evolved to play a 
central role in apoptosis through the release of proapoptotic molecules from the 
mitochondrial intermembrane space (Green 2005; Green & Kroemer 2004; Youle & 
Karbowski 2005). 
 
 
1.2 THE TETRAHYDROISOQUINOLINES 
 
 After systemic administration, MPTP (Figure 1-1B) readily crosses the blood-
brain barrier and enters glial cells.  There, MPTP is converted to 1-methyl-4-phenyl-2, 3-
dihydropyridium (MPDP+) by monoamine oxidase (MAO)-B.  A presumed spontaneous 
deprotonation within the cyotsol produces the 1-methyl-4-pyridinium ion (MPP+).  MPP+ 
then crosses the glial membrane by a currently unknown mechanism and is actively 
transported into presynaptic dopaminergic nerve terminals via the plasma membrane 
dopamine transporter (DAT).  MPP+ selectively inhibits complex 1 of the mitochondrial 
ETC, which then leads to oxidative cell damage and apoptosis (Smeyne & Jackson-
Lewis 2005).  The discovery that environmental compounds, such as MPTP, can cause 
parkinsonism lead to a search for other potential toxins that may also lead to neuronal 
cell death (Ballard et al 1985; Langston et al 1983).  The isoquinolines (Figure 1-1) are 
one family of compounds that share remarkable structural homology with MPTP and 
thus have become strong candidates for a chemical link to dopaminergic cell death in 
PD (Kajita et al 1994; Nagatsu 1997; Yoshida et al 1993).  The tetrahydroisoquinolines 
(TIQs) and dihydroisoquinolines are members of the isoquinoline family and are potent 
inhibitors of complex I of the ETC, MAO and α-ketoglutarate dehydrogenase, all known 
defects in the SN of PD patients (McNaught et al 1995a; McNaught et al 1995b; Thull et 
al 1995).  TIQ and its derivatives (Figure 1-1C) are also natural substances found in  
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Figure 1-1.  Isoquinoline, MPTP and TIQ derivatives. 
(A) Isoquinoline.  (B) MPTP is converted to MPP+ by MAO.  (C) Chemical structures of 
selected TIQ derivatives. Reticuline is an exogenous TIQ derivative found in the leaves 
and bark of Annonaceae trees. 
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many plants and have been detected in several common foods such as cheese, 
bananas, milk, wine and cocoa (Deng et al 1997; Makino et al 1988; Makino et al 1990; 
Niwa et al 1989).  In addition, several TIQ derivatives have also been localized within 
rodent, PD and normal human brain (Makino et al 1990; Musshoff et al 2003; Musshoff 
et al 2005; Musshoff et al 2000; Musshoff et al 1999; Niwa et al 1987).  Systemic 
administration of TIQ to marmosets and squirrel monkeys has produced PD-like 
features, despite the lack of cell death within the SNpc (Nagatsu & Yoshida 1988; 
Yoshida et al 1993).  Moreover, TIQ appears to be a significantly less potent neurotoxin 
than MPTP when administered to mice (Ogawa et al 1989).  However, there is mounting 
evidence to suggest that N-methylated and benzylated TIQ derivatives (Figure 1-1) are 
more neurotoxic than their parent compound (Kawai et al 1998; Kotake et al 2003; 
Kotake et al 1995; Kotake et al 1996; Maruyama et al 1997a; Maruyama et al 1997b; 
Maruyama et al 1993; Nagatsu 1997; Naoi et al 2000; Naoi et al 1996a; Takahashi et al 
1997).  Although several TIQ derivatives have been shown to cause cell death in 
dopaminergic neurons, convincing anatomical proof of cell death in animals exposed to 
TIQ derivatives, and therefore a link to neurodegenerative disease, is needed. 
 
 Central to our hypothesis, TIQ derivatives can be formed endogenously by 
condensation of dopamine with aldehydes or α-keto acids (Cohen & Collins 1970; 
Schöpf & Bayerle 1934).  For example, metabolic pathways may convert 
neurotransmitters such as dopamine to N-methylated TIQ derivatives (Figure 1-2).  
Cellular processes may also convert exogenously acquired TIQ derivatives into more 
powerful neurotoxins.  TIQ derivatives may thus accumulate in neurons through 
combinations of endogenous and exogenous means.  Susceptible neuronal populations 
may then gradually shrink in number via apoptotic or necrotic cell death caused by the 
slow accumulation of these toxins.  Unlike the relatively acute effects of MPTP, 
dopaminergic cell death within the SNpc in idiopathic PD is generally considered to 
occur gradually over the course of many years.  With this in mind, TIQ derivatives are 
one class of mitochondrial neurotoxins that may exert cytotoxic effects chronically over 
time and thus be important in the pathogenesis of idiopathic PD.   
 
 
1.2.1 Neuronal Production 
 
Neurons and glia may convert certain TIQs into more toxic derivatives.  For 
example, dopamine may be converted into norsalsolinol or (R/S)salsolinol, which then 
can be methylated by glial enzymes to form N-methyl-norsalsolinol or N-methyl-
(R/S)salsolinol, respectively.  Other neurotoxins in this family may be produced 
endogenously from catecholamines, particularly dopamine, and either aldehydes or -
keto acids by several combinations of enzymatic and non-enzymatic pathways. 
 
 The synthesis of the (R/S)salsolinol in briefly summarized in Figure 1-2.  
Endogenous formation of (R/S)salsolinol by Pictet-Spengler condensation of 
acetaldehyde with dopamine yields a racemic mixture of enantiomers (Cohen & Collins 
1970; Schöpf & Bayerle 1934).  In contrast, stereoselective enzymatic synthesis via 
salsolinol synthase would generate the (R)-enantiomer (Naoi et al 2002; Naoi et al 
1996b).  Interestingly, the levels of (R)salsolinol tend to be greater than those of 
(S)salsolinol in human brain tissue which supports the existence of both mechanisms 
(Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 2000; Musshoff et al 1999).  
Norsalsolinol, on the other hand, is generated from the condensation of dopamine with 
formaldehyde (the Pictet-Spengler condensation).   
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Figure 1-2.  Overview of endogenous synthetic pathways. 
General schematic for putative endogenous synthesis of (R/S)salsolinol, enantiomeric N-
methylated salsolinol derivatives and benzyl TIQ derivates from dopamine. 
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 The methylated derivatives of (R)salsolinol and norsalsolinol appear to be much 
more toxic than their parent compounds.  PD patients have increased N-methyl-
transferase activity that may not be isolated to the brain.  Using lymphocytes from 
peripheral blood, markedly elevated N-methyl-transferase activity in PD patients has 
been observed (Naoi et al 1998b).  Several N-methyl-transferase enzymes such as 
phenylethanolamine N-methyl-transferase, nicotinamide N-methyl-transferase and 
histamine N-methyl-transferase that are present in neurons are capable of TIQ 
methylation.   
 
 Nicotinamide N-methyl-transferase (NNMT), a cytosolic enzyme that requires S-
adenosyl methionine, catalyzes the catabolic N-methylation of nicotinamide to N-methyl-
nicotinamide.  NNMT protein levels have been measured in the CSF from PD patients 
and controls (Aoyama et al 2001).  The CSF levels of NNMT were higher in younger PD 
patients than in age-matched controls.  NNMT expression was also higher in PD than in 
control brains using quantitative immunohistochemistry (Parsons et al 2003).  Increased 
NNMT activity could reduce the levels of nicotinamide available for synthesis of 
nicotinamide adenine dinucleotide and increase the formation of N-methylated TIQs 
(Parsons et al 2003).   
 
 Several groups have reported that TIQs can be oxidized to more potent 
neurotoxins (see next section).  Booth and colleagues showed that TIQ and N-methyl-
TIQ are oxidized, but at only 3% of the rate of MPTP (Booth et al 1989).  However, TIQ 
and many of its derivatives (1-methyl-TIQ, N-methyl-TIQ, (R/S)salsolinol, N-methyl-
(R/S)salsolinol, and N-methyl-norsalsolinol) do not appear to be substrates for either 
MAO (Bembenek et al 1990).  Instead, isoquinolines and TIQs show selective inhibition 
of either MAO-A or MAO-B (Bembenek et al 1990; Collins et al 1973; Dostert et al 1989; 
Meyerson et al 1976; Minami et al 1993; Naoi et al 2004; Thull et al 1995; Yamada 
1971).  These facts, combined with the lack of physical data proving the successful 
laboratory synthesis of these ions, make enhanced toxicity of oxidation products unlikely.   
 
 However, biosynthetic schemes for benzylated TIQ derivatives depend on 
precursor compounds generated by MAO.  For example, MAO can convert endogenous 
2-phenylethylamine to phenylacetaldehyde and dopamine to 3,4-
dihydroxyphenylacetaldehyde (DOPAL).  As shown in Figure 1-2, these compounds 
can, via condensation, form different benzyl-TIQs: 3’,4’-dihydroxy-benzyl-TIQ and 6,7-
dihydroxy-benzyl-TIQ (Kawai et al 1998). 
 
 
1.2.2 Environmental Sources 
 
TIQs are latent natural substances found in many plants, some of which are 
consumed by humans and animals as food sources (Rommelspacher & Susilo 1985).  
TIQ derivatives have been detected in several common foods and beverages including 
cheese, cocoa powder, bananas, flour, eggs, beer, milk and even fish such as sardines 
(Collins et al 1990; Deng et al 1997; Duncan & Smythe 1982; Duncan et al 1984; Makino 
et al 1988; Makino et al 1990; Niwa et al 1989; Riggin & Kissinger 1976; Riggin et al 
1976).  Various TIQ derivatives are have also been detected in mucuna beans derived 
from the tropical legume Mucuna pruriens (commonly known as Nescafe, a coffee 
substitute) (Siddhuraju et al 2000).  The commonality of TIQ derivatives in many plant- 
and protein-derived food sources provides an important exogenous link of TIQs to 
neurodegenerative disease. 
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 The development of PD has been associated with a number of environmental 
factors such as pesticides, well water, herbicides, wood pulp and rural living (Barbeau et 
al 1987; Hertzman et al 1990; Koller et al 1990; Seidler et al 1996; Semchuk et al 1991; 
1992; Svenson 1991; Svenson et al 1993; Tanner et al 1989).  Rural living and 
dependence on market gardening might also be related to increased consumption of 
fresh fruits and vegetables that concentrate TIQ derivatives.   
 
      
1.2.3 TIQs and the Blood-Brain Barrier 
 
For exogenous TIQ derivatives to exert toxic effects on neurons, they must cross 
the blood-brain-barrier after oral consumption.  The blood-brain barrier of mammals is 
composed of tight junctions between endothelial cells of the central nervous system 
(CNS) blood vessels in combination with astrocyte foot processes that provide 
biochemical support.  This “barrier” restricts the movement of large or hydrophilic 
molecules into the cerebrospinal fluid (CSF).  Many TIQ derivatives are non-polar 
molecules with good lipid penetration.  In this regard, TIQ and a number of its derivatives 
have been shown to cross the blood-brain barrier (Kikuchi et al 1991; Makino et al 1988; 
Thumen et al 2002).  Makino and colleagues demonstrated that both 1-methyl-TIQ and 
TIQ accumulate in rat brain after intraperitoneal injection (Makino et al 1988).  Rats were 
injected with both 1-methyl-TIQ (5 mg/kg) and TIQ (5 mg/kg) daily for a period of five 
days.  Two days after the last injection, rats were sacrificed and levels of both 
compounds were found to be increased over threefold in whole brain homogenate.  A 
study detected TIQ and 1-methyl-TIQ in the brain four hours after oral administration 
(Kikuchi et al 1991).  
 
 However, more hydrophilic TIQ derivatives can also cross the blood-brain barrier.  
For example, N-methyl-norsalsolinol was present at significantly higher levels than at 
baseline in the caudate nucleus of rats after intraperitoneal injection (Thumen et al 
2002).  Interestingly, the N-methyl group of N-methylated salsolinols may aid blood-brain 
barrier penetration in some way.  Two studies by separate groups were both unable to 
show transport of salsolinol across the blood-brain barrier after intraperitoneal injection 
of racemic salsolinol (Origitano et al 1981; Song et al 2006).  Since several other 
research groups have identified and quantified (R/S)salsolinol in brain tissue, its 
presence may indicate a predominance of endogenous synthesis over exogenous 
accumulation (Deng et al 1997; Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 
2000; Musshoff et al 1999).  Transport of other large, hydrophobic TIQ derivatives such 
as 1-benzyl-TIQ across the blood-brain barrier has also been demonstrated after 
intraperitoneal injection by both their biochemical and pathological effects on rodent 
brain and by LC-MS/MS detection (Abe et al 2001; Song et al 2006).  
 
Before reaching the brain, TIQ and its derivatives are metabolized in the liver via 
first pass metabolism.  For example, TIQ accumulation in the rat brain was shown to be 
enhanced in those with CYP2D6 polymorphisms (poor debrisoquine metabolizers) (Ohta 
et al 1990).  Furthermore, the CYP2D6 enzyme has recently been shown to protect 
against MPP+ toxicity in SH-SY5Y cells (Mann & Tyndale 2010).  Not surprisingly, 
several cytochrome P450 polymorphisms have been associated with the development of 
PD, including several in CYP2D6 (Bon et al 1999; Singh et al 2010).     
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1.2.4 TIQ Membrane Transport 
 
 Several lines of evidence indicate that monoamine transporters could be 
fundamental to the selective cell death in PD.  For instance, the DAT has been shown to 
be necessary for the in vivo dopaminergic neurotoxicity of MPTP (Gainetdinov et al 
1997).  In relation to TIQs, Storch and colleagues studied the dopaminergic toxicity of a 
large selection of isoquinoline derivatives (Storch et al 2002).  Human embryonic kidney 
(HEK-293) and mouse neuroblastoma Neuro-2A cells transfected with the DAT were 
utilized for cell viability assays.  Only N-methylated derivatives showed enhanced toxicity 
in DAT-expressing cell lines.  However, the toxicity of N-methylated TIQ derivatives was 
very weak in comparison to MPTP.  For example, in HEK-293 cell lines, MPP+ showed 
almost 1000-fold more DAT-specific toxicity than either N-methyl-norsalsolinol or N-
methyl-(R/S)salsolinol.  A recent study by Kotake and colleagues measured the DAT 
affinity of 17 different isoquinoline derivatives, including isoquinoline, TIQ, 1-methyl-TIQ, 
N-methyl-TIQ and 1-benzyl-TIQ, in synaptosomes obtained from rat striatum (Kotake et 
al 2007).  A range of 1.7 to 700 µM was reported for all compounds.  Notably, TIQ 
exhibited the greatest observed affinity for the DAT.  Derivatization of TIQ decreased 
DAT affinity by at least 100 fold, as seen in 1-methyl-TIQ and 1-benzyl-TIQ.  
Unfortunately, salsolinol derivatives were not analyzed.   
 
 In mammalian systems, both central and peripheral transport mechanisms exist 
for the accumulation of TIQs in dopaminergic and noradrenergic neurons.   
For instance, in the peripheral nervous system, 6,7-dihydroxy-TIQ is taken up by 
sympathetic nerve terminals (Cohen et al 1972; Tennyson et al 1973).  Uptake is 
blocked by desmethylimipramine, which indicates that the norepinephrine transporter 
(NET) is responsible for accumulation of TIQs in sympathetic synapses.  Interestingly, 
6,7-dihydroxy-TIQ can then accumulate in synaptic vesicles and potentially act as a false 
neurotransmitter (Tennyson et al 1973).   
 
 
1.3 TOXICITY OF TETRAHYDROISOQUINOLINES 
 
 Although neurotoxins may disrupt a variety of cellular activities, cell death 
precipitated by inhibition of mitochondrial oxidative phosphorylation may be the 
mechanism most relevant to PD.  In a seminal study, the effects of three classes of 
isoquinoline derivatives (isoquinolines, dihydroisoquinolines and TIQs) and MPP+ were 
examined on ETC complexes I, II-III and IV from rat brain mitochondria (McNaught et al 
1995b).  The isoquinoline derivatives or MPP+ were added to reactions mixtures at a 
concentration of 10 mM and complexes I, II-III and IV activities were compared to 
controls.  MPP+ produced approximately 70% inhibition of complex I but had no effects 
on complexes II-III and IV.  The effects of TIQ (20%), N-methyl-TIQ (65%), 
(R/S)salsolinol (55%) and N-methyl-(R/S)salsolinol (60%) were less dramatic.  Only 
isoquinoline, 6,7-dimethoxyisoquinoline and N-methyl-(R/S)salsolinol produced notable 
inhibition of complex II-III, and none of the isoquinoline derivatives inhibited complex IV.  
Notably, there was no significant observed correlation between lipophilicity and complex 
I inhibition.   
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1.3.1 In Vitro Toxicity 
 
 The in vitro toxicity of TIQ derivatives has been studied using both molecular and 
morphological assays in a variety of cell lines (Chun et al 2001; Kobayashi et al 2009; 
Kotake et al 2003; Kotake et al 2007; Maruyama et al 1997b; Naoi et al 2002; Naoi et al 
2000; Nijima et al 1991; Nishi et al 1994; Scholz et al 1997; Shavali & Ebadi 2003; 
Shavali et al 2003; Storch et al 2000; Wanpen et al 2004).  However, the most reliable 
cell line for studies of TIQ derivative toxicity is arguably the human SH-SY5Y 
neuroblastoma line.  These dopaminergic neurons express the DAT and thus most 
closely resemble the neurons of the SNpc.  Unfortunately, only a handful of studies to 
date have employed this model.  Using these cells, TIQ derivatives have been shown to 
induce caspase-dependent apoptotic cell death via inhibition of complex I of the ETC 
with subsequent oxidative DNA damage and inhibition of cellular energy production 
(Kobayashi et al 2009; Kotake et al 2007; Naoi et al 2002; Shavali & Ebadi 2003; Storch 
et al 2000; Wanpen et al 2004).   
 
In general, derivatives of TIQ, namely the members of the salsolinol subfamily, 
appear to be more toxic than TIQ itself (Kobayashi et al 2009; Kotake et al 2007; Storch 
et al 2000; Wanpen et al 2004).  N-methylated salsolinol derivatives appear to be more 
toxic than their non-methylated parent compound and (R)-enantiomers are more toxic 
than (S)-enantiomers.  For example, using an assay of DNA fragmentation, N-methyl-
(R)salsolinol was shown to be at least tenfold more toxic than N-methyl-(S)salsolinol 
(Maruyama et al 1997b).  Additionally, apoptosis has been demonstrated with TUNEL 
labeling, Hoechst 33342 staining and Western blot detection of caspase-3 activation 
(Akao et al 1999; Maruyama et al 1997b).  SH-SY5Y overexpressing Bcl-2 (an anti-
apoptotic mitochondrial membrane protein) are resistant to apoptosis by (R)salsolinol 
enantiomers (Maruyama et al 2001).  Interestingly, methylation at the N-position has 
also been shown to decrease a compound’s affinity for the DAT (Kotake et al 2007)  
However, this study failed to demonstrate a significant relationship between cytotoxicity 
and affinity for the DAT, and uptake of most the TIQ derivatives seemed to be 
dependent on lipophilicity rather than active transport.    
 
 The most toxic TIQ derivatives, however, appear to be the benzyl-TIQs (Kotake 
et al 2003; Kotake et al 2007; Shavali & Ebadi 2003).  In SH-SY5Y cells, the IC50 values 
of several benzylated TIQs ranged from 0.02 to 0.09 mM after 48 hrs of exposure, 
several orders of magnitude lower than TIQ or N-methylated TIQ derivatives (Kotake et 
al 2007).  Furthermore, these compounds are very lipophilic and pass through the blood-
brain barrier readily (Song et al 2006).  However, it should be noted that to date only 1-
benzyl-TIQ has been detected in either rodent or human brain, and plant levels of 1-
benzyl-TIQ are extremely low in comparison to other TIQ and salsolinol derivatives.  
Thus, while the benzyl-TIQs may be more toxic, rarity in the brain and foods may limit 
their relevance to PD pathogenesis.         
 
 Much like MPTP, at lower doses several TIQ derivatives have been shown to 
inhibit tyrosine hydroxylase (TH) (Hirata & Nagatsu 1985; Maruyama et al 1993; Scholz 
et al 1997).  In a comparison of six N-methylated salsolinol derivatives, N-methyl-
norsalsolinol was found to be the most potent inhibitor of TH (Maruyama et al 1993).  A 
separate report demonstrated that the inhibition of TH by N-methyl-norsalsolinol was 
noncompetitive with an IC50 of 10 M (Scholz et al 1997).  Therefore, reductions in 
dopamine content and TH immunoreactivity noted in many reports may be 
manifestations of TH inhibition.  However, whether neuronal TH inhibition is a direct 
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effect TIQs on the enzyme or their overall reduction in cellular energy production 
remains to be seen.    
 
 
1.3.2 In Vivo Toxicity 
 
To date, in vivo neurotoxicological studies of TIQ and its derivatives have failed 
to provide convincing evidence of cell death within the SNpc.  Studies in marmosets and 
squirrel monkeys suggest that both the behavioral and biochemical effects of 
subcutaneously injected TIQ in doses up to 20 mg/kg/day for 100 days could be due to 
TH inhibition rather than cell death within the SNpc (Nagatsu & Yoshida 1988; Yoshida 
et al 1993).  These primates exhibited rigidity and bradykinesia, reduced nigral 
dopamine and decreased TH activity.  TIQ was injected subcutaneously on a daily basis 
for at least four weeks in two studies utilizing C57BL/6J mice (Ogawa et al 1989; Perry 
et al 1988).  Reduced TH immunoreactivity in the absence of overt cell death was again 
reported.  Surprisingly, there was no reduction in striatal dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC) or homovanillic acid (HVA) content. 
 
 In a single report of N-methyl-TIQ administration in marmosets, three out of four 
animals died after prolonged subcutaneous injection (Perry et al 1987).  Unfortunately, 
pathological findings were not reported and the single surviving marmoset showed no 
reduction in dopamine, DOPAC or HVA content.  Rhesus monkeys exposed to 
prolonged administration of N-methyl-TIQ again showed no reduction in dopamine, 
DOPAC or HVA content and only slight motor disturbance.  In the same report, 
cynomolgous monkeys exposed to N-methyl-isoquinolinium ion exhibited only mild 
bradykinesia after eight weeks of intraventricular administration (Yoshida et al 1993).  
However, in mice, intraperitoneal injection of N-methyl-TIQ for 20 weeks was associated 
with atrophy of the SNpc and reduced nigral TH immunoreactivity (Fukuda 1994).  In 
rats, N-methyl-isoquinolinium ion reportedly demonstrated cytotoxicity when directly 
infused into the striatum (Booth et al 1989).   
 
 Naoi and coworkers delivered N-methyl-(R)salsolinol to rats by intrastriatal 
infusion with a mini-osmotic pump over a period of one week (Naoi et al 1996a).  
Parkinsonian behavioral changes, including hypokinesia, stiff tail and postural 
abnormalities were noted in treated rats.  Dopamine and norepinephrine levels were 
reduced in both the striatum and SN and TH-immunoreactive neurons were reduced by 
more than 50% in the striatum of infused animals.  Neuronal density was also reduced, 
although the differences between control and injected sides did not reach statistical 
significance.  N-methyl-norsalsolinol was injected into the left medial forebrain bundle of 
rats and both the behavioral response to apomorphine and striatal dopamine levels were 
determined three weeks later (Moser et al 1996b).  There was no response to 
apomorphine, and the mild reductions in dopamine, DOPAC and HVA did not reach 
statistical significance. 
 
 In a single monkey, chronic subcutaneous injection of 1-benzyl-TIQ produced 
behavioral parkinsonism (Kotake et al 1996).  Morphological and biochemical effects 
were not reported.  After short-term intraperitoneal injections of 1-benzyl-TIQ in the 
mouse, motor testing demonstrated mild parkinsonism that was corrected by 
carbidopa/levodopa (Kotake et al 1995).  In another study, mice receiving 1-benzyl-TIQ 
intraperitoneally were bradykinetic, but showed no reductions in striatal dopamine levels 
or TH+ neurons in the SNpc (Abe et al 2001).  In yet another report, intraperitoneal 
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injections of 1-benzyl-TIQ were performed for 17 days in mice prior to quantification of 
striatal catecholamines (Antkiewicz-Michaluk et al 2001).  Chronic injection of 1-benzyl-
TIQ was associated with muscular rigidity and a 60% reduction in striatal dopamine 
levels.  The benzyl-TIQ derivative 3’,4’-dihydroxy-benzyl-TIQ induced behavioral 
parkinsonism in mice after five days of intraperitoneal administration, but striatal 
dopamine levels and SNpc morphology were not reported (Kawai et al 1998).  In the 
same report, administration of 1-benzyl-6,7-dihydroxy-TIQ produced no behavioral 
effects. 
 
Unfortunately, the above in vivo studies are largely invalid, riddled with poor to 
non-existent synthetic mechanisms of TIQ derivatives and antiquated delivery systems.  
For instance, all studies utilizing oxidized TIQ derivatives (e.g. N-methyl-isoquinolinium 
ion) were reportedly produced by the action of purified MAO enzyme.  Besides the fact 
that several studies report that TIQs are not substrates for or even inhibit MAO, the 
chances of successfully isolating purified ions for administration from a protein mixture 
are very poor.  With this in mind, no study to date has published any physical data to 
prove successful synthesis of isoquinolinium ions.  Furthermore, peripheral 
administrations of even supraphysiologic doses of TIQ derivatives are unlikely to 
produce toxic levels within the critical dopaminergic neurons of the SNpc when enzymes 
such as CYP2D6 and likely other metabolic mechanisms are taken into account.  Finally, 
as demonstrated in several reports, the cytotoxicities of TIQs are orders of magnitude 
weaker than MPTP or even rotenone.  With this in mind, TIQ derivative delivery may 
require months or even years to produce convincing evidence of cell death.  Without 
question, more data describing the exact mechanism(s) of cellular penetration and 
toxicity of TIQ derivatives in the in vitro model is necessary for proper in vivo 
experimental design.       
 
 
1.4 TETRAHYDROISOQUINOLINES IN PARKINSON DISEASE 
 
 The brain and CSF concentrations of several TIQ derivatives have been 
determined in humans with PD (Antkiewicz-Michaluk et al 1997; Kotake et al 1995; 
Maruyama et al 1999; Moser et al 1995; Muller et al 1999; Niwa et al 1987; Niwa et al 
1991; Sandler et al 1973).  In a single PD case, TIQ was quantified in the frontal cortex 
at 10 ng/g (Niwa et al 1987).  Analysis of frontal cortex from a single normal human brain 
detected TIQ at less than 1 ng/g.  This same study also quantified N-methyl-TIQ in 
frontal cortex at 2 ng/g in PD brain and 3 ng/g in control brain, whereas 1-methyl-TIQ 
was reportedly undetectable in both normal human and PD brain.  In a subsequent 
publication from the same group, TIQ was detected in the occipital cortex of a single PD 
brain at 7 ng/g (Niwa et al 1991).  The same study only provided “estimated” wet tissue 
concentrations for both N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol.  The use of 
single brains and estimated concentrations provide little meaningful information and 
therefore no reasonable conclusions can be made.  A more rigorous and systematic 
topological analysis of TIQ derivatives in PD and normal human brain is obviously 
needed.   
 
(R/S)salsolinol has been detected in the plasma and urine of both PD patients 
and controls.  Concentrations of (R/S)salsolinol were higher in plasma than in CSF in 
one study (Muller et al 1999).  Although the differences did not reach statistical 
significance, both salsolinol enantiomers were detected at lower concentrations in PD 
patients than in controls.  The CSF levels of N-methyl-(R)salsolinol levels were reported 
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to decrease after two years of treatment with levodopa (Maruyama et al 1999).  In 
another study, N-methyl-norsalsolinol was detected in the CSF of PD patients and 
negatively correlated with disease duration (Moser et al 1995).  Interestingly, N-methyl-
norsalsolinol was not detected in the CSF of controls.  This data may suggest that, over 
time, dying dopaminergic neurons release (R/S)salsolinol, N-methyl-norsalsolinol and N-
methyl-(R/S)salsolinol into the CSF.   
 
 The risk of PD has been shown to be decreased by certain behaviors such as 
smoking cigarettes and drinking coffee (Grandinetti et al 1994; Paganini-Hill 2001).  
Interestingly, some components in tobacco smoke limit the conversion of TIQ to more 
toxic N-methylated derivatives (Soto-Otero et al 1996).  Administration of cigarette 
smoke has also been shown to reduce the brain tissue levels of TIQ in rats (Soto-Otero 
et al 2001).  A logical hypothesis derived from this data could suggest that decreased 
accumulation and/or metabolism of TIQ in the brain of smokers explains the 
epidemiological effect of cigarette smoking on the incidence of PD.   
 
 Finally, a role for neurotoxins in the pathogenesis of idiopathic PD may also be 
suggested by the incidence of levodopa-resistant atypical parkinsonism on the French 
West Indies island of Guadeloupe.  This syndrome is similar in nature to an earlier 
discovery in Guam and may be caused by exposure to tropical plants containing 
mitochondrial complex I inhibitors (quinolines, acetogenins and rotenoids) found in 
certain fruit and teas made from trees in the Annonaceae family (Caparros-Lefebvre et al 
2002).  These tree products contain known neurotoxins like reticuline (Figure 1-1), a 
benzyl-TIQ derivative.  Patients with Guadeloupean Parkinsonism present with rigidity 
and bradykinesia, in addition to ophthalmoparesis, pseudo-bulbar palsy and frontal lobe 
signs similar to those of progressive supranuclear plasy (PSP).  In a study by Lannuzel 
and co-workers, the IC50 for reticuline in cultured mesencephalic dopaminergic neurons 
at 24 hrs was 100 M (Lannuzel et al 2002).  Furthermore, acetogenins like annonacin 
appear to be more potent inhibitors of complex I than most TIQ derivatives (Lannuzel et 
al 2003; Yuan et al 2003).  When added to mesencephalic cultures for 24 hrs, 
annonacin was much more potent than MPP+ (IC50 = 0.018 M vs.1.9 M) in killing 
dopaminergic neurons and overall dopamine uptake was reduced.  Toxic effects were 
even seen at very low concentrations when the incubation time was extended by several 
days. 
 
 
1.5 SIGNIFICANCE OF STUDY 
 
The risk of developing idiopathic PD is due to the effects and interactions of 
numerous genetic and environmental risk factors.  Subtle environmental risk factors 
could be those associated with the consumption or ingestion of undefined neurotoxins 
through the respiratory and gastrointestinal systems and accumulation in the brain over 
a lifetime.  Despite recent advances in genetics and epidemiology, the etiopathogenesis 
of sporadic PD remains obscure in the vast majority of cases.  
 
In PD, the most prominent neurodegenerative cell death is seen in the 
dopaminergic neurons of the SNpc and noradrenergic neurons of the locus ceruleus.  
Thus a straightforward explanation for the relatively selective cell death seen in PD is the 
accumulation of neurotoxins derived from catecholamines.  Isoquinoline derivatives 
(isoquinolines, dihydroisoquinolines and TIQs) have been shown to inhibit complex I of 
the mitochondrial ETC and are one family of compounds that can be synthesized from 
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catecholamine precursors.  Several TIQs can cross the blood-brain barrier and certain 
TIQs are taken up by the NET.  TIQ derivatives may thus accumulate in dopaminergic 
neurons over time and, upon reaching critical levels, could generate oxidative stress and 
initiate apoptosis by inhibiting complex I of the mitochondrial ETC.  Dopaminergic 
neurons in elderly persons with a naturally lowered oxidative phosphorylation capacity 
may not tolerate a significant buildup of complex I inhibitors and in time these cells may 
die. 
 
Although considerable evidence suggests that isoquinolines such as the TIQs 
may contribute to dopaminergic cell loss in PD, data detailing the anatomical distribution 
and definitive toxicity of these potential neurotoxins in mammalian tissues is 
unfortunately inconsistent and unreliable.  Using enantiomeric-selective HPLC-EC and 
LC-MS/MS, the concentrations of TIQ, 1-methyl-TIQ, N-methyl-TIQ, 1-benzyl-TIQ, 
(R)salsolinol, (S)salsolinol, N-methyl-(R)salsolinol, N-methyl-(S)salsolinol, norsalsolinol 
and N-methyl-norsalsolinol were systematically determined in multiple regions of rodent, 
human, and PD brain (DeCuypere et al 2008a; DeCuypere et al 2008b).  As TIQ 
derivates have been demonstrated to be normal constituents of many plants, these 
compounds were quantified in the 20 most commonly consumed fruits and vegetables in 
the United States.  Furthermore, data detailed in Chapter 4 demonstrates the definitive 
neurotoxicity of N-methylated derivatives of salsolinol in dopaminergic SH-SY5Y cells.  
Based on our results, it is logical to conclude that several tetrahydoisoquinoline toxins 
(such as N-methyl-(R/S)salsolinol and N-methyl-norsalsolinol), all of which inhibit 
complex I of the ETC, can accumulate in neurons with aging and contribute to 
neurodegeneration via apoptotic cell death.  Prevention of the onset and progression of 
PD demands a profound and comprehensive understanding of potential neurotoxins and 
their relationship to disease pathogenesis. 
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CHAPTER 2. LOCALIZATION OF N-METHYL-NORSALSOLINOL WITHIN RODENT 
AND HUMAN BRAIN* 
 
 
2.1 INTRODUCTION 
 
The discovery that MPTP can cause Parkinsonism (Ballard et al 1985; Langston 
et al 1983) led to a search for MPTP analogues as possible endogenous or exogenous 
dopaminergic neurotoxins.   As shown in Figure 2-1, N-methylated isoquinolines share 
structural homology with MPTP.  Currently available data suggests that isoquinoline 
derivatives may be endogenous and/or exogenous neurotoxins that contribute to 
dopaminergic cell death in PD.  For example, McNaught and colleagues showed that 
several isoquinoline derivatives are potentially more potent inhibitors of complex I of the 
respiratory chain than the MPTP derivative, MPP+ (McNaught et al 1995b).   
 
 Both "exogenous" and "endogenous" pathways have been proposed for 
isoquinoline neurotoxicity.  In the exogenous pathway depicted in Figure 2-1B, TIQ is 
acquired from dietary sources, transported across the blood-brain barrier, converted by 
an N-methyl-transferase to N-methyl-TIQ, and then oxidized to N-methylisoquinolium 
ion (NMIQ+) by a MAO (Makino et al 1988; Niwa et al 1989).  Nagatsu and Yoshida 
stirred interest in TIQ and related compounds by showing that systemic administration 
of TIQ produced Parkinsonism in marmosets despite the absence of demonstrable cell 
death within the substantia nigra pars compacta (Nagatsu & Yoshida 1988).  Similarly, 
TIQ does not appear to produce dramatic dopaminergic cell death in mice (Ogawa et al 
1989).  However, cell death could have easily been missed in both studies since 
neither markers of apoptosis nor stereological counting methods were employed.  
Irrespective of these caveats, N-methylated derivatives of TIQ appear to be more 
neurotoxic than TIQ and have been shown to destroy cultured dopaminergic neurons 
(Nijima et al 1991; Nishi et al 1994).   
 
 As shown in Figure 2-1C, N-methylated isoquinoline derivatives such as N-
methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (N-methyl-norsalsolinol) can be 
formed by a special type of condensation from catecholamines and aldehydes (Cohen 
& Collins 1970) in the "endogenous" pathway of isoquinoline neurotoxicity.  
Furthermore, N-methyl-norsalsolinol has been identified in normal human and PD brain 
using gas chromatography-mass spectrometry (Niwa et al 1991; Niwa et al 1993).  N-
methyl-norsalsolinol has also been detected in the CSF of PD patients but not in 
normal human controls (Moser et al 1995).  N-methyl-norsalsolinol inhibits both TH 
(Scholz et al 1997) and MAO activity (Moser et al 1996a) and may be neurotoxic 
(Maruyama et al 1993; Naoi et al 1995).  
  
 To address the issue of neuronal accumulation and the subsequent potential for 
neurotoxicity, the cellular and cell-type localization and regional distribution of N-
methylated isoquinoline derivatives must first be determined.  In this study, high-
performance liquid chromatography with electrochemical detection (HPLC-EC) was used 
to quantify the regional distribution of N-methyl-norsalsolinol in mouse, rat, and human 
brain.  Due to the limited spatial resolution of liquid chromatography, a monoclonal  
                                                
* Permission to reproduce from Wiley-Liss, Inc.  DeCuypere M, Kalabokis VN, Hao R,   
  Schroeder D, Miller DD, LeDoux MS. 2008. Localization of N-methyl-norsalsolinol  
  within rodent and human brain. J Neurosci Res 86:2543-52. 
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Figure 2-1.  Synthesis of MPP+ and isoquinoline neurotoxins.   
(A) MPTP crosses the blood-brain barrier and is converted to the neurotoxin MPP+ by a 
monoamine oxidase (MAO).  (B) One potential exogenous pathway for 
tetrahydroisoquinoline (TIQ) neurotoxicity.  (C) One potential endogenous pathway for 
synthesis of N-methyl-norsalsolinol and its neurotoxic derivative N-methyl-6,7-dihydroxy-
isoquinolinium ion. 
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antibody to N-methyl-norsalsolinol was generated and used to characterize the cellular 
and cell-type localization of this N-methylated isoquinoline.  PD brain samples were also 
analyzed to help address previously reported findings that (1) N-methyl-norsalsolinol 
cannot be detected in normal human CSF by liquid chromatography and (2) CSF levels 
of N-methyl-norsalsolinol are negatively correlated with disease duration in PD (Moser & 
Kompf 1992; Moser et al 1995). 
 
 
2.2 MATERIALS AND METHODS 
 
All experiments were approved by the University of Tennessee Health Science 
Center Animal Care and Use Committee and performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals.  Mice and rats 
were maintained in a temperature-controlled environment with free access to food and 
water. 
 
 
2.2.1 Chemicals 
 
Acetaldehyde, dimethylsulfate, ethylenediaminetetraacetic acid (EDTA), 
formaldehyde, ortho-phosphoric acid, papaveroline, perchloric acid, serotonin 
hydrochloride, sodium bisulfite, sodium cyanoborohydride, tetrahydroisoquinoline, 
triethylamine (TEA), 3-hydroxytyramine, 3,4-dihydroxybenzylamine (DHBA), 9H-
pyrido[3,4-b]indole, and 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and were used without further treatment.  5-
hydroxyisoquinoline was purchased from Sigma-Aldrich and was recrystallized twice 
from methanol.  Sulfosuccinimidyl-6-(biotinamido) hexanoate was purchased from 
Pierce (Rockford, IL, USA).  Sodium octylsulphonate (SOS) and monobasic anhydrous 
sodium dihydrogen phosphate used in mobile phase preparation were purchased from 
Fluka Chemie (Buchs, Switzerland).  HPLC grade water, acetonitrile, and β-
cyclodextrin were obtained from Fisher Scientific (Hampton, NH, USA). 
 
 
2.2.2 Synthesis of Derivatives of TIQ and Isoquinoline 
 
An aqueous solution of 3-hydroxytyramine (0.5 M) was mixed with a four-fold 
molar excess of formaldehyde to prepare 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline 
(norsalsolinol) or a four-fold molar excess of acetaldehyde to prepare (R/S) salsolinol.  
The pH of the solution was adjusted to 4.5 and the sample was incubated overnight at 
room temperature under nitrogen in the dark.  The solvent was evaporated under 
diminished pressure and the product was crystallized from isopropyl alcohol. 
 
 The tertiary amines N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol were 
prepared from the respective secondary amines norsalsolinol and (R/S)salsolinol by 
reductive methylation in the presence of formaldehyde and sodium cyanoborohydride.  
The reaction mixture contained 0.5 M of the secondary amine, 2.5 M formaldehyde, 0.2 
M sodium acetate, and 1 M sodium cyanoborohydride at pH 5.  The reaction mixture 
was incubated at room temperature overnight under nitrogen in the dark.  The sample 
was clarified by centrifugation and the clear solution was acidified with HCl to pH 0.1 to 
decompose unreacted cyanoborohydride.  The solvent was evaporated and the 
product was extracted from the residue with isopropyl alcohol.  Evaporation of the 
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solvent and extraction of the residue was repeated twice.  The final product was stored 
as a solution in isopropyl alcohol at -20 C. 
 
 N-methyl-5-hydroxyisoquinoline was prepared according to Schulman and 
Fernando (Schulman & Fernando 1968).  Dimethylsulfate was used as the methylating 
agent.  5-hydroxyisoquinoline was dissolved in anhydrous ethanol and allowed to react 
with a two-fold molar excess of dimethylsulfate for 20 hrs.  The excess of 
dimethylsulfate was destroyed by the addition of water.  The solvent was evaporated 
and the product was crystallized from methanol.  The structures of all synthesized 
compounds were confirmed by mass spectrometry. 
 
 
2.2.3 HPLC-EC Analysis of N-Methyl-Norsalsolinol 
 
 
2.2.3.1 Chromatography Standard and Sample Preparation   
 
Primary stock standard solutions were prepared by dissolving 10 mg of N-methyl-
norsalsolinol in 25 ml of a dissolution buffer, which consisted of 0.1 M perchloric acid, 
0.1 mM sodium bisulfite, and 0.1 mM EDTA.  These concentrates were then were then 
divided into 1 ml aliquots, frozen, stored at -80 C, and thawed prior to use at 4 C.  
Working standards in the nM range were freshly prepared in dissolution buffer prior to 
each assay.  Standard curves employed for analyte quantitation were generated with the 
internal standard 3,4-dihydroxybenzylamine (DHBA).  The relationship between 
concentration and relative response was linear over two orders of magnitude (sample 
correlation coefficient > 0.98), with an overall electrochemical sensitivity of 0.001 nA.  
The detection limit for N-methyl-norsalsolinol was 20 g per injection in standards and 
28 g per injection in tissue.   
 
Mice (N = 5, age = 3.5 mo, Balb/c strain, Jackson Labs, Bar Harbor, Maine, USA) 
and rats (N = 5, age = 3.5 mo, Sprague-Dawley strain, Harlan Sprague Dawley, Inc., 
Indianapolis, IN, USA) were anesthetized with aerosolized halothane and fresh brain 
samples were obtained and partitioned using a dissecting microscope.  Tissue samples 
(0.1 - 0.2 g) of striatum, ventral midbrain, frontal cerebral cortex, cerebellar cortex, and 
hippocampus were weighed and then homogenized in 100 µl of ice-cold dissolution 
buffer per 10 mg wet weight.  Cryopreserved blocks of fresh frozen post-mortem brain 
tissue from normal human controls (N = 5, mean age = 70.4 years, standard deviation = 
9.4 years) and human patients with a clinical diagnosis of PD (N = 5, mean age = 69.6 
years, standard deviation = 10.8 years) used for HPLC-EC analysis were obtained from 
the National Institute of Child Health and Human Development (NICHD) Brain and 
Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-
4-3383 (Baltimore, MD, USA).  Frozen blocks of caudate nucleus, putamen, substantia 
nigra, frontal cerebral cortex, cerebellar cortex, locus ceruleus, and hippocampus were 
partitioned into 0.2-0.4 g fragments and homogenized as above.  All homogenates were 
centrifuged at 20,000 g for 25 min at 4 C.  Supernatants were filtered through 0.22 µm 
pore size polyvinylidene fluoride (PVDF) syringe-driven membrane filters (Millipore 
Corp., Bedford, MA, USA) and immediately frozen and stored at -80 C until the time of 
analysis.  The recovery of N-methyl-norsalsolinol was 87.6 +/- 7.2 % based on spiked 
(2.0 ng standard) tissue samples subjected to the above extraction procedure.  
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2.2.3.2 Mobile Phase Preparation   
 
A stock buffer solution containing 75 mM monobasic sodium dihydrogen 
phosphate, 2 mM SOS, 25 µM EDTA, 20 mM β-cyclodextrin, and 100 µl of TEA was 
prepared in 1800 ml of HPLC grade water.  To prepare the mobile phase, this solution 
was then mixed with 200 ml of HPLC grade acetonitrile and buffered to pH 3.0 using 
concentrated ortho-phosphoric acid.  The mobile phase was stored at room temperature 
for no more than 2 days, filtered through a 0.20 µm pore size white nylon filter 
membrane (Millipore Corp.), and degassed under vacuum for 30 min prior to use. 
 
 
2.2.3.3 Liquid Chromatography   
 
HPLC-EC analysis was performed with an ESA Model 5600A CoulArray® system 
(ESA Inc., Chemlsford, MA, USA), equipped with Shimadzu Model DGU-14A on-line 
degassing unit (Shimadzu Scientific Instruments, Columbia, MD, USA), an ESA Model 
582 pump, and an ESA Model 542 refrigerated autosampler.  The detection system 
consisted of three coulometric array modules, each containing four electrochemical 
detector cells.  Electrode potentials were selected over the range of 0 to +700 mV, with a 
50 mV increment against palladium electrodes.  Chromatographic separation was 
achieved by auto-injecting 30 µl sample aliquots at 5 C onto a MetaChem Intersil 
(MetaChem Technologies, Torrance, CA, USA) reversed-phase C18 column (5 µm 
particle size, 250X4.6 mm I.D) with an ESA Hypersil C18 pre-column (5 µm particle size, 
7.5X4.6 mm I.D.).  A mobile phase flow rate of 1.25 ml/min and analysis time of 45 min 
was used for all experiments.  System control and data acquisition/processing were 
performed using ESA CoulArray software (version 1.02).  All samples were processed in 
technical triplicate with median values used for mean calculations.  The results of HPLC-
EC experiments were analyzed by means of a student’s t test for each region of interest.  
An alpha (α) of 0.05 was chosen for statistical significance. 
 
 
2.2.4 Synthesis of Immunogen 
 
Cationized bovine serum albumin (cBSA) was used as a carrier protein for 
immunizations.  cBSA was prepared by coupling the carboxylates of BSA to ethylene 
diamine in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(Hermanson 1996).  N-methyl-norsalsolinol was cross-linked to cBSA using the 
Mannich reaction.  In this procedure the carbon atoms at ortho-positions to the 
phenolic group of the hapten are attached to the primary amino groups of the protein 
through a methylene group.  Haptens were similarly attached to cationized lysozyme to 
facilitate the screening of monoclonal antibodies. 
 
 
2.2.5 Production of Monoclonal Antibody 
 
The antibody was produced by a hybridoma obtained from a mouse that had 
been immunized with N-methyl-norsalsolinol coupled to cBSA.  The IgG fraction from 
ascites fluid was purified by Protein G chromatography.  Initial screenings were done 
against a panel of six different compounds by direct enzyme-linked immunoabsorbant 
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assay (ELISA).  Positive clones were subcloned and screened against the specific 
compound.   
 
 
2.2.6 Antibody Characterization 
 
 
2.2.6.1 Tracer Synthesis   
 
The tracer was N-methyl-norsalsolinol labeled with biotin.   Biotinylation of N-
methyl-norsalsolinol was carried out in two steps.  A linker (H2NCH2CH2NH2) 
containing a primary amino group was introduced at carbon atom 5 or 8 of N-methyl-
norsalsolinol.  This modification occurred by treating N-methyl-norsalsolinol with a 20-
fold molar excess of ethylene diamine and 50-fold molar excess of formaldehyde in 0.1 
M MES buffer, pH 4.8, at 50 C for 24 hrs.  Excess of unreacted ethylene diamine was 
removed by precipitation with ten volumes of methanol.  The methanol precipitation 
step was repeated twice following evaporation of the solvent.  The primary amino 
group of the modified N-methyl-norsalsolinol was labeled with biotin in a reaction with a 
three-fold molar excess of sulfosuccinimidyl-6-(biotinamido) hexanoate in 50 mM 
phosphate, pH 8. 
 
 
2.2.6.2 Inhibition Assay   
 
The cross-reactivities of the antibody with structurally related compounds to N-
methyl-norsalsolinol were estimated by competitive inhibition assay.  The assay buffer 
for all the measurements was Tris-buffered saline, pH 7.5, containing 1 mg/ml BSA and 
0.05% Tween 20.  All assays were carried out at room temperature.  Cross reactivities 
were determined by competitive inhibition experiments where a trace amount of 
biotinylated N-methyl-norsalsolinol competed with various inhibitors for binding to the 
antibody.  The relative amount of antibody-N-methyl-norsalsolinol-biotin complex was 
determined by HRP-labeled streptavidin (R&D Systems, Inc., Minneapolis, MN, USA).  
The apparent dissociation constants of the interaction of the antibody with N-methyl-
norsalsolinol and its biotinylated analogue were 0.6 and 2 µM, respectively. 
  
In a typical experiment the antibody was coated on the wells of microtiter plates 
at 2 µg/ml in PBS for 24 h at 4 C.  The wells were blocked with a solution composed of 
assay buffer supplemented with 5 mg/ml of BSA and were rinsed twice with assay 
buffer prior to use.  Aliquots of 100 µl of solutions containing a fixed concentration of 
tracer (20 nM) and various concentrations of competitors were added to the wells and 
the samples were incubated for 2.5 hrs.  The wells were rinsed three times with assay 
buffer and 100 µl of HRP-streptavidin conjugate was added to each well.  Following a 1 
hr incubation, the wells were rinsed five times with assay buffer and 100 µl of color 
development reagent (R&D Systems) was added.  The reaction was stopped by the 
addition of 100 µl of 1 M H2SO4 and the color was read at 450 ηm in a plate reader. 
  
 
2.2.6.3 Absorption Control   
 
N-methyl-norsalsolinol was mixed with the monoclonal antibody to N-methyl-
norsalsolinol or with an antibody to TH in a proportion of 10:1 (antigen:antibody) molar 
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ratio.  The mixtures were incubated on a rocking plate overnight at 4 C.  These 
mixtures were then used for immunohistochemical staining of rat and human brain 
tissue.  
 
 
2.2.7 Immunocytochemistry 
 
Mice (N = 3, age = 3.5 mo, Balb/c strain, Jackson Labs) and rats (N = 3, age = 
3.5 mo, Sprague-Dawley strain, Harlan Sprague Dawley) were anesthetized with an 
overdose of pentobarbital and transcardially perfused with heparinized saline followed by 
phosphate-buffered 4% paraformaldehyde.  Brains were post-fixed with phosphate-
buffered 4% paraformaldehyde for 2 hrs and then transferred to a phosphate-buffered 
30% sucrose solution.   
 
For immunocytochemistry, post-mortem brain tissue from patients with a clinical 
diagnosis of PD and normal human controls was obtained from the National 
Neurological Research Specimen Bank (Veterans Administration Medical Center 
[VAMC], Los Angeles, CA 90073), which is sponsored by the National Institute of 
Neurological Disorders and Stroke/National Institute of Mental Health (NINDS/NIMH), 
National Multiple Sclerosis Society, Veterans Administration Greater Los Angeles 
Healthcare System (11301 Wilshire Blvd., Los Angeles, CA 90073), and the Veterans 
Health Services and Research Administration, Department of Veterans Affairs.  We 
analyzed two PD and control tissue blocks from three regions (midbrain, striatum, and 
locus ceruleus). 
 
Tissues were sectioned on a cryostat at 20 μm and collected in multiple series 
onto glass slides (Fisher Scientific) and circled with a PAP pen (Ted Pella, Redding, CA, 
USA).  Human tissue sections were fixed with phosphate-buffered 4% paraformaldehyde 
for 30 min.  Mouse, rat, normal human control, and PD tissue were subsequently 
processed in identical fashion for detection of N-methyl-norsalsolinol or TH in individual 
sections and co-localization of N-methyl-norsalsolinol with TH, neuron-specific enolase 
(NSE), and glial fibrillary acidic protein (GFAP).  For each block of tissue, one series of 
sections was stained with cresyl violet or hematoxylin and eosin for anatomical 
localization.  
    
The steps for detection of N-methyl-norsalsolinol were as follows: (1) rinsed 
slides in 0.02 M phosphate buffered saline (PBS) with 0.1% sodium azide (NaN3; Sigma-
Aldrich) x 2 over 30 min on a rotary shaker; (2) quenched endogenous peroxidases with 
10% methanol and 3% hydrogen peroxide in PBS for 5 min on a rotary shaker; (3) rinsed 
in PBS x 3 over 30 min on a rotary shaker; (4) blocked with 2% nonfat dry milk and 0.3% 
Triton X-100 (Sigma-Aldrich) for 1 hr; (5) incubated in primary antibody [mouse anti-N-
methyl-norsalsolinol, 1:500], 3% horse serum, and 0.1% Triton in PBS/NaN3 overnight; 
(6) rinsed in PBS x 3 over 30 min on a rotary shaker; (7) incubated in secondary 
antibody [biotinylated horse anti-mouse; Vector Laboratories (Burlingame, CA, USA); 
1:500], 3% horse serum, and 0.1% Triton in PBS/NaN3 for 4 hrs; (8) rinsed in PBS x 3 
over 30 min on a rotary shaker; (9) incubated in Elite ABC reagent [Vector Laboratories] 
and 0.1% Triton in PBS for 75 min at room temperature; (10) rinsed in PBS x 3 over 30 
min on a rotary shaker; (11) subjected to a nickel-intensified diaminobenzidine [black] 
reaction; (12) rinsed, air-dried, dehydrated, cleared, and coverslipped.  Staining for TH 
using monoclonal antibody 318 from Chemicon (Temecula, CA, USA) at a 1:1,000 
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dilution was performed in similar fashion to help confirm localization in the substantia 
nigra pars compacta. 
 
For double-label immunocytochemistry, the monoclonal antibody to N-methyl-
norsalsolinol was used at a 1:250 dilution and detected with either an indocarbocyanine-
tagged donkey anti-mouse secondary antibody (Cy5, 1:250; Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) or a cyanine-tagged donkey anti-goat antibody 
(Cy2, 1:250; Jackson ImmunoResearch Laboratories).  Primary antibodies to TH (1:250; 
Protos Biotech Co., New York, NY, USA), NSE (1:1500; Accurate Chemical & Scientific 
Co., Westbury, NY, USA), and GFAP (1:1000; DiaSorin, Inc., Stillwater, MN, USA) were 
detected with either Cy2- or Cy5-tagged donkey anti-mouse antibodies.  
  
Tissue was incubated with secondary antibodies for 3 hrs, rinsed, air-dried, 
dehydrated, cleared and coverslipped with 1,3 diethyl-8-phenylxanthine mounting 
compound (DPX; Sigma-Aldrich, St. Louis, MO, USA).  Fluorescence was visualized 
with a confocal laser-scanning microscope (Bio-Rad, Hercules, CA, USA). 
 
 
2.3 RESULTS 
 
 
2.3.1 Quantitative Analysis of N-Methyl-Norsalsolinol in Brain 
 
With HPLC-EC, N-methyl-norsalsolinol was detected in all rodent and human 
brain regions subjected to analysis.  In rat and mouse, N-methyl-norsalsolinol levels 
were very similar across brain regions with no apparent concentration of N-methyl-
norsalsolinol within the nigrostriatal pathways of the ventral midbrain and striatum (Table 
2-1).  However, in human brain, the highest concentrations of N-methyl-norsalsolinol 
were found in structures with dopamine neurons (SN) and dense dopaminergic 
innervation (caudate and putamen) (Table 2-2).  Importantly, in comparison to normal 
human controls, N-methyl-norsalsolinol levels were significantly lower in the caudate 
nuclei and substantia nigra from PD patients (P < 0.05 for both).  In contrast, the 
difference in N-methyl-norsalsolinol concentrations within the putamen of normal human 
and PD brain failed to reach statistical significance. 
 
 
2.3.2 Monoclonal Antibody to N-Methyl-Norsalsolinol 
 
The competitive inhibition assay revealed that the monoclonal antibody to N-
methyl-norsalsolinol showed some cross-reactivity with norsalsolinol and slight cross-
reactivity with N-methyl-salsolinol and salsolinol (Table 2-3, Figure 2-2).  In contrast, 
cross-reactivity with other tested compounds was weak.   The adsorption control 
experiment was consistent with a high degree of antigen-antibody specificity.  N-
methyl-norsalsolinol staining was completely eliminated whereas TH staining was 
unaffected by preincubation with N-methyl-norsalsolinol. 
 
 
 
 
 
 
  35
Table 2-1.  Concentration of N-methyl-norsalsolinol within regions of rodent CNS. 
 
 
*  Values are expressed as ng/g wet tissue weight +/- standard error. 
 
 
 
 
Table 2-2. Concentration of N-methyl-norsalsolinol within regions of human CNS.   
 
 
*  Values are expressed as ng/g wet tissue weight +/- standard error. 
** Indicates a significant difference between normal and PD human. 
 
 
 
 
 
 
 
 
 
 
 
Region Sprague-Dawley Rat N = 5 
Balb/c Mouse 
N = 5 
Frontal Cortex 9.84 +/- 3.16 12.88 +/- 1.51  
Ventral Midbrain 12.36 +/- 2.43 10.42 +/- 3.34  
Striatum 10.523 +/- 1.95 14.53 +/- 4.54  
Hippocampus 14.23 +/- 2.35 18.08 +/- 7.87  
Cerebellum 9.54 +/- 2.82 12.75 +/- 3.16  
Region Normal Human  N = 5 
PD Human  
N = 5 
Frontal Cortex 62.32 +/- 14.76 35.77 +/- 16.28 
Caudate Nucleus** 570.03 +/- 43.44 105.63 +/- 23.55 
Putamen 314.87 +/- 28.73 265.47 +/- 39.03 
Substantia Nigra** 191.17 +/- 12.91 65.75 +/- 6.27 
Inferior Olive 31.54 +/- 9.04 29.77 +/- 7.75 
Locus Ceruleus 18.44 +/- 3.66 21.53 +/- 5.67 
Hippocampus 39.02 +/- 7.82 46.78 +/- 5.95 
Cerebellar Cortex 28.15 +/- 7.35 23.76 +/- 4.31 
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Table 2-3.  Percentage (%) cross-reactivities of the monoclonal antibody with 
compounds structurally related to N-methyl-norsalsolinol. 
 
 
*  The cross-reactivities were determined using the equation: % cross-reactivity of   
    compound A = (IC50 of N-methyl-norsalsolinol/IC50 of compound A) x 100. 
 
 
 
 
 
 
 
 
 
 
 
 
Compound % Cross-Reactivity* 
N-methyl-6,7-dihydroxytetrahydroisoquinoline 100 
6,7-dihydroxytetrahydroisoquinoline 60 
1,N-dimethyl-6,7-dihydroxytetrahydroisoquinoline 15 
1-methyl-6,7-dihydroxytetrahydroisoquinoline 6 
Tetrahydroisoquinoline <1 
5-hydroxyisoquinoline <1 
N-methyl-5-hydroxyisoquinolinium ion <1 
Serotonin <1 
Tetrahydropapaveroline <1 
9H-pyrido[3,4-b]indole <1 
1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole <1 
Dopamine 1 
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Figure 2-2.  Cross-reactivities of the monoclonal antibody with compounds 
structurally related to N-methyl-norsalsolinol.   
Binding of the tracer (biotinylated N-methyl-norsalsolinol) was inhibited by N-methyl-
norsalsolinol (■).  The closely related compound (R/S)1,N-dimethyl-norsalsolinol () 
produced less inhibition of tracer binding.  Tetrahydroisoquinoline (△) and serotonin (X) 
minimally inhibited tracer binding.  Data points obtained with N-methyl-norsalsolinol and 
(R/S)1,N-dimethyl-norsalsolinol were fitted to a simple binding isotherm.  
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2.3.3 Localization and Distribution of N-Methyl-Norsalsolinol Immunoreactivity  
 
As shown in Figures 2-3 and 2-4, N-methyl-norsalsolinol-immunoreactivity (IR) 
was widely distributed in rat, mouse and human brain.  In rodents, the vast majority of 
neurons demonstrated clearly detectable N-methyl-norsalsolinol-IR.  Within each brain 
area studied (striatum, midbrain, rostral medulla), neuron-to-neuron variability in N-
methyl-norsalsolinol-IR was more notable in human than in rodent tissues. 
 
 Double-labeling studies with antibodies to GFAP and NSE demonstrated that N-
methyl-norsalsolinol-IR was limited to neurons and not present in glia.  N-methyl-
norsalsolinol-IR was concentrated in the soma and proximal dendritic arbors of neurons.  
As seen in Figures 2-3E and 2-3F, nuclear N-methyl-norsalsolinol-IR was much weaker 
than cytoplasmic N-methyl-norsalsolinol-IR.  
 
 Examination of cresyl violet-stained tissue along with immunocytochemistry for 
TH confirmed the presence of N-methyl-norsalsolinol-IR within the substantia nigra pars 
compacta in both rodent and human tissue.  In addition, TH-IR co-localized with N-
methyl-norsalsolinol-IR in both rodent and human tissue.  In rodents, N-methyl-
norsalsolinol-IR was only minimally more intense in the substantia nigra pars compacta 
and other dopaminergic cell groups than elsewhere in the brain.  However, in normal 
human tissue, N-methyl-norsalsolinol-IR was significantly more intense in the SNpc than 
in other cell groups. 
         
 
2.3.4 Effect of Parkinson Disease on N-Methyl-Norsalsolinol Immunoreactivity 
 
As shown in Figure 2-4F-J, relative to normal control brains, N-methyl-
norsalsolinol-IR was reduced in PD substantia nigra.  TH-IR was markedly reduced in 
PD substantia nigra and localized to dystrophic neurons and dendritic processes.  Lewy 
bodies were seen in H & E sections from both PD brains used in the 
immunocytochemical study.  
 
 
2.4 DISCUSSION 
 
Several studies have suggested that isoquinolines such as the 
tetrahydroisoquinolines and dihydroisoquinolines may contribute to dopaminergic cell 
loss in PD (Kajita et al 1994; Nagatsu 1997; Ohta et al 1987; Yoshida et al 1993), data 
detailing the anatomical distribution of these potential neurotoxins in mammalian tissues 
is inconsistent and fragmentary.  Using HPLC-EC and immunocytochemistry, our work 
describes the regional and cellular distributions of the clinically-relevant and potentially 
neurotoxic tetrahydroisoquinoline derivative, N-methyl-norsalsolinol.  Our results indicate 
that N-methyl-norsalsolinol is found in neurons throughout the brain.  Of utmost 
importance, (1) N-methyl-norsalsolinol was concentrated in dopaminergic cell groups in 
human brain and (2) N-methyl-norsalsolinol levels were significantly decreased in 
dopaminergic regions of PD brain as compared to controls.   
 
The results of this study raise several issues regarding the origin and potential 
neurotoxicity of isoquinolines, in general, and N-methyl-norsalsolinol, more specifically, 
in the pathobiology of PD.  Not limited to the dopamine-rich ventral midbrain and  
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Figure 2-3.  N-methyl-norsalsolinol-IR in rodents and humans.   
Examples of N-methyl-norsalsolinol-IR are shown from rat substantia nigra pars 
compacta (A), rat cerebral cortex (B), mouse presubiculum (C), and human inferior olive 
(D).  N-methyl-norsalsolinol-IR (green) did not co-localize with GFAP (red) in the CA3 
region of rat hippocampus (E).  Gray scale images of N-methyl-norsalsolinol-IR (F) and 
GFAP-IR (G) are shown for comparison with (E).  N-methyl-norsalsolinol-IR (green) did 
co-localize (yellow) with NSE-IR (red) in the CA3 region of rat hippocampus (H).  Gray 
scale images of N-methyl-norsalsolinol-IR (I) and NSE-IR (J) are shown for comparison 
with (H).  Bars: 100 μm for A; 250 μm for B, C, and D; and 50 μm for E-J.     
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Figure 2-4.  N-methyl-norsalsolinol-IR in the Substantia Nigra.   
Adjacent sections (A, B) through normal human substantia nigra showing TH-IR (A) and 
N-methyl-norsalsolinol-IR (B).  All TH-IR (green) neurons in rat midbrain were also N-
methyl-norsalsolinol-IR (red) (C).  Gray scale images of N-methyl-norsalsolinol-IR (D) 
and TH-IR (E) are shown for comparison with C.  Adjacent sections through PD 
substantia nigra (F, G) show that TH-IR (F) was weak while N-methyl-norsalsolinol-IR 
(G) was virtually non-existent in some regions.  Confocal images (H-J) from PD 
substantia nigra show co-localization of N-methyl-norsalsolinol-IR (red) and TH-IR 
(green).  Gray scale images of N-methyl-norsalsolinol-IR (I) and TH-IR (J) are shown for 
comparison with fusion image (H). 
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striatum, N-methyl-norsalsolinol was also found and quantified in cerebellum, 
hippocampus, and frontal cortex.  Consistent with our findings, Niwa and co-workers 
were able to detect N-methyl-norsalsolinol in frontal cortex using gas chromatography-
mass spectroscopy (Niwa et al 1991).  Plausible explanations for the broad distribution 
of N-methyl-norsalsolinol include the following: N-methyl-norsalsolinol can be formed in 
cells with very low levels of dopamine and subsequently accumulate in those cells; N-
methyl-norsalsolinol is formed by conceivable enzymatic and/or non-enzymatic 
biosynthetic pathways other than the one indicated in Figure 2-1C; and N-methyl-
norsalsolinol (or its parent isoquinoline derivatives) is present in foods and/or beverages 
and crosses the blood-brain barrier (Collins et al 1990; Duncan & Smythe 1982; Duncan 
et al 1984; Riggin & Kissinger 1976; Riggin et al 1976).  Data demonstrating that N-
methyl-norsalsolinol is able to cross the blood-brain barrier in vivo suggests that 
exogenous sources may contribute to its presence in brain (Thumen et al 2002).  
However, a potential precursor of N-methyl-norsalsolinol, (R/S)salsolinol, does not cross 
the intact blood-brain barrier of young rats (Origitano et al 1981; Song et al 2006).   
 
 Unlike the situation with MPTP, our immunocytochemical data suggests that glial 
cells may not be critical to the potential neurotoxicity of N-methyl-norsalsolinol and other 
N-methylated isoquinolines.  Instead, N-methylated isoquinolines like N-methyl-
norsalsolinol and other closely-related tetrahydroisoquinolines may accumulate in 
neurons over time and subsequently lead to cell damage/death via aggregate inhibition 
of complex I of the mitochondrial electron transport chain.  The relatively high 
concentrations of N-methyl-norsalsolinol in midbrain and striatum from older humans 
(age = 70 yrs) compared to the lower concentrations in young rodents (age = 3.5 mo) 
supports the hypothesis of slow, time-dependent neuronal accumulation.  Furthermore, 
dopaminergic regions of PD brain were found to contain lower levels of N-methyl-
norsalsolinol relative to similar regions in control human brain.  This result reached 
statistical significance in the caudate nucleus and substantia nigra.  Taken together, 
these findings suggest that N-methyl-norsalsolinol is concentrated and/or synthesized 
from dopamine within dopaminergic neurons and subsequently released upon apoptotic 
lysis from the cell body (within the substantia nigra) and/or from axon terminals (within 
the caudate nucleus and/or putamen).  In agreement with this concept, Scholz and 
colleagues demonstrated increased systemic N-methyl-norsalsolinol concentrations in 
patients on high-dose levodopa therapy (Scholz et al 2004).  If N-methyl-norsalsolinol 
and other N-methylated isoquinolines do, in fact, play a role in PD, then dopaminergic 
neurons may have relatively selective vulnerability to their toxic effects.  On the other 
hand, cell death in PD and other neurodegenerative disorders such as Alzheimer 
disease is not limited to the SNpc and the widespread distribution of N-methyl-
norsalsolinol may be compatible with a global neurodegenerative process.  Alternatively, 
N-methyl-norsalsolinol may simply be a dopamine metabolite formed in relatively small 
amounts, not sufficiently toxic to be significant to the pathogenesis of PD, and released 
by dying dopaminergic neurons along with dopamine and its more abundant metabolites, 
HVA and DOPAC.   
 
 Although supplementary to the main results derived from HPLC-EC, our 
immunocytochemical experiments must be cautiously interpreted in the context of our 
competitive inhibition assay since norsalsolinol, N-methyl-salsolinol, and salsolinol have 
been detected in human brain (Musshoff et al 2000; Niwa et al 1991).  These three 
compounds showed some evidence of cross-reactivity with the antibody generated 
against N-methyl-norsalsolinol.  However, the absorption control experiment indicates 
that there were no antigens in brain tissue with higher affinity for the antibody than N-
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methyl-norsalsolinol.  Thus, in the broadest sense, our antibody can be viewed as a tool 
for localizing N-methyl-norsalsolinol and, to a lesser degree, closely related 
tetrahydroisoquinolines.    
 
 An N-methylated isoquinoline closely related to N-methyl-norsalsolinol, N-
methyl-(R)salsolinol, has also received attention as another possible endogenous 
dopaminergic neurotoxin.  N-methyl-(R)salsolinol is toxic to both cultured human 
dopaminergic cells and rat nigral dopaminergic neurons (Maruyama et al 1997a; Naoi 
et al 1996a).  Additionally, cell death caused by N-methyl-(R)salsolinol in dopaminergic 
human neuroblastoma SH-SY5Y cells is apoptotic (Naoi et al 2000).  N-methyl-
(R)salsolinol may be synthesized in brain in a two-step pathway: (1) synthesis of 
(R)salsolinol from dopamine and acetaldehyde mediated by salsolinol synthase, and 
(2) transfer of a methyl group to (R)salsolinol by N-methyl-transferase to form N-
methyl-(R)salsolinol.  N-methyl-(R)salsolinol has been detected in both normal and PD 
CSF (Maruyama et al 1999).  CSF levels of N-methyl-(R)salsolinol were higher in 
newly diagnosed, untreated PD patients than in normal controls but decreased with 
progression of PD as has been described for N-methyl-norsalsolinol (Maruyama et al 
1999; Moser & Kompf 1992).  These results suggest that: (1) dying dopaminergic 
neurons release both N-methyl-(R)salsolinol and N-methyl-norsalsolinol into the CSF, 
(2) healthy neurons release little N-methyl-(R)salsolinol and N-methyl-norsalsolinol into 
the CSF, and (3) at later stages of PD there are too few dying cells to release 
significant amounts of N-methyl-(R)salsolinol and N-methyl-norsalsolinol into the CSF.  
  
Limited evidence to date suggests that N-methyl-(R)salsolinol may be a more 
potent neurotoxin than N-methyl-norsalsolinol (Naoi et al 1996a).  N-methyl-
(R)salsolinol induced Parkinsonism in rats after injection into the striatum whereas N-
methyl-norsalsolinol failed to produce an obvious behavioral effect (Naoi et al 1996a).  
Unfortunately, the histological effects of N-methyl-norsalsolinol were not compared to 
those of N-methyl-(R)salsolinol.  A single injection N-methyl-norsalsolinol (8 µg) also 
failed to produce overt histological damage of dopaminergic neurons after injection into 
the medial forebrain bundle in rats (Moser et al 1996b).  In a single monkey, 
intraventricular injection of N-methyl-norsalsolinol (30 mg over 4 wks) produced neither 
behavioral changes nor gross morphological abnormalities in the substantia nigra 
(Yoshida et al 1993).  In contrast to the in vivo studies, N-methyl-norsalsolinol is nearly 
as toxic to cultured PC12 cells as N-methyl-(R)salsolinol (Maruyama et al 1993; Naoi et 
al 1995).  Clearly, the sensitivity of in vivo neurotoxicity studies of N-methyl-
norsalsolinol has been limited by sample size, dosing, injection routes and weak 
histological analyses.  Alternatively, it is possible that N-methyl-norsalsolinol is not 
taken up by the synapses of dopaminergic neurons after intraparenchymal or 
intraventricular injection or that the neurotoxicity of N-methyl-norsalsolinol is mediated 
by conversion to its oxidation product, N-methyl-6,7-dihydroxy-isoquinolinium ion. 
  
 A substantial body of evidence suggests that the development of idiopathic PD 
is due to exogenous and/or endogenous toxins interacting with a genetically and/or 
environmentally vulnerable host.  It is tempting to hypothesize that several isoquinoline 
toxins such as N-methyl-TIQ, N-methyl-(R)salsolinol and N-methyl-norsalsolinol, all of 
which inhibit complex I of the respiratory chain, accumulate in neurons with aging and 
eventually lead to cell death and contribute to neurodegeneration via apoptosis.       
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2.5 CONCLUSIONS 
 
The isoquinoline derivative N-methyl-6,7-dihydroxytetrahydroisoquinoline (N-
methyl-norsalsolinol) is present in normal human brain and has been identified in the 
CSF of patients with PD.  Endogenously, N-methyl-norsalsolinol may be derived from 
dopamine by condensation with aldehydes or α-ketoacids.  In vitro experiments suggest 
that N-methyl-norsalsolinol is neurotoxic.  In this study, HPLC-EC was used to determine 
N-methyl-norsalsolinol concentrations in mouse, rat, normal human and PD brain.  In 
addition, a monoclonal antibody was generated against N-methyl-norsalsolinol and used 
to determine the cellular localization of N-methyl-norsalsolinol in brain.  With HPLC-EC, 
N-methyl-norsalsolinol was detected in all regions of rodent and human brain subjected 
to analysis.  In rodent brains, N-methyl-norsalsolinol tissue concentrations were similar 
among frontal cortex, ventral midbrain, striatum, hippocampus and cerebellum.  
Conversely, in normal human control brains, N-methyl-norsalsolinol was concentrated in 
the SN and striatum.  In comparison to normal human controls, N-methyl-norsalsolinol 
levels were significantly lower in the SN and caudate nuclei from PD patients, a finding 
possibly related to the death of nigrostriatal dopaminergic neurons.  N-methyl-
norsalsolinol-immunoreactivity co-localized with a general neuronal marker (NSE) and a 
monoaminergic marker (TH), but not with a glial marker (GFAP).  The widespread 
neuronal localization of N-methyl-norsalsolinol in several mammalian species suggests 
that, in isolation, this compound is a "weak" neurotoxin.  However, endogeneously-
derived N-methyl-norsalsolinol could contribute to the pathobiology of PD in genetically 
predisposed individuals after years of accumulation in dopaminergic neurons.  
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CHAPTER 3. REGIONAL DISTRIBUTION OF TETRAHYDROISOQUINOLINE 
DERIVATIVES IN RODENT, HUMAN, AND PARKINSON DISEASE BRAIN* 
 
 
3.1 INTRODUCTION 
 
The pathological hallmark of PD is progressive degeneration of dopaminergic 
neurons in the SNpc.  While the precise molecular mechanisms underlying the etiology 
of cell death in the SNpc remain unclear, oxidative stress, mitochondrial dysfunction, 
and environmental risk factors including exposure to neurotoxins are well documented 
contributors to the pathobiology of PD (Fratiglioni & Wang 2000; Naoi et al 2002; 
Schapira 2001; Shavali & Ebadi 2003).  The landmark finding that an exogenous 
mitochondrial neurotoxin, MPTP, can cause Parkinsonism provided strong support for 
a neurotoxicological component to disease pathogenesis (Ballard et al 1985; Langston 
et al 1983).  Dopaminergic cell death in PD has also been linked to excessive oxidative 
stress via auto- and enzymatic oxidation of dopamine (Figure 3-1) and reduced activity 
of complex I of mitochondrial electron transport (Hirsch & Faucheux 1998).  TIQ and its 
derivatives (Figures 3-1 and 3-2) comprise a family of compounds that can be derived 
from catecholamines, are structurally similar to MPTP, are present both endogenously 
in brain and exogenously in food and beverages, and have been shown to inhibit 
mitochondrial electron transport leading to oxidative cell injury and consequent death 
via apoptotic mechanisms (Maruyama et al 1997a; McNaught et al 1995b; Naoi et al 
2000; Naoi et al 2004; Ogawa et al 1989; Shavali & Ebadi 2003). 
 
 Several “endogenous” TIQ derivatives can be synthesized from dopamine or its 
metabolites.  The catechol TIQ, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline 
(salsolinol; [SAL]), can be synthesized endogenously from dopamine and acetaldehyde 
via two distinct mechanisms (Figure 3-1).  Stereoselective synthesis of the (R)-
enantiomer occurs via a putative salsolinol synthase (Naoi et al 1996b).  SAL can also 
be non-enzymatically synthesized from dopamine via the Pictet-Spengler condensation 
reaction with acetaldehyde to yield a racemic mixture of both (R)- and (S)-enantiomers 
(Cohen & Collins 1970; Schöpf & Bayerle 1934).  Other derivatives can then be 
generated from SAL via the addition and/or subtraction of methyl groups via 
transferases (Naoi et al 1997).  As a result, SAL and a number of its derivatives have 
been detected in brain tissue (Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 
2000; Musshoff et al 1999; Naoi et al 2002; Naoi et al 2004; Sjoquist et al 1982a; b; 
Toth et al 2001).   
 
 In addition to endogenous synthesis, TIQ derivatives may also derive from 
exogenous sources.  For example, TIQ and many of its derivatives are natural 
substances in plants (Rommelspacher & Susilo 1985) and have been detected in 
certain foods and beverages consumed by humans (Collins et al 1990; Duncan & 
Smythe 1982; Duncan et al 1984; Makino et al 1988; Niwa et al 1989; Riggin & 
Kissinger 1976; Riggin et al 1976).  Several TIQ derivates have also demonstrated  
                                                
* Permission to reproduce from the International Society for Neurochemistry.  DeCuypere  
  M, Lu Y, Miller DD, LeDoux MS. 2008. Regional distribution of tetrahydroisoquinoline  
  derivatives in rodent, human, and Parkinson's disease brain. J Neurochem 107:1398- 
  413. 
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Figure 3-1.  Endogenous synthesis of (R)SAL and (S)SAL. 
Enzymatic formation via salsolinol synthase yields only the (R)-enantiomer of salsolinol, 
while the non-enzymatic Pictet-Spengler condensation reaction yields a racemic mixture 
of (R)- and (S)-enantiomers.  Enzymatic methylation of (R)SAL and (S)SAL via cellular 
N-methyl-transferases then yields the respective enantiomer of N-methyl-salsolinol. 
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Figure 3-2.  Chemical structures TIQ and its methylated (A) and benzylated (B) 
derivatives.   
Norsalsolinol (B), a catechol TIQ derivative, is shown for structural comparison. 
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blood-brain permeability (Makino et al 1988; Song et al 2006; Thumen et al 2002).  
These results, taken together, suggest that, in conjunction with endogenous synthesis, 
environmental sources may contribute to accumulation of TIQ derivatives in the 
nervous system. 
 
 To elucidate the potential role of TIQ neurotoxins in the pathogenesis of 
idiopathic PD, the tissue concentration of these compounds must be rigorously 
characterized.  Brain distribution studies of TIQ derivatives to date have been largely 
incomplete, focusing on only a few regions of the brain in a single species and/or 
involving only a subset of TIQ derivatives, often ignoring enantiomeric considerations.  
Moreover, stability of TIQ derivatives has been neglected, raising concerns about the 
validity of previous experimental studies and questions regarding the feasibility of 
neuronal accumulation.   
 
 Using HPLC-EC and LC-MS/MS, the present study was undertaken to 
determine the regional distribution of TIQ, 1-methyl-TIQ, N-methyl-TIQ, 1-benzyl-TIQ, 
(R/S)SAL, N-methyl-(R/S)SAL, NorSAL, dopamine, DOPAC and HVA across multiple 
brain regions in mouse, rat, and human brain.  PD brains were also analyzed to 
examine the relationship of TIQ neurotoxin accumulation and disease status.  Finally, 
the stability of TIQ derivatives was investigated using thermal and freeze/thaw 
exposure in aqueous solution.     
 
 
3.2 MATERIALS AND METHODS 
 
All experiments were approved by the University of Tennessee Health Science 
Center Animal Care and Use Committee and performed in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals.  Mice and rats 
were maintained in a temperature-controlled environment with free access to food and 
water.  
 
 
3.2.1 Chemicals 
 
Ethylenediaminetetraacetic acid (EDTA), formaldehyde, ortho-phosphoric acid, 
perchloric acid, sodium acetate, sodium bisulfite, sodium cyanoborohydride, 
triethylamine (TEA), tetramethylsilane (TMS), trifluoroacetic acid, dopamine, DOPAC, 
HVA, and 3,4-dihydroxybenzylamine (DHBA) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  Deuteriated dimethylsulfoxide (DMSO-d6) was purchased from 
Cambridge Isotope Labs (Woburn, MA, USA).  TIQ, 1-benzyl-TIQ, (R/S)SAL, and 
NorSAL were purchased from Acros Organics (Geel, Belgium).  1-methyl-TIQ and N-
methyl-TIQ were purchased from AsisChem Inc. (Cambridge, MA, USA). Sodium 
octylsulphonate (SOS) and monobasic anhydrous sodium dihydrogen phosphate used 
in mobile phase preparation were purchased from Fluka Chemie (Buchs, Switzerland).  
HPLC grade water, acetonitrile, and β-cyclodextrin were obtained from Fisher Scientific 
(Hampton, NH, USA). 
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3.2.2 Synthesis of N-methyl-(R/S)salsolinol 
 
The tertiary amine N-methyl-(R/S)SAL was prepared from the respective 
secondary amine (R/S)SAL by reductive methylation in the presence of formaldehyde 
and sodium cyanoborohydride.  The reaction mixture contained 0.5 M of the secondary 
amine, 2.5 M formaldehyde, 0.2 M sodium acetate, and 1 M sodium cyanoborohydride 
at pH 5.  The reaction mixture was incubated at room temperature overnight under 
nitrogen in the dark.  The sample was clarified by centrifugation and the clear solution 
was acidified with HCl to pH 0.1 to decompose unreacted cyanoborohydride.  The 
solvent was evaporated and the product was extracted from the residue with isopropyl 
alcohol.  Evaporation of the solvent and extraction of the residue was repeated twice.  
The final product was stored as a solution in isopropyl alcohol at -20 C. 
 
 
3.2.3 Sample Preparation 
 
Mice (N = 5, age = 3.5 mo, C57BL/6 strain, Jackson Labs, Bar Harbor, Maine, 
USA) and rats (N = 5, age = 3.5 mo, Sprague-Dawley strain, Harlan Sprague Dawley, 
Inc., Indianapolis, IN, USA) were anesthetized with aerosolized isoflurane and fresh 
brain samples were obtained and partitioned using a dissecting microscope.  Tissue 
samples (0.1-0.2 g) of striatum, ventral midbrain, frontal cerebral cortex, cerebellar 
cortex, and hippocampus were weighed and then homogenized in 100 µl of ice-cold 
dissolution buffer (0.1 M perchloric acid, 0.1 mM sodium bisulfite, and 0.1 mM EDTA) 
per 10 mg wet weight.  Cryopreserved blocks of fresh frozen post-mortem brain tissue 
from normal human controls (N = 5, mean age = 70.4 years, standard deviation = 9.4 
years) and human patients with a clinical diagnosis of PD (N = 5, mean age = 69.6 
years, standard deviation = 10.8 years) used for HPLC-EC and LC-MS/MS analyses 
were obtained from the National Institute of Child Health and Human Development 
(NICHD) Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-
4-3368 and N01-HD-4-3383 (Baltimore, MD, USA).  Frozen blocks of caudate nucleus, 
putamen, substantia nigra, frontal cerebral cortex, cerebellar cortex, inferior olive, locus 
ceruleus and hippocampus were partitioned into 0.2-0.4 g fragments and homogenized 
as above.  All homogenates were centrifuged at 20,000 g for 25 min at 4 C.  
Supernatants were filtered through 0.22 µm pore size polyvinylidene fluoride (PVDF) 
syringe-driven membrane filters (Millipore Corp., Bedford, MA, USA) and immediately 
frozen and stored at -80 C until the time of analysis. 
 
Due to the high organic content of the tissue supernatants, solid phase extraction 
(SPE) was performed on all samples prior to LC-MS/MS analysis.  A Waters Oasis HLB 
extraction cartridge (1 ml/30 mg; Waters Corporation, Milford, MA, USA) was 
conditioned with 1 ml of methanol followed by a 1 ml wash with water.  The supernatant 
was loaded onto the cartridge and washed with 2 ml deionized water and 1 ml 5% (v/v) 
acetonitrile with 0.1% (v/v) trifluoroacetic acid.  Analytes were eluted from the cartridge 
with 1 ml of acetonitrile with 0.1% (v/v) trifluoroacetic acid.  The final solution was 
evaporated to dryness and the residue was reconstituted in 10 ml of 10% (v/v) 
acetonitrile. 
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3.2.4 HPLC-EC Analysis 
 
 
3.2.4.1 Chromatography Standard Preparation   
 
Primary stock standard solutions were prepared by dissolving 10 mg of 
(R/S)SAL, N-methyl-(R/S)SAL, NorSAL, dopamine, DOPAC and HVA in 25 ml of 
dissolution buffer.  These concentrates were then divided into 1 ml aliquots, frozen, 
stored at -80 C, and thawed prior to use at 4 C.  Working standards in the nM range 
were freshly prepared prior to each assay.  Standard curves employed for analyte 
quantification were generated with a DHBA internal standard.  The relationship between 
concentration and relative response was linear over two orders of magnitude (sample 
correlation coefficient > 0.98), with an overall electrochemical sensitivity of 0.001 µA.  
With HPLC-EC, the limit of quantification for all analytes was 0.7 ng/ml.  Instrumental 
limits of detection and quantification for each analyte appears in Appendix A, Table A-1. 
 
 
3.2.4.2 Mobile Phase Preparation 
 
A stock buffer solution containing 75 mM monobasic sodium dihydrogen 
phosphate, 2 mM SOS, 25 µM EDTA, 20 mM β-cyclodextrin, and 100 µl of TEA was 
prepared in 1800 ml of HPLC grade water.  To prepare the mobile phase, this solution 
was then mixed with 200 ml of HPLC grade acetonitrile and buffered to pH 3.0 using 
concentrated ortho-phosphoric acid.  The mobile phase was stored at room temperature 
for no more than 2 days, filtered through a 0.20 µm pore size white nylon filter 
membrane (Millipore Corp.), and degassed under vacuum for 30 min prior to use.  The 
chiral mobile phase additive β-cyclodextrin is a cyclic oligosaccharide which 
preferentially binds to one face of an enantiomer.  This binding changes the hydrogen-
bonding patterns of the enantiomers and allows for their separation using a standard 
reverse-phase column.   
 
 
3.2.4.3 Liquid Chromatography   
 
HPLC-EC analysis was performed with an ESA Model 5600A CoulArray® system 
(ESA Inc., Chemlsford, MA, USA), equipped with Shimadzu Model DGU-14A on-line 
degassing unit (Shimadzu Scientific Instruments, Columbia, MD, USA), an ESA Model 
582 pump, and an ESA Model 542 refrigerated autosampler.  The detection system 
consisted of three coulometric array modules, each containing four electrochemical 
detector cells.  Electrode potentials were selected over the range of 0 to +700 mV, with a 
50 mV increment against palladium electrodes.  Chromatographic separation was 
achieved by auto-injecting 30 µl sample aliquots at 5 C onto a MetaChem Intersil 
(MetaChem Technologies, Torrance, CA, USA) reversed-phase C18 column (5 µm 
particle size, 250X4.6 mm I.D) with an ESA Hypersil C18 pre-column (5 µm particle size, 
7.5X4.6 mm I.D.) [Figure 3-3A].  A mobile phase flow rate of 1.25 ml/min and analysis 
time of 45 min were used for all experiments.  System control and data 
acquisition/processing were performed using ESA CoulArray software (version 1.02).  All 
samples were processed in technical triplicate with median values used for statistical 
analyses.   
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Figure 3-3.  Chromatography of TIQ derivatives.  
(A) HPLC-EC chromatogram of a standard solution [250 ng/ml; 150 mV] of (1) 
norsalsolinol, (2) dopamine, (3) N-methyl-norsalsolinol, (4) (R)SAL, (5) (S)SAL, (6) N-
methyl-(R)SAL, (7) N-methyl-(S)SAL, (8) DOPAC, and (9) HVA used in system 
calibration. (B) LC-MS/MS extracted ion chromatogram [224  140 m/z] of C57BL/6 
mouse striatum homogenate demonstrating the presence of (10) 1-methyl-TIQ and (11) 
1-benzyl-TIQ, along with their respective ESI mass spectra: (C) molecular ion of 1-
methyl-TIQ; (D) molecular ion of 1-benzyl-TIQ.   
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3.2.5 LC-MS/MS Analysis 
 
 
3.2.5.1 Chromatography Standard Preparation   
 
Primary stock standard solutions were prepared by dissolving 10 mg of TIQ, 1-
methyl-TIQ, N-methyl-TIQ, and 1-benzyl-TIQ in 25 ml of a mixture of 50% water and  
50% acetonitrile.  These concentrates were then divided into 1 ml aliquots and stored at 
-80 C.  Working standards in the nM range were freshly prepared prior to each assay.  
 
 
3.2.5.2 Liquid Chromatography   
 
LC-MS/MS analysis was performed using an Agilent model 1100 series HPLC 
system equipped with a Bruker Esquire-LC ion trap tandem mass selective detector 
(Bruker Daltronics Inc., Billerica, MA, USA), a Model 1327A temperature controlled 
autosampler, a Model 1316A temperature controlled column compartment, and a Model 
G1312A binary pump with Model G1322A solvent degassing module, and a Model 
G1314A variable wavelength UV–vis detector (Agilent Technologies, Santa Clara, CA).  
Ultraviolet absorbance monitoring was performed at 220 nm.  Separation was achieved 
by auto-injecting 10 µl sample aliquots at 5 C onto a Thermo Hypersil-Keystone 
reversed-phase C18 column (5 μm; 50 x 2.1 mm I.D.; Thermo Fisher Scientific, Waltham, 
MA, USA) in combination with a C18 Hypersil guard column (10 x 2.1 mm I.D.)  
[Figure 3-3B].  A binary mobile phase flow rate of 0.7 ml/min and analysis time of 25 min 
was utilized.  Mobile phase A consisted of water with 0.1% formic acid and mobile phase 
B consisted of acetonitrile with 0.1% formic acid.  The following mobile phase gradient 
was used: 0 min A/B = 95:5, 5 min A/B = 70:30, 10 min A/B = 50:50, 15 min A/B = 70:30, 
20 min A/B = 95:5.  The column was given a 5 min post-run period to allow for re-
equilibration.  System control and data acquisition/processing were performed using 
ChemStation software revision A.08.03 for LC-MS systems (Agilent Technologies).   
 
 
3.2.5.3 Ion Trap Tandem Mass Spectrometry   
 
Full-scan mode was used to acquire mass spectra, precursor ions, and product 
ions.  EsquireControl software version 6.16 (Bruker Daltronics Inc.) was employed for 
control of all mass spectrometric conditions.  The mass spectrometer was equipped with 
a heated capillary interface and an electrospray ionization (ESI) source, operating in 
positive ion mode.  The ESI source and MS/MS parameters were automatically 
optimized.  Spray needle voltage was 4.0 kV and capillary temperature was set to  
220 C.  Sheath and auxiliary nitrogen gas flow were set to 40 and 0 psi, respectively.  
Automatic gain control was utilized with a maximum isolation time of 300 ms.  A relative 
collision energy of 33% was used for all analyses.  The product ions producing the 
highest intensity were used for quantification to increase analytical sensitivity and 
selectivity in LC-MS/MS mode (Figure 3-3C-D).  Quantification was based on detector 
response, defined as the ratio of the base peak ion of interest to the base peak ion of the 
standard compound.  The relationship between concentration and relative response was 
linear over two orders of magnitude (sample correlation coefficient > 0.998) for the 
MS/MS procedure.  All samples were processed in technical triplicate with median 
values used for statistical analyses.  With LC-MS/MS, 0.3 ng/ml was the limit of 
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quantification for all analytes.  Instrumental limits of detection and quantification for each 
analyte appears in Appendix A, Table A-1. 
 
 
3.2.6 Compound Stability Experiments 
 
All compounds were subjected to freeze/thaw and thermal stability testing under 
closed conditions.  A 10 mg sample of each compound was weighted and dissolved in 
DMSO-d6.  Four sets of sealed tubes were exposed to either three freeze-thaw cycles (-
80 C /22 C) or a maximum of 28 days of heat exposure at 22 C, 37 C, and 60 C, 
respectively.  To assess structural integrity after each freeze/thaw cycle and 7-day heat 
exposure interval, 1H NMR spectra were recorded on a Bruker AX 300 spectrometer 
(Bruker Daltronics Inc.) at 300 MHz using TMS as an internal standard.  
 
 
3.2.7 Statistical Analysis 
 
Statistical analyses were based on median values derived from technical 
triplicates.  Enantiomeric, methylation and TIQ derivative/dopamine ratios were then 
determined for each individual sample.  Concentrations derived from all HPLC-EC and 
LC-MS/MS experiments were analyzed with individual Student’s t-tests.  Student’s t-
tests were also utilized to examine TIQ derivative/dopamine ratios and the hypotheses 
that regional enantiomeric and methylation ratios differed from unity (1:1).  An alpha () 
of 0.05 was chosen for statistical significance.  Holm’s method was used to correct for 
multiple comparisons (Holm 1979). 
 
 
3.3 RESULTS 
 
 
3.3.1 Quantitative Analysis of TIQ Derivatives in Brain 
 
Using HPLC-EC and LC-MS/MS, TIQ derivatives were detected in all rodent and 
human brain regions subjected to analysis.  Analysis of Tables 3-1 and 3-2 reveals 
several general patterns and trends in the tissue distribution of TIQ derivatives.  First of 
all, TIQ was present at higher concentrations than its methylated and benzylated 
derivatives (1-methyl-TIQ, N-methyl-TIQ, and 1-benzyl-TIQ) in all brain regions.  
Second, TIQ and its methylated and benzylated derivatives were found at lower 
concentrations than (R/S)SAL and its derivatives in all species.  Lastly, the tissue 
concentrations of NorSAL tended to be intermediate between the concentrations of TIQ 
and (R/S)SAL.  
  
In rat and mouse, the levels of many TIQ derivatives were very similar across 
brain regions with no apparent differences in concentrations (Table 3-1).  For example, 
the regional concentrations of TIQ, 1-methyl-TIQ, N-methyl-TIQ, and 1-benzyl-TIQ 
exhibited minimal variation across the brain.   However, in the striatum, the 
concentrations of both N-methyl-(R)SAL and N-methyl-(S)SAL were significantly higher 
in mice (P < 0.0008).  In contrast, N-methyl-(S)SAL content of the ventral midbrain was 
significantly higher in the rat (P < 0.0008).  While analysis of rat ventral midbrain 
revealed greater dopamine content, NorSAL concentration was decreased in this region 
as compared to the mouse (P < 0.0008).  The trend of increased dopamine metabolite  
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Table 3-1.  Regional distribution of TIQ derivatives in rodent brain. 
 
Compound SD Rat Striatum C57BL6 Mouse Striatum ng / g  nM ng / g  nM 
TIQ 4.64 +/- 1.19 0.033 +/- 0.009 5.58 +/- 1.2 0.042 +/- 0.009 
0.014 +/- 0.005 
0.008 +/- 0.002 
0.018 +/- 0.005 
0.684 +/- 0.17 
0.59 +/- 0.13 
0.52 +/- 0.04 * 
0.47 +/- 0.03 * 
0.03 +/- 0.01 
0.077 +/- 0.006 
13.80 +/- 0.31 
1.31 +/- 0.11 
0.97 +/- 0.12 
1-Me-TIQ 1.06 +/- 0.30 0.007 +/- 0.002 2.00 +/- 0.76 
N-Me-TIQ 0.88 +/- 0.24 0.006 +/- 0.002 1.22 +/- 0.27 
1-Benzyl-TIQ 2.19 +/- 0.92 0.010 +/- 0.004 4.12 +/- 1.11 
(R)SAL 28.00 +/- 3.27 0.16 +/- 0.02 122.50 +/- 30.33 
(S)SAL 24.50 +/- 1.79 0.14 +/- 0.01 106.45 +/- 22.95 
N-Me-(R)SAL 19.98 +/- 2.60 * 0.13 +/- 0.01 * 100.40 +/- 8.13 * 
N-Me-(S)SAL 17.38 +/- 1.45 * 0.090 +/- 0.008 * 92.07 +/- 6.55 * 
NorSAL 5.13 +/- 1.34  0.031 +/- 0.008 5.19 +/- 1.74 
N-Me-NorSAL 10.52 +/- 1.95 0.06 +/- 0.01 13.85 +/- 1.07 
Dopamine 2347.95 +/- 59.95 15.33 +/- 0.39 2114.19 +/- 47.24 
DOPAC 225.45 +/- 10.60 1.34 +/- 0.06 221.12 +/- 18.50 
HVA 183.06 +/- 8.51 1.00 +/- 0.05 177.02 +/- 21.56 
Compound SD Rat Ventral Midbrain C57BL6 Mouse Ventral Midbrain ng / g  nM ng / g  nM 
TIQ 5.43 +/- 1.14 0.041 +/- 0.009 7.18 +/- 1.22 0.054 +/- 0.009 
1-Me-TIQ 1.13 +/- 0.57 0.008 +/- 0.004 2.52 +/- 0.43 0.017 +/- 0.003 
N-Me-TIQ 0.82 +/- 0.27 0.006 +/- 0.002 1.73 +/- 0.21 0.012 +/- 0.001 
1-Benzyl-TIQ 3.39 +/- 1.20 0.015 +/- 0.005 2.14 +/- 0.31 0.010 +/- 0.001 
(R)SAL 211.02 +/- 13.76 1.18 +/- 0.08 148.82 +/- 11.73 0.83 +/- 0.06 
(S)SAL 170.89 +/- 18.89 0.95 +/- 0.10 80.25 +/- 22.27 0.45 +/- 0.12 
N-Me-(R)SAL 240.90 +/- 15.75 1.25 +/- 0.08 215.58 +/- 8.55 1.12 +/- 0.04 
N-Me-(S)SAL 233.50 +/- 4.49 * 1.21 +/- 0.02 * 194.84 +/- 3.71 * 1.00 +/- 0.02 * 
NorSAL 6.40 +/- 1.04 * 0.039 +/- 0.006 * 24.04 +/- 2.03 * 0.15 +/- 0.01 * 
N-Me-NorSAL 12.36 +/- 2.43 0.07 +/- 0.01 43.93 +/- 5.99 0.24 +/- 0.03 
Dopamine 2363.49 +/- 28.08 * 15.43 +/- 0.18 * 1248.38 +/- 19.02 * 8.15 +/- 0.12 * 
DOPAC 62.76 +/- 3.63 0.37 +/- 0.02 61.29 +/- 5.22 0.364 +/- 0.03 
HVA 50.87 +/- 6.39 0.28 +/- 0.03 45.54 +/- 8.21 0.25 +/- 0.04 
Compound SD Rat Frontal Cortex C57BL6 Mouse Frontal Cortex ng / g  nM ng / g  nM 
TIQ 7.32 +/- 1.91 0.05 +/- 0.01 10.19 +/- 1.57 0.08 +/- 0.01 
1-Me-TIQ 3.20 +/- 0.93 0.022 +/- 0.006 1.89 +/- 0.33 0.013 +/- 0.002 
N-Me-TIQ 1.70 +/- 0.63 0.012 +/- 0.004 2.03 +/- 0.71 0.014 +/- 0.005 
1-Benzyl-TIQ 0.93 +/- 0.36 0.004 +/- 0.002 2.52 +/- 0.63 0.011 +/- 0.003 
(R)SAL 15.08 +/- 4.55 0.08 +/- 0.02 23.48 +/- 1.40 0.131 +/- 0.008 
(S)SAL 4.18 +/- 1.29 0.023 +/- 0.007 17.58 +/- 6.22 0.10 +/- 0.03 
N-Me-(R)SAL 45.64 +/- 6.08 0.24 +/- 0.03 12.66 +/- 6.98 0.07 +/- 0.04 
N-Me-(S)SAL 25.19 +/- 3.34 0.13 +/- 0.02 8.32 +/- 1.14 0.043 +/- 0.006 
NorSAL 5.22 +/- 0.71 0.032 +/- 0.004 4.22 +/- 0.93 0.026 +/- 0.006 
N-Me-NorSAL 9.84 +/- 3.16 0.05 +/- 0.02 15.54 +/- 2.16 0.09 +/- 0.01 
Dopamine 545.22 +/- 42.83 3.56 +/- 0.28 728.17 +/- 38.34 4.75 +/- 0.25 
DOPAC 273.45 +/- 15.45 1.63 +/- 0.09 244.08 +/- 25.86 1.45 +/- 0.15 
HVA 232.96 +/- 24.61 1.28 +/- 0.13 167.70 +/- 14.03 0.92 +/- 0.08 
Compound SD Rat Hippocampus C57BL6 Mouse Hippocampus ng / g  nM ng / g  nM 
TIQ 6.75 +/- 1.40 0.05 +/- 0.01 6.04 +/- 1.89 0.04 +/- 0.01 
1-Me-TIQ 2.32 +/- 0.90 0.016 +/- 0.006 5.88 +/- 1.55 0.04 +/- 0.01 
N-Me-TIQ 3.46 +/- 1.04 0.024 +/- 0.007 1.31 +/- 0.81 0.009 +/- 0.006 
1-Benzyl-TIQ 5.29 +/- 1.44 0.024 +/- 0.006 4.55 +/- 1.28 0.020 +/- 0.006 
(R)SAL 12.10 +/- 2.50 * 0.07 +/- 0.01 * 34.20 +/- 1.55 * 0.191 +/- 0.009 * 
(S)SAL 6.38 +/- 1.70 0.036 +/- 0.009 19.30 +/- 2.51 0.11 +/- 0.01 
N-Me-(R)SAL 7.07 +/- 1.10 0.037 +/- 0.006 8.75 +/- 1.09 0.045 +/- 0.006 
N-Me-(S)SAL 5.50 +/- 0.74 0.028 +/- 0.004 3.19 +/- 0.31 0.017 +/- 0.002 
NorSAL 8.38 +/- 1.52 0.051 +/- 0.009 6.57 +/- 2.06 0.04 +/- 0.01 
N-Me-NorSAL 14.23 +/- 2.35 0.08 +/- 0.01 18.51 +/- 5.72 0.10 +/- 0.03 
Dopamine 54.54 +/- 9.52 0.36 +/- 0.06 66.78 +/- 6.85 0.44 +/- 0.04 
DOPAC 20.42 +/- 2.34 * 0.12 +/- 0.01 * 67.55 +/- 3.43 * 0.40 +/- 0.02 * 
HVA 26.57 +/- 5.78 0.15 +/- 0.03 65.00 +/- 8.20 0.36 +/- 0.04 
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Table 3-1 (Continued). 
 
 
Values are expressed as ng/g wet tissue weight +/- standard error.  
*  Significant difference between groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound SD Rat Cerebellum C57BL6 Mouse Cerebellum ng / g  nM ng / g  nM 
TIQ 3.03 +/- 0.90 0.023 +/- 0.007 4.12 +/- 0.32 0.031 +/- 0.002 
1-Me-TIQ 0.79 +/- 0.21 0.005 +/- 0.001 1.24 +/- 0.21 0.008 +/- 0.001 
N-Me-TIQ 1.92 +/- 0.46 0.013 +/- 0.003 0.69 +/- 0.13 0.005 +/- 0.001 
1-Benzyl-TIQ 0.88 +/- 0.16 0.004 +/- 0.001 1.24 +/- 0.27 0.006 +/- 0.001 
(R)SAL 12.26 +/- 2.53 0.07 +/- 0.01 16.84 +/- 1.20 0.094 +/- 0.007 
(S)SAL 7.28 +/- 2.07 0.04 +/- 0.01 9.65 +/- 1.85 0.05 +/- 0.01 
N-Me-(R)SAL 15.80 +/- 2.85 0.08 +/- 0.01 17.10 +/- 3.86 0.09 +/- 0.02 
N-Me-(S)SAL 8.93 +/- 2.65 0.05 +/- 0.01 3.52 +/- 0.43 0.018 +/- 0.002 
NorSAL 5.40 +/- 1.65 0.03 +/- 0.01 8.49 +/- 1.32 0.052 +/- 0.008 
N-Me-NorSAL 9.54 +/- 2.82 0.05 +/- 0.02 22.44 +/- 4.96 0.12 +/- 0.03 
Dopamine 43.62 +/- 3.46 0.28 +/- 0.0 38.81 +/- 4.56 0.253 +/- 0.030 
DOPAC 15.59 +/- 2.77 0.09 +/- 0.02 17.74 +/- 2.55 0.11 +/- 0.01 
HVA 22.94 +/- 4.56 0.13 +/- 0.02 13.12 +/- 2.98 0.07 +/- 0.02 
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Table 3-2.  Regional distribution of TIQ derivatives in normal human and PD brain. 
 
Compound Normal Human Caudate PD Human Caudate ng / g  nM ng / g  nM 
TIQ 2.84 +/- 0.82 0.021 +/- 0.006 3.81 +/- 1.10 0.029 +/- 0.008 
1-Me-TIQ 1.33 +/- 0.77 0.009 +/- 0.005 2.00 +/- 0.21 0.014 +/- 0.001 
N-Me-TIQ 0.93 +/- 0.25 0.006 +/- 0.002 1.40 +/- 0.36 0.010 +/- 0.002 
1-Benzyl-TIQ 1.37 +/- 0.41 0.006 +/- 0.002 1.79 +/- 0.27 0.008 +/- 0.001 
(R)SAL 393.40 +/- 10.95 * 2.19 +/- 0.06 * 255.79 +/- 18.66 * 1.43 +/-0.10 * 
(S)SAL 394.38 +/- 15.51 * 2.20 +/- 0.09 * 249.69 +/- 17.34 * 1.39 +/- 0.10 * 
N-Me-(R)SAL 272.06 +/- 20.58 * 1.41 +/- 0.11 * 90.30 +/- 13.98 * 0.47 +/- 0.07 * 
N-Me-(S)SAL 281.92 +/- 13.91 * 1.46 +/- 0.07 * 83.57 +/- 14.06 * 0.43 +/- 0.07 * 
NorSAL 65.97 +/- 5.96 0.40 +/- 0.04 50.17 +/- 3.01 0.31 +/- 0.02 
N-Me-NorSAL 570.03 +/- 43.44 * 3.18 +/- 0.24 * 105.63 +/- 23.55 * 0.59+/- 0.13 * 
Dopamine 6944.17 +/- 32.81 * 45.33 +/- 0.21 * 1295.59 +/- 80.20 * 8.46 +/- 0.52 * 
DOPAC 1204.95 +/- 85.28 7.17 +/- 0.51 786.95 +/- 67.55 4.68 +/- 0.40 
HVA 2179.01 +/- 71.75 * 11.96 +/- 0.39 * 1082.70 +/- 48.66 * 5.94 +/- 0.27 * 
Compound Normal Human Putamen PD Human Putamen ng / g  nM ng / g  nM 
TIQ 3.49 +/- 0.97 0.026 +/- 0.007 4.45 +/- 1.31 0.03 +/- 0.01 
1-Me-TIQ 2.12 +/- 0.68 0.014 +/- 0.005 1.62 +/- 0.81 0.011 +/- 0.006 
N-Me-TIQ 1.90 +/- 0.42 0.013 +/- 0.003 1.34 +/- 0.24 0.009 +/- 0.002 
1-Benzyl-TIQ 1.42 +/- 0.36 0.006 +/- 0.002 0.73 +/- 0.16 0.003 +/- 0.001 
(R)SAL 593.68 +/- 32.38 3.31 +/- 0.18 379.44 +/- 23.74 2.12 +/- 0.13 
(S)SAL 591.87 +/- 32.04 3.30 +/- 0.18 347.65 +/- 36.91 1.94 +/- 0.21 
N-Me-(R)SAL 383.03 +/- 31.31 1.98 +/- 0.16 341.20 +/- 27.87 1.77 +/- 0.14 
N-Me-(S)SAL 376.81 +/- 17.68 1.95 +/- 0.09 358.01 +/- 43.85 1.85 +/- 0.23 
NorSAL 109.59 +/- 15.04 0.67 +/- 0.09 50.21 +/- 4.09 0.31 +/- 0.02 
N-Me-NorSAL 314.87 +/- 28.73 1.76 +/- 0.16 265.47 +/- 39.03 1.48 +/- 0.22 
Dopamine 4142.33 +/- 38.88 * 27.04 +/- 0.25 * 1639.81 +/- 30.53 * 10.70 +/- 0.20 * 
DOPAC 386.16 +/- 15.47 * 2.30 +/- 0.09 * 152.17 +/- 8.08 * 0.90 +/- 0.05 * 
HVA 1014.04 +/- 18.41 * 5.57 +/- 0.10 * 358.13 +/- 9.80 * 1.97 +/- 0.05 * 
Compound Normal Human Substantia Nigra PD Human Substantia Nigra ng / g  nM ng / g  nM 
TIQ 4.48 +/- 0.91 0.034 +/- 0.007 3.97 +/- 0.92 0.030 +/- 0.007 
1-Me-TIQ 1.63 +/- 0.17 0.011 +/- 0.001 2.05 +/- 0.88 0.014 +/- 0.006 
N-Me-TIQ 2.16 +/- 0.30 0.015 +/- 0.002 1.83 +/- 0.67 0.012 +/- 0.005 
1-Benzyl-TIQ 1.49 +/- 0.42 0.007 +/- 0.002 0.90 +/- 0.19 0.004 +/- 0.001 
(R)SAL 204.79 +/- 21.91 1.14 +/- 0.12 221.32 +/- 15.90 1.23 +/- 0.09 
(S)SAL 213.19 +/- 25.83 1.19 +/- 0.14 210.88 +/- 17.73 1.18 +/- 0.10 
N-Me-(R)SAL 174.92 +/- 19.42 * 0.90 +/- 0.10 * 61.44 +/- 6.26 * 0.32 +/- 0.03 * 
N-Me-(S)SAL 187.22 +/- 24.54 0.97 +/- 0.13 56.25 +/- 5.67 0.29 +/- 0.03 
NorSAL 62.24 +/- 7.55 0.38 +/- 0.05 54.60 +/- 9.54 0.33 +/- 0.06 
N-Me-NorSAL 191.17 +/- 12.91 * 1.07 +/- 0.07 * 29.77 +/- 7.75 * 0.17 +/- 0.04 * 
Dopamine 1432.05 +/- 26.56 * 9.35 +/- 0.17 * 114.42 +/- 11.81 * 0.75 +/- 0.08 * 
DOPAC 945.17 +/- 36.82 * 5.62 +/- 0.22 * 90.12 +/- 21.42 * 0.54 +/- 0.13 * 
HVA 1276.78 +/- 11.79 * 7.01 +/- 0.06 * 84.44 +/- 11.31 * 0.46 +/- 0.06 * 
Compound Normal Human Locus Ceruleus PD Human Locus Ceruleus ng / g  nM ng / g  nM 
TIQ 5.61 +/- 1.81 0.04 +/- 0.01 4.92 +/- 1.05 0.037 +/- 0.008 
1-Me-TIQ 2.03 +/- 0.25 0.014 +/- 0.002 1.86 +/- 0.61 0.013 +/- 0.004 
N-Me-TIQ 1.85 +/- 0.40 0.013 +/- 0.003 1.74 +/- 0.55 0.012 +/- 0.004 
1-Benzyl-TIQ 2.19 +/- 0.52 0.010 +/- 0.002 1.87 +/- 0.33 0.008 +/- 0.001 
(R)SAL 168.49 +/- 31.91 0.94 +/- 0.18 340.12 +/- 25.70 1.90 +/- 0.14 
(S)SAL 177.29 +/- 34.83 0.99 +/- 0.19 319.78 +/- 27.25 1.78 +/- 0.15 
N-Me-(R)SAL 193.02 +/- 21.32 1.0 +/- 0.11 82.36 +/- 13.54 0.43 +/- 0.07 
N-Me-(S)SAL 181.43 +/- 32.54 0.94 +/- 0.10 102.54 +/- 18.70 0.53 +/- 0.10 
NorSAL 42.24 +/- 12.55 0.26 +/- 0.08 44.54 +/- 10.74 0.27 +/- 0.07 
N-Me-NorSAL 18.44 +/- 3.66 0.10 +/- 0.02 21.53 +/- 5.67 0.12 +/- 0.03 
Dopamine 987.74 +/- 120.55 6.45 +/- 0.79 503.38 +/- 72.71 3.29 +/- 0.47 
DOPAC 750.39 +/- 40.69 * 4.46 +/- 0.24 * 362.06 +/- 38.50 * 2.15 +/- 0.23 * 
HVA 833.00 +/- 63.12 4.57 +/- 0.35 399.41 +/- 57.25 2.19 +/- 0.31 
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Table 3-2 (Continued). 
 
Compound Normal Human Frontal Cortex PD Human Frontal Cortex 
 ng / g  nM ng / g  nM 
TIQ 4.61 +/- 1.03 0.035 +/- 0.008 5.22 +/- 1.37 0.04 +/- 0.01 
1-Me-TIQ 1.24 +/- 0.64 0.008 +/- 0.004 0.77 +/- 0.24 0.005 +/- 0.002 
N-Me-TIQ 1.03 +/- 0.33 0.007 +/- 0.002 0.61 +/- 0.13 0.004 +/- 0.001 
1-Benzyl-TIQ 0.89 +/- 0.24 0.004 +/- 0.001 0.80 +/- 0.19 0.004 +/- 0.001 
(R)SAL 52.63 +/- 1.28 0.294 +/- 0.007 60.36 +/- 3.07 0.34 +/- 0.02 
(S)SAL 10.84 +/- 6.41 0.060 +/- 0.04 14.98 +/- 6.54 0.08 +/- 0.04 
N-Me-(R)SAL 71.30 +/- 2.36 * 0.37 +/- 0.01 * 168.80 +/- 15.82 * 0.87 +/- 0.08 * 
N-Me-(S)SAL 66.75 +/- 4.77 0.34 +/- 0.02 135.43 +/- 22.05 0.70 +/- 0.11 
NorSAL 50.40 +/- 16.02 0.31 +/- 0.10 44.07 +/- 10.92 0.27 +/- 0.07 
N-Me-NorSAL 62.32 +/- 14.76 0.35 +/- 0.08 35.77 +/- 16.28 1.97 +/- 0.09 
Dopamine 4.77 +/- 1.63 0.03 +/- 0.01 2.60 +/- 0.12 0.017 +/- 0.001 
DOPAC 4.73 +/- 0.58 0.028 +/- 0.003 3.55 +/- 0.87 0.021 +/- 0.005 
HVA 3.86 +/- 1.53 0.021 +/- 0.008 3.53 +/- 0.85 0.019 +/- 0.005 
Compound Normal Human Hippocampus PD Human Hippocampus ng / g  nM ng / g  nM 
TIQ 2.84 +/- 0.53 0.021 +/- 0.004 3.19 +/- 1.05 0.024 +/- 0.008 
1-Me-TIQ 0.44 +/- 0.06 0.0030 +/- 0.0004 0.72 +/- 0.20 0.005 +/- 0.001 
N-Me-TIQ 0.69 +/- 0.10 0.005 +/- 0.001 1.04 +/- 0.15 0.007 +/- 0.001 
1-Benzyl-TIQ 1.30 +/- 0.27 0.006 +/- 0.001 0.70 +/- 0.08 0.0031 +/- 0.0004 
(R)SAL 52.54 +/- 12.54 * 0.29 +/- 0.07 * 182.73 +/- 12.73 * 1.02 +/- 0.07 * 
(S)SAL 20.19 +/- 7.92 * 0.11 +/- 0.04 * 194.86 +/- 19.49 * 1.09 +/- 0.11 * 
N-Me-(R)SAL 125.90 +/- 20.50 * 0.65 +/- 0.11 * 612.65 +/- 27.23 * 3.17 +/- 0.14 * 
N-Me-(S)SAL 35.26 +/- 8.39 * 0.18 +/- 0.04 * 445.45 +/- 40.55 * 2.30 +/- 0.21 * 
NorSAL 70.94 +/- 4.21 0.43 +/- 0.03 68.79 +/- 3.79 0.42 +/- 0.02 
N-Me-NorSAL 39.02 +/- 7.82 0.22 +/- 0.04 46.78 +/- 5.95 0.26 +/- 0.03 
Dopamine 21.11 +/- 6.02 0.14 +/- 0.04 1.76 +/- 0.91 0.011 +/- 0.006 
DOPAC 16.20 +/- 3.07 0.10 +/- 0.02 1.51 +/- 0.81 0.009 +/- 0.005 
HVA 24.61 +/- 5.68 0.13 +/- 0.03 1.37 +/- 0.68 0.008 +/- 0.004 
Compound Normal Human Inferior Olive PD Human Inferior Olive ng / g  nM ng / g  nM 
TIQ 1.95 +/- 0.26 0.015 +/- 0.002 2.31 +/- 0.80 0.017 +/- 0.006 
1-Me-TIQ 0.53 +/- 0.18 0.004 +/- 0.001 0.79 +/- 0.21 0.005 +/- 0.001 
N-Me-TIQ 0.60 +/- 0.07 0.0041 +/- 0.0005 1.18 +/- 0.44 0.008 +/- 0.003 
1-Benzyl-TIQ 1.52 +/- 0.44 0.007 +/- 0.002 0.91 +/- 0.31 0.004 +/- 0.001 
(R)SAL 23.78 +/- 2.10 0.13 +/- 0.01 14.61 +/- 5.64 0.08 +/- 0.03 
(S)SAL 24.05 +/- 4.58 0.13 +/- 0.03 8.27 +/- 3.37 0.05 +/- 0.02 
N-Me-(R)SAL 46.36 +/- 8.99 0.24 +/- 0.05 56.33 +/- 14.60 0.29 +/- 0.08 
N-Me-(S)SAL 16.77 +/- 4.21 0.09 +/- 0.02 31.75 +/- 8.12 0.16 +/- 0.04 
NorSAL 65.47 +/- 7.18 0.40 +/- 0.04 87.45 +/- 11.96 0.54 +/- 0.07 
N-Me-NorSAL 31.54 +/- 9.04 0.18 +/- 0.05 29.77 +/- 7.75 0.17 +/- 0.04 
Dopamine 8.54 +/- 2.10 0.06 +/- 0.01 7.56 +/- 2.15 0.05 +/- 0.01 
DOPAC 2.84 +/- 0.37 0.017 +/- 0.002 5.81 +/- 1.99 0.03 +/- 0.01 
HVA 4.70 +/- 0.79 0.026 +/- 0.004 6.33 +/- 1.11 0.035 +/- 0.006 
Compound Normal Human Cerebellar Cortex PD Human Cerebellar Cortex ng / g  nM ng / g  nM 
TIQ 3.28 +/- 0.94 0.025 +/- 0.007 4.17 +/- 0.94 0.031 +/- 0.007 
1-Me-TIQ 1.76 +/- 0.59 0.012 +/- 0.004 1.47 +/- 0.24 0.010 +/- 0.002 
N-Me-TIQ 1.34 +/- 0.23 0.009 +/- 0.002 1.63 +/- 0.36 0.011 +/- 0.002 
1-Benzyl-TIQ 2.02 +/- 0.63 0.009 +/- 0.003 1.19 +/- 0.14 0.005 +/- 0.001 
(R)SAL 252.46 +/- 12.51 1.41 +/- 0.07 157.36 +/- 19.19 0.88 +/- 0.11 
(S)SAL 184.88 +/- 0.90 1.032  +/- 0.005 99.68 +/- 17.39 0.56 +/- 0.10 
N-Me-(R)SAL 60.85 +/- 6.63 0.31 +/- 0.03 33.45 +/- 6.01 0.17 +/- 0.03 
N-Me-(S)SAL 11.97 +/- 1.62 0.062 +/- 0.008 9.11 +/- 2.35 0.05 +/- 0.01 
NorSAL 112.62 +/- 9.47 0.69 +/- 0.06 78.12 +/- 10.11 0.48 +/- 0.06 
N-Me-NorSAL 28.15 +/- 7.35 0.16 +/- 0.04 23.76 +/- 4.31 0.13 +/- 0.02 
Dopamine 8.24 +/- 1.18 0.054 +/- 0.008 3.45 +/- 0.56 0.023 +/- 0.004 
DOPAC 4.41 +/- 0.72 0.026 +/- 0.004 1.67 +/- 0.43 0.010 +/- 0.003 
HVA 5.20 +/- 0.92 0.029 +/- 0.005 3.78 +/- 0.76 0.021 +/- 0.004 
 
Values are expressed as ng/g wet tissue weight +/- standard error. 
*  Significant difference between normal and PD.  
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content in the mouse was also noted in the hippocampus, where (R)SAL and DOPAC 
levels were greater than in the rat (P < 0.0008). 
 
As in rodents, the levels of TIQ, 1-methyl-TIQ, N-methyl-TIQ and 1-benzyl-TIQ 
were similar across all regions in both normal human and PD brain, with an observed 
abundance of TIQ content over its derivatives.  Importantly, several SAL derivatives 
were present at significantly lower concentrations in the caudate nucleus of PD patients 
in comparison with human controls (Table 3-2).  Both (R)SAL and (S)SAL, as well as N-  
methyl-(R)SAL and N-methyl-(S)SAL were noted at lower concentrations in this region of 
PD brain (P < 0.0006).  The content of N-methyl-(R)SAL in the substantia nigra of PD 
brain was also lower than that of normal human brain (Table 3-2; P < 0.0006).  
Conversely, (R)SAL, (S)SAL and N-methyl-(S)SAL were present at significantly higher 
concentrations in the hippocampus of PD humans as compared to controls (Table 3-2; P 
< 0.0006).  Additionally, the concentration of N-methyl-(R)SAL was significantly greater 
in the frontal cortex and hippocampus of PD brain (P < 0.0006).  With the exception of 
DOPAC in the caudate nucleus, the concentrations of dopamine, DOPAC, and HVA 
were significantly lower in the nigrostriatal pathway (substantia nigra, caudate and 
putamen) of PD subjects in comparison with human controls (Table 3-2; P < 0.0005). 
 
 A racemic mixture of the enantiomers of (R/S)SAL and N-methyl-(R/S)SAL was 
observed in regions of increased dopamine content, such as the striatum and ventral 
midbrain of rodents, and the caudate, putamen, substantia nigra and locus ceruleus of 
humans (Table 3-3).  In the frontal cortices and cerebellae of humans and rodents, 
trends towards predominance of (R)SAL over (S)SAL did not attain statistical 
significance.  However, similar trends towards predominance of N-methyl-(R)SAL over 
N-methyl-(S)SAL were significant in SD rats (frontal cortex), humans (cerebellar cortex) 
and C57BL/6 mice (cerebellum).   
 
Regional methylation patterns were prominent in human brain (Table 3-4).  For 
example, methylation of (S)SAL was robust in human frontal cortex and minimal in 
cerebellar cortex.  In catecholaminergic regions such as the substantia nigra, caudate, 
putamen and locus ceruleus, both enantiomers of SAL tended to exhibit higher 
concentrations than their methylated derivatives.  In PD hippocampus, methylated 
derivatives of SAL were over two-fold more concentrated than their parent SAL.  In 
contrast, this ratio was reversed in mouse and, to a lesser degree, in rat hippocampus.  
  
Ratios of TIQ and TIQ derivatives to dopamine are presented in Table 3-5.  In 
the hippocampus, all TIQ derivative/dopamine ratios were markedly higher in PD brain in 
comparison with normal human brain.  Similar findings were noted in substantia nigra 
and were statistically significant for all of the salsolinols.  For example, the 
(R)SAL/dopamine ratio was 14.9 times higher in PD brain (2.09) than in normal human 
brain (0.14).  In the putamen and caudate, TIQ derivative/dopamine ratios also tended to 
show higher values in PD brain relative to tissues from the control brains.  In contrast, 
frontal cortex, inferior olive and cerebellar cortex showed no differences in TIQ 
derivative/dopamine ratios between normal human and PD brain. 
 
 
3.3.2 Compound Stability 
 
Using 1H NMR, all compounds under study were analyzed for stability after 
thermal (22 °C, 37 °C and 60 °C) and freeze/thaw (-80 °C/22 °C) exposure.  All TIQ  
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Table 3-3.  Regional enantiomeric ratios. 
 
Brain Region (R)SAL / (S)SAL RatioNormal Human PD Human SD Rat C57BL/6 Mouse 
Frontal Cortex 2.18 (P < 0.0428) 
1.83 
(P < 0.0173) 
2.23 
(P < 0.0378) 
1.69 
(P < 0.0443) 
Striatum – – 1.14 (P < 0.3602) 
1.44 
(P < 0.3091) 
Caudate 1.01 (P < 0.9111) 
1.03 
(P < 0.7139) – – 
Putamen 1.01 (P < 0.9275) 
1.12 
(P < 0.1565) – – 
Ventral Midbrain – – 1.12 (P < 0.1793) 
1.49 
(P < 0.0806) 
Substantia Nigra 1.05 (P < 0.8101) 
1.08 
(P < 0.5574) – – 
Hippocampus 1.60 (P < 0.0301) 
0.94 
(P < 0.0942) 
1.66 
(P < 0.0456) 
1.92 
(P < 0.0186) 
Locus Ceruleus 1.16 (P < 0.6481) 
1.09 
(P < 0.2802) – – 
Inferior Olive 1.07 (P < 0.6684) 
2.27 
(P < 0.0350) – – 
Cerebellum –  – 
1.92 
(P < 0.0401) 
1.60 
(P < 0.0284) 
Cerebellar Cortex 1.37 (P < 0.0293) 
1.35 
(P < 0.0324) – – 
 
Brain Region N-Methyl-(R)SAL / N-Methyl-(S)SAL Ratio Normal Human PD Human SD Rat C57BL/6 Mouse 
Frontal Cortex 1.08 (P < 0.1098) 
1.37 
(P < 0.1056) 
1.89* 
(P < 0.0031) 
1.62 
(P < 0.0557) 
Striatum – – 1.25 (P < 0.1890) 
1.10 
(P < 0.1818) 
Caudate 0.98 (P < 0.8617) 
1.15 
(P < 0.2457) – – 
Putamen 1.01 (P < 0.8780) 
1.04 
(P < 0.8423) – – 
Ventral Midbrain – – 1.03 (P < 0.6505) 
1.10 
(P < 0.1203) 
Substantia Nigra 0.94 (P < 0.0760) 
1.10 
(P < 0.5649) – – 
Hippocampus 4.02 (P < 0.0128) 
1.41 
(P < 0.0802) 
1.38* 
(P < 0.0120) 
2.93* 
(P < 0.0097) 
Locus Ceruleus 1.13 (P < 0.3017) 
0.80* 
(P < 0.0059) – – 
Inferior Olive 3.18 (P < 0.0343) 
1.71 
(P < 0.0126) – – 
Cerebellum – – 1.59 (P < 0.0185) 
4.39* 
(P < 0.0073) 
Cerebellar Cortex 4.97* (P < 0.0005) 
4.24* 
(P < 0.0060) – – 
 
*  Significantly different from 1. 
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Table 3-4.  Regional methylation ratios. 
 
Brain Region N-methyl-(R)SAL / (R)SAL RatioNormal Human PD Human SD Rat C57BL/6 Mouse 
Frontal Cortex 1.35 (P < 0.0180) 
2.90* 
(P < 0.0061) 
3.07* 
(P < 0.0008) 
0.71 
(P < 0.4444) 
Striatum – – 0.76 (P < 0.1171) 
0.90 
(P < 0.5672) 
Caudate 0.70 (P < 0.0582) 
0.37* 
(P < 0.0009) – – 
Putamen 0.66 (P < 0.0165) 
0.92 
(P < 0.4969) – – 
Ventral Midbrain – – 1.15 (P < 0.1436) 
1.48 
(P < 0.0231) 
Substantia Nigra 0.89 (P < 0.4236) 
0.29* 
(P < 0.0005) – – 
Hippocampus 4.06 (P < 0.2324) 
3.41* 
(P < 0.0009) 
0.72 
(P < 0.0803) 
0.26* 
(P < 0.0005) 
Locus Ceruleus 1.37 (P < 0.3013) 
0.24* 
(P < 0.0005) – – 
Inferior Olive 1.94 (P < 0.0618) 
4.12 
(P < 0.1261) – – 
Cerebellum – – 1.28 (P < 0.3684) 
1.08 
(P < 0.7712) 
Cerebellar Cortex 0.24* (P < 0.0005) 
0.22* 
(P < 0.0005) – – 
 
Brain Region N-methyl-(S)SAL / (S)SAL RatioNormal Human PD Human SD Rat C57BL/6 Mouse 
Frontal Cortex 2.73* (P < 0.0009) 
4.18* 
(P < 0.0005) 
6.33* 
(P < 0.0005) 
0.70 
(P < 0.3823) 
Striatum – – 0.70 (P < 0.0821) 
1.33 
(P < 0.6129) 
Caudate 0.71* (P < 0.0013) 
0.33* 
(P < 0.0005) – – 
Putamen 0.65* (P < 0.0010) 
1.05 
(P < 0.6867) – – 
Ventral Midbrain – – 1.25 (P < 0.0362) 
1.98 
(P < 0.0197) 
Substantia Nigra 0.91 (P < 0.5284) 
0.27* 
(P < 0.0005) – – 
Hippocampus 1.78 (P < 0.4818) 
2.34* 
(P < 0.0071) 
0.80 
(P < 0.0963) 
0.17* 
(P < 0.0005) 
Locus Ceruleus 1.12 (P < 0.6173) 
0.33* 
(P < 0.0005) – – 
Inferior Olive 0.72 (P < 0.2769) 
5.09* 
(P < 0.0005) – – 
Cerebellum – – 1.64 (P < 0.2748) 
0.34* 
(P < 0.0005) 
Cerebellar Cortex 0.07* (P < 0.0005) 
0.08* 
(P < 0.0005) – – 
 
*  Significantly different from 1. 
 
 
 
 
 
 
  60
Table 3-5.  Regional TIQ derivative/dopamine ratios in human brain. 
 
Compound Ratio Caudate Putamen 
Normal Human PD Human P Value Normal Human PD Human P Value 
TIQ / Dopamine 0.00041 0.0029 0.0431 0.00088 0.0026 0.0141 
1-methyl-TIQ / Dopamine 0.00019 0.0015 0.0002* 0.00049 0.00093 0.0224 
N-methyl-TIQ / Dopamine 0.00012 0.0010 0.0141 0.00045 0.00084 0.0996 
1-benzyl-TIQ / Dopamine 0.00020 0.0014 0.0011* 0.00034 0.00043 0.5218 
(R)SAL / Dopamine 0.057 0.20 0.0082 0.14 0.23 0.0037* 
(S)SAL / Dopamine 0.11 0.20 0.1685 0.51 0.21 0.0665 
N-methyl-(R)SAL / Dopamine 0.039 0.068 0.0180 0.093 0.21 0.0010* 
N-methyl-(S)SAL / Dopamine 0.040 0.062 0.0796 0.092 0.22 0.0087 
NorSAL / Dopamine 0.0096 0.040 0.0007* 0.026 0.030 0.3751 
Compound Ratio Substantia Nigra Locus Ceruleus 
Normal Human PD Human P Value Normal Human PD Human P Value 
TIQ / Dopamine 0.0030 0.035 0.0580 0.0051 0.010 0.0322 
1-methyl-TIQ / Dopamine 0.0011 0.016 0.0583 0.0021 0.0037 0.1415 
N-methyl-TIQ / Dopamine 0.0015 0.015 0.0456 0.0019 0.0032 0.1816 
1-benzyl-TIQ / Dopamine 0.00096 0.0073 0.0062 0.0021 0.0036 0.0522 
(R)SAL / Dopamine 0.14 2.09 0.0027* 0.19 0.75 0.0081 
(S)SAL / Dopamine 0.17 1.98 0.0034* 0.19 0.69 0.0094 
N-methyl-(R)SAL / Dopamine 0.12 0.54 <0.0001* 0.20 0.17 0.3874 
N-methyl-(S)SAL / Dopamine 0.13 0.50 <0.0001* 0.18 0.21 0.4979 
NorSAL / Dopamine 0.043 0.46 0.0022* 0.039 0.085 0.0139 
Compound Ratio Frontal Cortex Hippocampus 
Normal Human PD Human P Value Normal Human PD Human P Value 
TIQ / Dopamine 1.82 1.99 0.8534 0.18 4.65 0.0015* 
1-methyl-TIQ / Dopamine 0.42 0.28 0.6216 0.04 0.77 0.0017* 
N-methyl-TIQ / Dopamine 0.66 0.22 0.3393 0.04 1.75 0.0045* 
1-benzyl-TIQ / Dopamine 0.29 0.31 0.8523 0.07 1.42 0.0035* 
(R)SAL / Dopamine 34.23 23.37 0.6612 5.16 390.17 <0.0001* 
(S)SAL / Dopamine 4.24 6.55 0.5899 1.39 408.16 <0.0001* 
N-methyl-(R)SAL / Dopamine 43.82 66.21 0.4733 6.76 1253.31 <0.0001* 
N-methyl-(S)SAL / Dopamine 38.16 53.02 0.0714 1.77 827.47 <0.0001* 
NorSAL / Dopamine 12.92 16.92 0.5243 5.35 136.82 0.0007* 
Compound Ratio Inferior Olive Cerebellar Cortex 
Normal Human PD Human P Value Normal Human PD Human P Value 
TIQ / Dopamine 0.27 0.29 0.8556 0.40 1.26 0.0087 
1-methyl-TIQ / Dopamine 0.07 0.13 0.1820 0.20 0.44 0.0497 
N-methyl-TIQ / Dopamine 0.09 0.18 0.2977 0.17 0.45 0.0060 
1-benzyl-TIQ / Dopamine 0.20 0.21 0.9294 0.21 0.39 0.0923 
(R)SAL / Dopamine 3.22 2.07 0.1523 35.01 54.47 0.3300 
(S)SAL / Dopamine 3.86 1.52 0.1204 28.17 28.98 0.9031 
N-methyl-(R)SAL / Dopamine 6.04 8.29 0.2732 7.90 9.55 0.2104 
N-methyl-(S)SAL / Dopamine 1.87 5.00 0.0099 1.60 2.44 0.1007 
NorSAL / Dopamine 9.10 22.75 0.0145 14.94 24.93 0.0129 
 
*  Significant difference between normal and PD.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  61
derivatives were resistant to any thermal-induced structural alterations, demonstrating 
the exceptional stability of these aromatic organic compounds.  For illustration, 
examination and comparison of NMR spectra for TIQ at baseline (Appendix A, Figure A-
1A) and after dry heat exposure at 60 °C for 28 days (Appendix A, Figure A-1B) 
revealed excellent stability in aqueous solution; no additional peaks or peak shifts were 
noted.  NMR spectra for all other study compounds are provided in Appendix A. 
 
 
3.4 DISCUSSION 
 
Consistent with the data presented herein, other investigators have detected 
select TIQ derivatives in rodent and human brain (Deng et al 1997; Kohno et al 1986; 
Kotake et al 1995; Makino et al 1988; Maruyama et al 1997c; Musshoff et al 2003; 
Musshoff et al 2005; Musshoff et al 2000; Musshoff et al 1999; Niwa et al 1987; Niwa et 
al 1991; Niwa et al 1989; Sasaoka et al 1988; Sjoquist et al 1982a; b; Tasaki et al 1991).  
Collectively, however, earlier studies were largely limited to individual compounds 
without adequate consideration of regional distribution, enantiomers or species 
differences.   In contrast, our work presents a comprehensive regional and quantitative 
picture of TIQ derivatives in mouse, rat, normal human and PD brain.  Although TIQ 
derivatives were detected in all brain regions analyzed across all species, (R/S)SAL and 
its methylated derivatives were detected at higher levels in regions of increased 
dopamine content in both rodents and humans.  Dopaminergic regions also revealed a 
racemic mixture of (R)- and (S)-enantiomers.  Of greatest importance, the 
concentrations of (R/S)SAL and N-methyl-(R/S)SAL were significantly lower in the 
caudate and, to a lesser degree, in the substantia nigra of PD brains in comparison with 
normal human controls.  In addition, the results of our stability experiments show that 
TIQ derivatives are not short-lived, unstable intermediates and, conceivably, could 
accumulate in catecholaminergic neuronal populations with aging. 
 
Previous results derived from homogenates of rodent whole brain are 
quantitatively similar to our own findings.  For instance, with gas chromatography-mass 
spectroscopy (GC-MS), Makino and colleagues detected TIQ in rat whole brain at a 
concentration of 4.2 ng/g (Makino et al 1988).  In similar fashion, Tasaki and colleagues 
quantified TIQ and 1-methyl-TIQ in mouse whole brain homogenate at concentrations of 
1.1 ng/g and 9.8 ng/g, respectively (Tasaki et al 1991).  Tasaki et al. also found 1-
methyl-TIQ in rat whole brain at a concentration of 1.7 ng/g.  Using GC-MS, Kohno and 
colleagues detected TIQ at concentrations ranging from 5 to 7 ng/g, and 1-methyl-TIQ at 
concentrations ranging from 1 to 3 ng/g in untreated rat brain (Kohno et al 1986).  More 
recently, Kotake and colleagues quantified 1-benzyl-TIQ in mouse brain at a 
concentration of 7.67 ng/g (Kotake et al 1995).  Our results in mice and rats indicate that 
TIQ, 1-methyl-TIQ, N-methyl TIQ and 1-benzyl-TIQ are widely distributed in brain with 
minimal regional variation in concentrations.  Since TIQ, 1-methyl-TIQ, N-methyl TIQ 
and 1-benzyl-TIQ are not concentrated in catecholaminergic pathways, it is possible that 
they arise from exogenous sources since all of these compounds readily cross the 
blood-brain barrier (Song et al 2006).   Alternatively, these compounds may arise from 
endogenous synthetic pathways that do not require catecholamines.    
 
 In contrast to TIQ, 1-methyl-TIQ, N-methyl TIQ and 1-benzyl-TIQ, regional 
quantification of (R)SAL, (S)SAL, and their methylated derivatives in rodent brain points 
out an important role for endogenous synthetic pathways.  Overall, our results 
demonstrate elevated concentrations of (R)SAL, (S)SAL and their methylated derivatives 
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in the nigrostriatal pathway of rodent brain.   Furthermore, generalized trends towards 
predominance of the (R)-enantiomer of SAL and its methylated derivative were noted in 
cerebral cortex, cerebellum and hippocampus.  As depicted in Figure 3-2, (R)-
enantiomeric excess could be the manifestation of stereoselective enzymatic synthesis 
via salsolinol synthase, coupled with low-level racemic Pictet-Spengler condensation, in 
areas with lower overall dopamine concentrations.  In areas with higher dopamine 
content, negligible enantiomeric excess was observed, suggesting a greater contribution 
from the Pictet-Spengler reaction.  These interpretations are supported by recent 
evidence of a dose-dependent increase in striatal (R/S)SAL levels and a concomitant 
decrease in striatal dopamine content upon intracerebral infusion of acetaldehyde in 
freely-moving rats (Wang et al 2007).   
 
 Species differences in the regional concentrations of TIQ derivatives among 
rodents were most prominent in the striatum where the concentrations of N-methyl-
(R)SAL and N-methyl-(S)SAL were much higher in mice than rats despite the absence of 
significant differences in either dopamine or (R/S)SAL content in this region.  The 
concentrations of ventral midbrain NorSAL and hippocampal (R)SAL were also elevated 
in the mouse as compared to the rat.  In contrast, the concentrations of dopamine and 
N-methyl-(S)SAL were higher in the ventral midbrains from rats compared to mice.  
Although this mixture of observations could be attributed to a multitude of factors, their 
magnitude suggests the presence of genetic contributions to endogenous synthesis and 
cellular metabolism of these compounds.   
 
 In humans, previous studies have focused on SAL and SAL derivatives in the 
context of alcoholism and, to a lesser degree, PD.  Comparatively little effort has been 
placed on TIQ and its methylated and benzylated derivatives.  Using GC-MS, TIQ, 1-
methyl-TIQ and N-methyl-TIQ have been detected in normal human and PD brain.  In a 
single PD case, TIQ was quantified in the frontal cortex at 10 ng/g (Niwa et al 1987).  
Analysis of frontal cortex from a single normal human brain detected TIQ at less than 1 
ng/g.  This same study also quantified N-methyl-TIQ in frontal cortex at 2 ng/g in PD 
brain and 3 ng/g in control brain whereas 1-methyl-TIQ was reportedly undetectable in 
both normal human and PD brain.  In a subsequent publication from the same group, 
TIQ was detected in the occipital cortex of a single PD brain at 7 ng/g (Niwa et al 1989).  
As was the case for rodents, we found that TIQ, 1-methyl-TIQ, N-methyl-TIQ and 1-
benzyl-TIQ are widely distributed in brain with no significant concentration differences 
among regions or between normal human and PD brain.  
  
 The discovery that (R/S)SAL can be synthesized from acetaldehyde and 
dopamine under physiological conditions in both plants and animals (Schöpf & Bayerle 
1934) stimulated a great deal of speculation and research regarding the potential role of 
SAL derivates in human diseases.  Seminal GC-MS studies by Sjoquist and colleagues 
documented (R/S)SAL and N-methyl-(R/S)SAL in postmortem caudate (5 to 23 ng/g and 
5 to 10 ng/g, respectively), putamen (9 to 35 ng/g and 6 to 12 ng/g, respectively), 
hippocampus (13 to 35 ng/g and 2 to 5 ng/g, respectively), and frontal cortex (1 to 32 
ng/g and 2 to 5 ng/g, respectively) in alcoholic (N = 5) and control (N = 5) human brain, 
and proposed a positive correlation between endogenous SAL formation and regional 
dopamine content (Sjoquist et al 1982a; b).  In subsequent work, liquid chromatography 
was employed for the detection of (R/S)SAL in the caudate (39 ng/g) and putamen (37 
ng/g) of a single normal human brain (Sasaoka et al 1988).  Semi-quantitative GC-MS 
analysis of N-methyl-(R/S)SAL in PD (N = 6) and normal human (N = 5) frontal cortex 
found an “estimated” concentration of 1 ng/g for both groups (Niwa et al 1991).  More 
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recently, Deng and colleagues used enantiomeric-selective HPLC to quantify (R)SAL 
and (S)SAL, as well as N-methyl-(R)SAL and N-methyl-(S)SAL in “gray matter” from a 
single normal human brain (Deng et al 1997).  While this analysis failed to detect either 
(S)SAL or N-methyl-(S)SAL, (R)SAL and N-methyl-(R)SAL were quantified at 12 ng/g 
and 17 ng/g, respectively.  In similar fashion, Maruyama and colleagues quantified 
(R)SAL, (S)SAL, N-methyl-(R)SAL and N-methyl-(S)SAL in the fronal cortex, caudate, 
putamen and substantia nigra of normal human brain (N = 10) (Maruyama et al 1997c).  
Once again, (S)-enantiomers were not detected, while concentrations of (R)SAL ranged 
from 6 ng/g in the putamen to 24 ng/g in the frontal cortex.  The content of N-methyl-
(R)SAL ranged from 1 ng/g in the frontal cortex to 20 ng/g in the putamen.  These results 
should be interpreted with caution, however, since complete absence of the (S)-
enantiomers of SAL and N-methyl-SAL in brain is not compatible with our own findings 
and unlikely based upon the (1) presence of (S)SAL in foods, (2) non-enzymatic, 
racemic SAL synthesis via the Pictet-Spengler condensation reaction, and (3) studies by 
Musshoff and co-workers outlined below  (Cohen & Collins 1970; Deng et al 1997; 
Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 2000; Musshoff et al 1999; 
Schöpf & Bayerle 1934). 
 
 From the late 1990s to 2005, Musshoff and colleagues established a large 
collection of postmortem alcoholic (N = 44) and control (N = 47) human brains (Musshoff 
et al 2003; Musshoff et al 2005; Musshoff et al 2000; Musshoff et al 1999).   Using SPE 
and GC-MS, (R)SAL, (S)SAL and NorSAL content was determined in several regions of 
the brain.  (R)SAL was detected in the caudate nuclei of both alcoholics and controls (17 
ng/g and 21 ng/g, respectively), as was (S)SAL (5 ng/g and 5 ng/g, respectively) and 
NorSAL (12 ng/g and 40 ng/g, respectively).  In the putamen, the content of (R)SAL in 
alcoholics and controls was 13 ng/g and 25 ng/g, respectively; (S)SAL was quantified at 
5 ng/g for both groups; NorSAL was detected at 16 ng/g and 30 ng/g, respectively.  In 
the substantia nigra, the content of (R)SAL in control subjects was 29 ng/g; (S)SAL was 
quantified at 19 ng/g; NorSAL was detected at 12 ng/g.  No data from the substantia 
nigra of alcoholic subjects was presented.  Furthermore, (R)SAL, (S)SAL and NorSAL 
were not detected in the hippocampus, frontal cortex or cerebellum.   
  
 As is readily apparent, considerable variability and discrepancies are present 
among previous studies of regional SAL derivative content in PD, alcoholic and normal 
human brain.  In general, however, our findings are qualitatively similar to those of 
Musshoff and co-workers (Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 
2000; Musshoff et al 1999) although the absolute concentrations for brain (R)SAL, 
(S)SAL and their derivatives determined with HPLC-EC are somewhat higher than 
previous reports generated with GC-MS.  These concentration differences may be 
attributed to one or more factors.  First of all, our control and PD subjects were 
approximately 70 years of age whereas Musshoff and colleagues used postmortem 
tissue from much younger subjects (e.g., 46.5 years for alcoholics and 37.0 years for 
controls).   Second, the postmortem interval was less than 6 hrs in our study but was 
extended to 144 hrs in the studies by Musshoff and colleagues.  Lastly, most studies of 
SAL and SAL derivatives in human brain utilized GC-MS rather than HPLC-EC.  Relative 
to HPLC-EC, GC-MS is associated with reduced compound retrieval since sample 
preparation requires multiple organic extractions and compound derivatization prior to 
analysis.  For example, in 47 control subjects, Musshoff’s group reported mean putamen 
dopamine concentration as 1305 ng/g.  In contrast, Konradi and colleagues reported 
mean putamen dopamine concentrations of 3000 to 7000 ng/g using HPLC analysis in a 
cohort of 24 normal human subjects (Konradi et al 1992).  Our own extraction protocol, 
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quantification methods and results (mean putamen dopamine concentration of 4142 
ng/g) are similar to those of Konradi et al. (Konradi et al 1992).  Thus, it is clear that 
tissue preparation and analyte extraction for GC-MS is much less efficient than the 
straightforward HPLC extraction procedures used in our study and the comparison of 
dopamine concentration can be extrapolated to analysis of TIQ derivatives.  As in 
rodents, (R/S)SAL and N-methyl-(R/S)SAL concentrations were highest in dopaminergic 
regions (caudate, putamen, substantia nigra) of both normal and PD human brain.  Also 
similar to rodents, general trends towards enantiomeric excess of (R)SAL and N-methyl-
(R)SAL were found in cerebral cortex, cerebellar cortex and hippocampus.   
 
 In comparison to human controls, the concentrations of (R)SAL, (S)SAL, N-
methyl-(R)SAL and N-methyl-(S)SAL were significantly decreased in PD caudate and 
the concentration of N-methyl-(R)SAL was significantly decreased in PD substantia 
nigra.  With correction for multiple comparisons, the mean differences in SAL and SAL 
derivative concentrations between PD and control brain in “catecholamingeric regions” of 
the brain (substantia nigra, caudate, putamen and locus ceruleus) did not reach 
statistical significance.  Among those compounds showing concentration differences 
between control and PD brain, N-methyl-(R)SAL deserves particular attention.  Although 
the neurotoxicity of 1-benzyl-TIQ (Shavali & Ebadi 2003) has been clearly documented 
and (R/S)SAL, NorSAL and N-methyl-NorSAL are associated with apoptosis in vitro 
(Maruyama et al 1997a; Storch et al 2000), current data suggests that N-methyl-(R)SAL 
may be the most potent TIQ neurotoxin (Naoi et al 2002).  N-methyl-(R)SAL has 
exhibited marked toxicity in cultured rat and human dopaminergic neurons (Akao et al 
1999; Maruyama et al 2001; Naoi et al 2000; Naoi et al 1997), inducing apoptosis in 
100% of dopaminergic human neuroblastoma SH-SY5Y cells after exposure (Maruyama 
et al 2001; Maruyama et al 1997a).  In the same study, (R/S)SAL and N-methyl-(S)SAL 
induced apoptotic cell death in only 10% and 11% of SH-SY5Y cells, respectively.   
When coupled with previous toxicity studies, our findings suggest that (R/S)SAL and N-
methyl-(R/S)SAL are derived from dopamine and concentrated within dopaminergic 
neurons.  At some critical concentration, these TIQ derivatives may contribute to the 
apoptotic cell death of dopaminergic neurons in PD and are released into the interstitial 
fluid.  In support of this concept, Moser and Kömpf detected both (R/S)SAL and N-
methyl-NorSAL in the lumbar cerebrospinal fluid of PD patients (Moser & Kompf 1992).  
Furthermore, the CSF content of N-methyl-(R)SAL is higher in newly diagnosed, 
untreated PD patients compared to normal human controls (Maruyama et al 1999). 
 
 In PD, the most prominent neurodegenerative cell death is seen in the 
catecholaminergic neurons of the SNpc (dopaminergic) and locus ceruleus 
(noradrenergic).  Accordingly, the most straightforward explanation for the relatively 
selective cell death seen in PD is the accumulation of neurotoxins derived from 
catecholamines.  TIQs have been shown to inhibit complex I of the respiratory chain 
(McNaught et al 1995b) and are one class of neurotoxins that can be derived from 
catecholamines.  Several TIQs can cross the blood-brain barrier and, in the peripheral 
sympathetic nervous system, certain TIQs are taken up by the norepinephrine 
transporter.  Thus, TIQs may accumulate in dopaminergic and noradrenergic systems 
with aging via a combination of exogenous and endogenous pathways.  Furthermore, in 
comparison with normal human brain, there may be greater production, accumulation or 
persistence of TIQ derivatives, particularly the salsolinols, in PD brain.  Aggregate 
accumulation of TIQs and other neurotoxic derivatives of dopamine and norepinephrine 
may reach critical levels in aged individuals and contribute to catecholaminergic cell 
death in PD.  
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 Using 1H NMR spectroscopy, all TIQ derivatives utilized in this study were fully 
stable at 60 C for 28 days in aqueous solution.  This finding is most readily attributable 
to the aromaticity and general planar structure of the TIQ family of compounds (Martin & 
Gudzinowicz 1963).  In the context of PD, the relatively high thermal stability of TIQ 
derivatives permits consideration of environmental sources, such as foods and well 
water. 
 
 Catecholamines, such as dopamine and norepinephrine, are typically 
metabolized in the brain via the enzymatic action of MAO and catechol-O-methyl 
transferase (COMT).  Likewise, several studies describe the COMT mono-O-methylation 
pattern of SAL in intact rat brain and suggest that delayed O-methylation in 
dopaminergic regions may be a result of active uptake and storage mechanisms in these 
areas (Bail et al 1980; Collins & Origitano 1983; Origitano & Collins 1980).  Furthermore, 
similar methylation patterns from multiple brain regions suggest that a ubiquitous COMT 
enzyme is responsible for catechol TIQ derivative metabolism (Collins & Origitano 1983).  
In contrast, however, TIQ and many of its derivatives (1-methyl-TIQ, N-methyl-TIQ, 
(R/S)SAL, N-methyl-(R/S)SAL and N-methyl-NorSAL) do not appear to be substrates for 
either MAO-A- or MAO-B (Bembenek et al 1990).  Instead, isoquinolines and TIQs show 
selective inhibition of either MAO-A or MAO-B (Bembenek et al 1990; Collins et al 1973; 
Dostert et al 1989; Meyerson et al 1976; Minami et al 1993; Thull et al 1995; Yamada 
1971).  Based on the high thermal stability of TIQ derivatives, it is possible that the major 
pathway for TIQ metabolism in vivo is enzymatic via COMT.  It should be noted, 
however, that other catecholamine metabolizing enzymes, such as the phenol 
sulfotransferases (Axelrod et al 1959; Levy et al 1975; Pacifici et al 1994; Richter 1940; 
Young et al 1984), and non-enzymatic pathways may contribute the 
metabolism/degradation of TIQ derivatives. 
 
 The widespread pathology in PD was first emphasized in seminal work published 
by Den Hartog Jager and Bethlem in 1960.  In their study, Lewy bodies, the pathological 
hallmark of PD, were detected in the sympathetic ganglia in five of six PD cases (Den 
Hartog Jager & Bethlem 1960).  In the CNS, there were Lewy bodies in the SNpc, locus 
ceruleus, hypothalamus and several brainstem nuclei.  The marked topological 
prevalence of Lewy bodies for catecholaminergic cell groups is compatible with the 
hypotheses that the accumulation of neurotoxic by-products of catecholamines, such at 
salsolinols, may play a role in the etiopathogenesis of PD. 
 
 
3.5 CONCLUSIONS 
 
Several members of the TIQ family of monoamine alkaloids can be formed from 
dopamine or its oxidized metabolites and may be involved in the pathogenesis of 
monoaminergic cell death in PD.  Using enantiomeric-selective HPLC-EC and LC-
MS/MS, the regional concentrations of several TIQ derivatives, including salsolinols, 
were determined in mouse, rat, normal human and PD brain.  TIQ derivatives were 
detected in all regions subjected to analysis.  In general, salsolinols were present at 
higher concentrations than TIQ and its benzyl and methyl derivatives, especially in 
human brain.  Moreover, salsolinols were concentrated in areas with increased 
dopamine synthesis and turnover such as the ventral midbrain and striatum, 
respectively.  A possible consequence of nigrostriatal dopaminergic cell death, 
significantly lower levels of (R)salsolinol, (S)salsolinol, N-methyl-(R)salsolinol and  
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N-methyl-(S)salsolinol were found in the caudate nuclei of PD in comparison with normal 
human brain.  This data supports the hypothesis of endogenous synthesis of salsolinols 
and provides evidence for their accumulation in catecholaminergic neurons. 
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CHAPTER 4.  ANALYSIS OF TETRAHYDROISOQUINOLINE DERIVATIVES IN 
COMMON FRUITS AND VEGETABLES AND THEIR ACCUMULATION IN BRAIN 
OVER TIME 
 
 
4.1 INTRODUCTION 
 
The heterocyclic alkaloids are a relatively small group of structurally related 
compounds composed of the isoquinolines, derived ultimately from phenylalanine, and 
the -carbolines derived from tryptophan or other indolic amines (Cohen & Collins 1970).  
In plants, these heterocyclic compounds arise as 1,2,3,4-tetrahydogenated derivatives 
(such as the TIQs) from non-enzymatic condensations of a variety of aldehydes or -
keto acids with the above amino acids or their amine products (Collins 2002).  The initial 
condensation step, Schiff base or imine formation, is quite ubiquitous in nature under 
neutral conditions and is found in reactions such as vitamin B6-dependent enzyme 
mechanisms and the addition of glucose molecues to various proteins.  Not surprisingly, 
various TIQ derivatives have been detected in several common food sources derived 
from plants such as bananas, cocoa, flour, whiskeky, wine and beer (Deng et al 1997; 
Makino et al 1988; Makino et al 1990; Niwa et al 1989).  TIQ derivatives have also been 
detected in protein-based foods such as milk, cheese, eggs, and even beef and fish, 
suggesting that these compounds may be taken up via dietary sources and stored in 
animal tissues (Makino et al 1988; Niwa et al 1989).           
 
The detection of various TIQ derivatives in the brain, their propensity to cause 
cell death in neurons and their ability to cross the blood-brain barrier make them 
interesting candidates for an environmental or exogenous component of PD 
pathogenesis.  Thus, diet may play an important role in the etiology of PD by altering the 
oxidative balance in the brain and by serving as a vehicle for environmental neurotoxins, 
such as the TIQs.  Although genetic components may be important in determining 
susceptibility to early onset PD, most idiopathic PD cases are nonfamilial and most likely 
involve environmental risk factors (Tanner et al 1987; Tanner et al 1999).  Potential roles 
of foods and nutrients in determining PD risk have been investigated to some extent.  
However, the results are largely inconsistent.  Elevated risk of PD has been associated 
with higher intake of total energy, dietary fats, carbohydrates, monosaccharides, 
disaccharides, chocolates, iron and lutein; reduced risk of PD has been associated with 
higher intake of potatoes, nuts and foods containing niacin (Anderson et al 1999; Davies 
et al 1994; Fall et al 1999; Hellenbrand et al 1996a; Hellenbrand et al 1996b; Johnson et 
al 1999; Logroscino et al 1996; Logroscino et al 1998).  
 
In this regard, liftetime dietary patterns may be revelant to the accumulation of 
dietary toxins and thus overall disease risk.  Principal components analysis and diet-
quality scores are two commonly used dietary pattern approaches.  Principal 
components analysis is a data-driven (a posteriori) method that describes the eating 
patterns of a certain population.  It is based on the assumption that between-person 
variations can, in part, be explained by underlying unmeasured variables.  Correlations 
between the consumption of different food items in the study population are used to 
identify these underlying factors or patterns, and individuals are then ranked in terms of 
how closely they conform to the total pattern (Hu 2002; Jacques & Tucker 2001). 
 
 Although TIQ derivatives have been detected in a subset of foods and 
beverages, this data is fundamentally disorganized and incomplete.  Moreover, previous 
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studies have neglected much more commonly consumed plant-based food sources such 
as fresh fruits and vegetables.  In this study, TIQ derivatives were quantified in the most 
commonly consumed fruits and vegetables in the United States using enantiomeric-
selective HPLC-EC and LC-MS/MS.  In addition, a dietary questionnaire was developed 
and administered to a population of PD patients and controls to determine if the risk of 
disease is associated with lifetime consumption of one or more foods items that may 
concentrate several TIQ derivatives.  Finally, in an effort to explore the hypothesis of 
lifetime accumulation of TIQ derivatives in the brain, various regions of the rat brain were 
analyzed for TIQ content at ages ranging from 1 day to 2 years.  
 
 
4.2 MATERIALS AND METHODS 
 
 
4.2.1 Chemicals 
 
Ethylenediaminetetraacetic acid (EDTA), formaldehyde, ortho-phosphoric acid, 
perchloric acid, sodium acetate, sodium bisulfite, sodium cyanoborohydride, 
triethylamine (TEA), tetramethylsilane (TMS), trifluoroacetic acid, dopamine, DOPAC, 
HVA, and 3,4-dihydroxybenzylamine (DHBA) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  Deuteriated dimethylsulfoxide (DMSO-d6) was purchased from 
Cambridge Isotope Labs (Woburn, MA, USA).  TIQ, 1-benzyl-TIQ, (R/S)salsolinol, and 
norsalsolinol were purchased from Acros Organics (Geel, Belgium).  1-methyl-TIQ and 
N-methyl-TIQ were purchased from AsisChem Inc. (Cambridge, MA, USA). Sodium 
octylsulphonate (SOS) and monobasic anhydrous sodium dihydrogen phosphate used 
in mobile phase preparation were purchased from Fluka Chemie (Buchs, Switzerland).  
HPLC grade water, acetonitrile, and β-cyclodextrin were obtained from Fisher Scientific 
(Hampton, NH, USA). 
 
 
4.2.2 Synthesis of N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol 
 
The tertiary amines N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol were 
prepared from their respective secondary amines norsalsolinol and (R/S)salsolinol by 
reductive methylation in the presence of formaldehyde and sodium cyanoborohydride.  
The reaction mixtures contained 0.5 M of the amine, 2.5 M formaldehyde, 0.2 M 
sodium acetate, and 1 M sodium cyanoborohydride at pH 5.  The reaction mixture was 
incubated at room temperature overnight under nitrogen in the dark.  The sample was 
clarified by centrifugation and the clear solution was acidified with HCl to pH 0.1 to 
decompose unreacted cyanoborohydride.  The solvent was evaporated and the 
product was extracted from the residue with isopropyl alcohol.  Evaporation of the 
solvent and extraction of the residue was repeated twice.  The final product was stored 
as a solution in isopropyl alcohol at -20 C. 
 
 
4.2.3 Procurement and Preparation of Fresh Fruits and Vegetables 
 
Fresh fruits (N = 20) and vegetables (N = 20) representing those most 
commonly consumed in the US were obtained in August 2007 (Table 4-1).  Fresh 
products were bought on the same day at three Memphis, TN locations: an outlet of a 
nationwide supermarket chain, a local grocery and an open-air market.  A  
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Table 4-1.  Plant products utilized for analysis. 
 
Common Name Family Common Family Genus and Species 
Kiwi Fruit Actinidiaceae Actinidia Family Actinidia chinensis 
Mushroom Agaricaceae Mushroom Family Agaricus bisporus 
Green Onion Amaryllidaceae Amaryllis Family Allium schoenoprasum 
Onion Amaryllidaceae Amaryllis Family Allium cepa 
Carrot Apiaceae Carrot Family Daucus carota 
Celery Apiaceae Carrot Family Apium graveolens 
Iceberg Lettuce Asteraceae Sunflower Family Lactuca sativa 
Leaf Lettuce Asteraceae Sunflower Family Lactuca sativa romana 
Broccoli Brassicaceae Mustard Family Brassica oleracea italica 
Cauliflower Brassicaceae Mustard Family Brassica oleracea 
Green Cabbage Brassicaceae Mustard Family Brassica oleracea 
Radish Brassicaceae Mustard Family Raphanus sativus 
Pineapple Bromeliaceae Pineapple Family Ananas comosus 
Sweet Potato Convolvulaceae Morning Glory Family Ipomoea batatas 
Cantaloupe Cucurbitaceae Gourd Family Cucumis melon 
Cucumber Cucurbitaceae Gourd Family Cucurbita sativus 
Honeydew Melon Cucurbitaceae Gourd Family Cucumis Inodorus 
Watermelon Cucurbitaceae Gourd Family Citrullus lanatus 
Yellow Squash Cucurbitaceae Gourd Family Cucurbita pepo 
Green Bean Fabaceae Pea Family Phaseolus vulgaris 
Avocado Lauraceae Laurel Family Persea americana 
Asparagus Liliaceae Lily Family Asparagus officinalis 
Banana Musaceae Banana Family Musa paradisiaca 
Yellow Corn Poaceae Grass Family Zea mays 
Apple Rosaceae Rose Family Malus sylvestris 
Cherry Rosaceae Rose Family Prunus avium 
Nectarine Rosaceae Rose Family Prunus persica 
Peach Rosaceae Rose Family Prunus persica 
Pear Rosaceae Rose Family Pyrus communis 
Plum Rosaceae Rose Family Prunus domestica 
Strawberry Rosaceae Rose Family Fragaria ananassa 
Grapefruit Rutaceae Rue Family Citrus paradisi 
Lemon Rutaceae Rue Family Citrus limon 
Lime Rutaceae Rue Family Citrus aurantiifolia 
Orange Rutaceae Rue Family Citrus sinensis 
Tangerine Rutaceae Rue Family Citrus nobilis 
Bell Pepper Solanaceae Nightshade Family Cpasicum annuum 
Potato Solanaceae Nightshade Family Solanum tuberosum 
Tomato Solanaceae Nightshade Family Lycopersicon esculentum
Grape Vitaceae Grape Family Vitis labrusca 
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minimum of 1 kg (or 0.5 kg for very small foods such as berries) or at least three units 
was sampled at each location.  Fresh fruits and vegetables were collected and 
transported to the laboratory in clean polyethylene bags within 1 day.  Each sample 
was identified clearly and indelibly by allocating a unique identification number.    After 
removal of nonedible parts, samples were homogenized in 10 ml of ice-cold dissolution 
buffer (0.1 M perchloric acid, 0.1 mM sodium bisulfite, and 0.1 mM EDTA) per 1 g wet 
weight.  Homogenates were then centrifuged at 20,000 X g for 25 min at 4 C.  
Supernatants were filtered through 0.22 µm pore size PVDF membrane filters.  
Chopping and blending of plant material was performed to ensure that the samples 
were homogeneous enough so that subsampling variability would be acceptable and 
the extracts were truly representative of the corresponding samples as a whole.  
 
Due to the high organic content of the supernatants, solid phase extraction (SPE) 
was performed on all samples prior to LC-MS/MS analysis.  A Waters Oasis HLB 
extraction cartridge (1 ml/30 mg; Waters Corporation, Milford, MA, USA) was 
conditioned with 1 ml of methanol followed by a 1 ml wash with water.  The supernatant 
was loaded onto the cartridge and washed with 2 ml deionized water and 1 ml 5% (v/v) 
acetonitrile with 0.1% (v/v) trifluoroacetic acid.  Analytes were eluted from the cartridge 
with 1 ml of acetonitrile with 0.1% (v/v) trifluoroacetic acid.  The final solution was 
evaporated to dryness and the residue was reconstituted in 10 ml of 10% (v/v) 
acetonitrile. 
 
 
4.2.4 Rodent CNS Sample Preparation 
 
Male rats (N = 40, 5 rats per age group, standard housing and feeding) in age 
groups of 1 day, 14 days, 30 days, 60 days,  90 days, 365 days, 547 days and 730 
days (Sprague-Dawley strain, Harlan Sprague Dawley, Inc., Indianapolis, IN, USA) 
were anesthetized with aerosolized isoflurane and fresh brain samples were obtained 
and partitioned using a dissecting microscope.  Tissue samples (0.1-0.2 g) of striatum, 
ventral midbrain, frontal cerebral cortex, cerebellar cortex, and hippocampus were 
weighed and then homogenized in 100 µl of ice-cold dissolution buffer (0.1 M 
perchloric acid, 0.1 mM sodium bisulfite, and 0.1 mM EDTA) per 10 mg wet weight.  All 
homogenates were centrifuged at 20,000 g for 25 min at 4 C.  Supernatants were 
filtered through 0.22 µm pore size polyvinylidene fluoride (PVDF) syringe-driven 
membrane filters (Millipore Corp., Bedford, MA, USA) and immediately frozen and 
stored at -80 C until the time of analysis.  As above, SPE was performed on all 
samples prior to LC-MS/MS analysis.   
   
 
4.2.5 HPLC-EC Analysis 
 
 
4.2.5.1 Chromatography Standard Preparation   
 
Primary stock standard solutions were prepared by dissolving 10 mg of 
(R/S)SAL, N-methyl-(R/S)SAL, NorSAL, dopamine, DOPAC, and HVA in 25 ml of 
dissolution buffer.  These concentrates were then divided into 1 ml aliquots, frozen, 
stored at -80 C, and thawed prior to use at 4 C.  Working standards in the nM range 
were freshly prepared prior to each assay.  Standard curves employed for analyte 
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quantification were generated with a DHBA internal standard.  The relationship between 
concentration and relative response was linear over two orders of magnitude (sample 
correlation coefficient > 0.98), with an overall electrochemical sensitivity of 0.001 µA.  
With HPLC-EC, the limit of quantification for all analytes was 0.7 ng/ml.  
 
 
4.2.5.2 Mobile Phase Preparation   
 
A stock buffer solution containing 75 mM monobasic sodium dihydrogen 
phosphate, 2 mM SOS, 25 µM EDTA, 20 mM β-cyclodextrin, and 100 µl of TEA was 
prepared in 1800 ml of HPLC grade water.  To prepare the mobile phase, this solution 
was then mixed with 200 ml of HPLC grade acetonitrile and buffered to pH 3.0 using 
concentrated ortho-phosphoric acid.  The mobile phase was stored at room temperature 
for no more than 2 days, filtered through a 0.20 µm pore size white nylon filter 
membrane (Millipore Corp.), and degassed under vacuum for 30 min prior to use.  The 
chiral mobile phase additive β-cyclodextrin is a cyclic oligosaccharide which 
preferentially binds to one face of an enantiomer.  This binding changes the hydrogen-
bonding patterns of the enantiomers and allows for their separation using a standard 
reverse-phase column.   
 
 
4.2.5.3 Liquid Chromatography   
 
HPLC-EC analysis was performed with an ESA Model 5600A CoulArray® system 
(ESA Inc., Chemlsford, MA, USA), equipped with Shimadzu Model DGU-14A on-line 
degassing unit (Shimadzu Scientific Instruments, Columbia, MD, USA), an ESA Model 
582 pump, and an ESA Model 542 refrigerated autosampler.  The detection system 
consisted of three coulometric array modules, each containing four electrochemical 
detector cells.  Electrode potentials were selected over the range of 0 to +700 mV, with a 
50 mV increment against palladium electrodes.  Chromatographic separation was 
achieved by auto-injecting 30 µl sample aliquots at 5 C onto a MetaChem Intersil 
(MetaChem Technologies, Torrance, CA, USA) reversed-phase C18 column (5 µm 
particle size, 250X4.6 mm I.D) with an ESA Hypersil C18 pre-column (5 µm particle size, 
7.5X4.6 mm I.D.) [Fig. 3A].  A mobile phase flow rate of 1.25 ml/min and analysis time of 
45 min were used for all experiments.  System control and data acquisition/processing 
were performed using ESA CoulArray software (version 1.02).  All samples were 
processed in technical triplicate with median values used for analysis. 
 
 
4.2.6 LC-MS/MS Analysis 
 
 
4.2.6.1 Chromatography Standard Preparation   
 
Primary stock standard solutions were prepared by dissolving 10 mg of TIQ, 1-
methyl-TIQ, N-methyl-TIQ, and 1-benzyl-TIQ in 25 ml of a mixture of 50% water and 
50% acetonitrile.  These concentrates were then divided into 1 ml aliquots and stored at 
-80 C.  Working standards in the nM range were freshly prepared prior to each assay.  
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4.2.6.2 Liquid Chromatography  
 
LC-MS/MS analysis was performed using an Agilent model 1100 series HPLC 
system equipped with a Bruker Esquire-LC ion trap tandem mass selective detector 
(Bruker Daltronics Inc., Billerica, MA, USA), a Model 1327A temperature controlled 
autosampler, a Model 1316A temperature controlled column compartment, and a Model 
G1312A binary pump with Model G1322A solvent degassing module, and a Model 
G1314A variable wavelength UV–vis detector (Agilent Technologies, Santa Clara, CA).  
Ultraviolet absorbance monitoring was performed at 220 nm.  Separation was achieved 
by auto-injecting 10 µl sample aliquots at 5 C onto a Thermo Hypersil-Keystone 
reversed-phase C18 column (5 μm; 50 x 2.1 mm I.D.; Thermo Fisher Scientific, Waltham, 
MA, USA) in combination with a C18 Hypersil guard column (10 x 2.1 mm I.D.).  A binary 
mobile phase flow rate of 0.7 ml/min and analysis time of 25 min was utilized.  Mobile 
phase A consisted of water with 0.1% formic acid and mobile phase B consisted of 
acetonitrile with 0.1% formic acid.  The following mobile phase gradient was used: 0 min 
A/B = 95:5, 5 min A/B = 70:30, 10 min A/B = 50:50, 15 min A/B = 70:30, 20 min A/B = 
95:5.  The column was given a 5 min post-run period to allow for re-equilibration.  
System control and data acquisition/processing were performed using ChemStation 
software revision A.08.03 for LC-MS systems (Agilent Technologies).   
 
 
4.2.6.3 Ion Trap Tandem Mass Spectrometry   
 
Full-scan mode was used to acquire mass spectra, precursor ions, and product 
ions.  EsquireControl software version 6.16 (Bruker Daltronics Inc.) was employed for 
control of all mass spectrometric conditions.  The mass spectrometer was equipped with 
a heated capillary interface and an electrospray ionization (ESI) source, operating in 
positive ion mode.  The ESI source and MS/MS parameters were automatically 
optimized.  Spray needle voltage was 4.0 kV and capillary temperature was set to      
220 C.  Sheath and auxiliary nitrogen gas flow were set to 40 and 0 psi, respectively.  
Automatic gain control was utilized with a maximum isolation time of 300 ms.  A relative 
collision energy of 33% was used for all analyses.  The product ions producing the 
highest intensity were used for quantification to increase analytical sensitivity and 
selectivity in LC-MS/MS mode.  Quantification was based on detector response, defined 
as the ratio of the base peak ion of interest to the base peak ion of the standard 
compound.  The relationship between concentration and relative response was linear 
over two orders of magnitude (sample correlation coefficient > 0.998) for the MS/MS 
procedure.  All samples were processed in technical triplicate with median values used 
for statistical analyses.  With LC-MS/MS, 0.3 ng/ml was the limit of quantification for all 
analytes.   
  
 
4.2.7 Parkinson Disease Lifetime Food Intake Questionnaire 
 
 
4.2.7.1 Instrument Development   
 
As an extension of the results from chromatographic analysis of TIQ derivatives 
in fresh fruits and vegetables, a lifetime food-serving-intake questionnaire was 
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developed to assess the eating habits of PD patients based on servings of specific 
individual foods (i.e. the top 20 most commonly consumed fruits and vegetables in the 
US) and to search for correlations between the intake of certain fruits and vegetables 
and the development of idiopathic PD.  This survey (see Appendix B), which requires 
approximately 30-45 min to complete, quantifies the frequency and servings of specific 
raw or cooked fruits and vegetables consumed over specific decades of a participant’s 
life, as well as overall lifetime intake.  Data was obtained from PD patients and age- and 
gender-matched controls over a period of three years.  Patients with a diagnosis of PD 
were recruited from clinics and hospitals in the greater Memphis, TN area. 
 
 
4.2.7.2 Instrument Statistical Analysis   
 
Multivariate analysis was performed via orthogonal linear transformation and 
determination of variance along principle axes (principal component analysis).  The 
principal axis method was used to extract all components, followed by a varimax 
rotation.  By convention, questionnaire items with eigenvalues greater than 1.000 were 
considered principal components of the survey.  Confidence intervals (95%) were 
calculated for each level of intake (0-20 yrs, 21-40 yrs, 41-60 yrs, and >60 yrs) and for 
average monthly lifetime intake for each food item. 
   
 
4.2.7.3 Reproducibility and Validity   
 
Reproducibility and validity were evaluated using methods common to dietary 
assessment questionnaires (Block & Hartman 1989; Buzzard et al 2001; Dennison et al 
2000; Hoelscher et al 2003).  Reproducibility (or reliability) is the ability of an instrument 
to produce the same estimate on two separate occasions, assuming no interim changes.  
Validity can be defined as the ability of an instrument to accurately measure its intended 
subject.  Cross-sectional reproducibility was determined using a re-administration of the 
questionnaire to 20 PD and 20 control subjects at a 6 month interval.  Cross-sectional 
validity was determined using a simple one month food diary completed by 20 PD and 
20 control subjects.  Reproducibility and validity was assessed by calculating Spearman 
rank order correlation coefficients and Cohen kappa () statistics.  Wilcoxon matched-
pair signed rank tests were used to determine if a significant difference existed between 
food intakes reported at the first and second questionnaire administration (for 
reproducibility) and between reported questionnaire intake values and food diary recall 
values for specific foods under each subject’s appropriate age category (for validation). 
  
 
4.3 RESULTS 
 
 
4.3.1 TIQ Derivatives in Common Fruits and Vegetables 
 
As shown in Tables 4-2 and 4-3, TIQ derivatives were detected in all fruits and 
vegetables subjected to analysis.  As shown in Table 4-4 and 4-5, derivatives of TIQ 
(TIQ, 1-methyl-TIQ, N-methyl-TIQ and 1-benzyl-TIQ) were detected in particularly high 
concentrations in banana, cherry, grapefruit, avocado, button mushroom, leaf lettuce 
and celery.  Derivatives of salsolinol ((R/S)SAL, NorSAL, N-methyl-(R/S)SAL and 
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Table 4-2.  Concentrations of TIQ derivatives in common fruits.   
 
Fruit TIQ 1-methyl-TIQ N-methyl-TIQ 1-benzyl-TIQ NorSAL 
Banana 984.35 +/- 10.60 255.83 +/- 17.46 307.64 +/- 28.94 125.64 +/- 15.33 1422.52 +/- 5.11
Apple 167.31 +/- 9.11 34.58 +/- 6.32 27.06 +/- 3.20 ND 141.81 +/- 6.49 
Watermelon 70.25 +/- 3.55 ND ND ND 117.31 +/- 7.78 
Orange 54.06 +/- 3.10 12.62 +/- 1.40 17.38 +/- 2.61 ND 21.92 +/- 1.39 
Cantaloupe 26.94 +/- 2.55 ND 3.19 +/- 0.89 1.54 +/- 0.30 112.4 +/- 5.26 
Grape 257.06 +/- 9.16 ND ND ND 532.23 +/- 12.49
Grapefruit 462.11 +/- 12.30 18.71 +/- 3.21 13.88 +/- 1.96 4.64 +/- 0.85 16.91 +/- 1.5 
Strawberry 107.05 +/- 10.20 ND 2.16 +/- 0.67 ND 217.81 +/- 8.94 
Peach 185.64 +/- 6.33 26.08 +/- 3.64 17.03 +/- 1.48 ND 75.11 +/- 1.65 
Pear 16.11 +/- 5.22 ND ND ND 69.39 +/- 4.42 
Nectarine 74.02 +/- 5.79 9.11 +/- 1.63 3.24 +/- 1.05 ND 100.52 +/- 7.02 
Honeydew Melon 60.20 +/- 4.21 ND 2.91 +/- 0.68 ND 71.71 +/- 8.12 
Plum 119.06 +/- 7.02 10.60 +/- 2.18 19.57 +/- 1.56 13.66 +/- 3.43 75.11 +/- 1.65 
Avocado 455.06 +/- 12.10 40.91 +/- 3.22 38.47 +/- 4.02 22.31 +/- 4.17 401.73 +/- 10.65
Lemon 331.12 +/- 7.20 15.29 +/- 0.78 6.35 +/- 1.02 8.44 +/- 1.30 25.13 +/- 9.32 
Pineapple 120.98 +/- 50.03 ND 14.36 +/- 2.44 ND 95.96 +/- 5.64 
Tangerine 261.35 +/- 12.00 67.73 +/- 5.82 96.35 +/- 9.02 ND 16.78 +/- 5.69 
Cherry 616.24 +/- 22.09 5.33 +/- 0.88 7.13 +/- 1.77 2.06 +/- 0.80 41.75 +/- 9.69 
Kiwi Fruit 184.33 +/- 8.10 33.14 +/- 4.35 21.09 +/- 3.05 ND 266.45 +/- 90 
Lime 368.26 +/- 4.68 38.06 +/- 3.69 17.93 +/- 1.17 ND 55.45 +/- 3.56 
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Table 4-2.  (Continued).  
 
Fruit (R)SAL (S)SAL N-methyl-(R)SAL N-methyl-(S)SAL N-methyl-NorSAL
Banana 2717.50 +/- 9.81 2870.87 +/- 10.95 1102.16 +/- 12.25 1133.59 +/- 7.86 1977.53 +/- 3.22 
Apple 29.63 +/- 0.25 30.41 +/- 1.72 16.05 +/- 1.55 17.10 +/- 0.17 309.93 +/- 6.21 
Watermelon 21.92 +/- 0.86 25.66 +/- 0.77 9.34 +/- 0.38 10.81 +/- 0.26 81.59 +/- 5.65 
Orange 232.34 +/- 4.79 246.94 +/- 3.77 280.90 +/- 5.11 287.86 +/- 3.28 13.89 +/- 0.93 
Cantaloupe 18.53 +/- 0.91 17.94 +/- 0.67 35.78 +/- 2.26 34.835 +/- 1.84 48.54 +/- 5.89 
Grape 951.62 +/- 11.71 980.84 +/- 12.96 ND ND 154.25 +/- 9.15 
Grapefruit 419.19 +/- 4.66 404.86 +/- 3.87 611.02 +/- 17.5 632.53 +/- 24.82 715.48 +/- 15.04 
Strawberry 389.8 +/- 7.35 362.28 +/- 9.07 74.68 +/- 8.12 81.28 +/- 5.07 112.48 +/- 8.83 
Peach 31.85 +/- 9.51 39.46 +/- 5.54 7008.16 +/- 26.4 7130.39 +/- 11.22 5.79 +/- 0.88 
Pear 34.09 +/- 1.44 35.18 +/- 9.74 4516.3 +/- 77.10 4670.65 +/- 63.32 5.76 +/- 0.31 
Nectarine 48.76 +/- 4.26 46.43 +/- 2.97 589.33 +/- 12.89 595.20 +/- 16.21 14.66 +/- 2.30 
Honeydew Melon 9.63 +/- 4.31 8.82 +/- 1.27 206.27+/- 8.16 197.95 +/- 4.41 101.72 +/- 6.92 
Plum ND ND 280.99 +/- 5.11 287.86 +/- 3.28 154.25 +/- 9.15 
Avocado 334.44 +/- 8.62 328.26 +/- 7.57 305.31 +/- 1.61 292.42 +/- 7.71 ND 
Lemon 282.33 +/- 12.66 289.20 +/- 8.51 81.33 +/- 4.02 75.92 +/- 8.03 ND 
Pineapple 48.16 +/- 13.06 47.17 +/- 18.03 1250.07 +/- 16.22 1318.66 +/- 11.85 322.83 +/- 20.3 
Tangerine 238.43 +/- 5.41 237.25 +/- 8.49 791.66 +/- 21.08 804.36 +/- 18.56 481.32 +/- 12.17 
Cherry 16.73 +/- 3.44 12.03 +/- 4.77 6103.49 +/- 18.78 6180.03 +/- 27.48 16.92 +/- 1.41 
Kiwi Fruit 114.65 +/- 7.28 120.32 +/- 2.46 540.62 +/- 11.60 551.27 +/- 5.35 174.49 +/- 5.90 
Lime 107.24 +/- 5.52 118.165 +/- 9.21 1167.33 +/- 15.64 1251.45 +/- 27.93 126.46 +/- 4.34 
 
  Values are expressed in ng/g wet weight.   
  ND, Not Detected.
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Table 4-3.  Concentrations of TIQ derivatives in common vegetables.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vegetable TIQ 1-methyl-TIQ N-methyl-TIQ 1-benzyl-TIQ NorSAL 
Potato 52.16 +/- 4.55 ND 2.57 +/- 0.45 ND 289.72 +/- 5.01 
Iceberg Lettuce 89.22 +/- 7.40 ND 8.24 +/- 1.32 ND 114.18 +/- 9.34 
Tomato 134.11 +/- 4.61 9.63 +/- 2.11 ND ND 28.47 +/- 3.70 
Onion 16.44 +/- 2.33 ND 3.28 +/- 1.60 1.57 +/- 0.40 50.43 +/- 6.46 
Carrot 24.61 +/- 4.41 ND ND ND 29.05 +/- 2.55 
Celery 467.66 +/- 20.10 8.46 +/- 1.66 12.44 +/- 2.28 5.13 +/- 0.23 9.66 +/- 0.72 
Yellow Corn 31.61 +/- 3.10 ND ND ND 94.78 +/- 3.36 
Broccoli 49.13 +/- 4.66 ND 1.86 +/- 0.33 ND 100.22 +/- 3.10 
Green Cabbage 55.49 +/- 8.20 3.83 +/- 0.87 5.16 +/- 0.75 1.60 +/- 0.40 60.67 +/- 5.55 
Cucumber 18.26 +/- 2.62 ND ND ND 27.56 +/- 5.25 
Bell Pepper 167.03 +/- 10.3 6.73 +/- 1.03 4.50 +/- 1.03 3.67 +/- 0.56 187.67 +/- 4.1 
Cauliflower 19.46 +/- 4.09 ND 2.67 +/- 0.98 ND 26.21 +/- 8.77 
Leaf Lettuce 493.54 +/- 16.20 15.33 +/- 2.45 12.11 +/- 3.00 7.99 +/- 1.37 167.91 +/- 5.08 
Sweet Potato 136.07 +/- 6.46 4.92 +/- 0.96 9.34 +/- 1.25 6.27 +/- 0.87 97.14 +/- 5.84 
Mushroom 1314.56 +/- 13.15 194.24 +/- 12.44 276.04 +/- 32.62 67.16 +/- 8.20 2174.58 +/- 27.92
Green Onion 87.01 +/- 6.14 ND 2.47 +/- 0.72 ND 147.55 +/- 9.71 
Green Bean 152.68 +/- 7.13 ND ND ND 51.92 +/- 9.60 
Radish 14.08 +/- 2.10 2.39 +/- 0.83 4.39 +/- 1.23 ND 39.86 +/- 1.37 
Yellow Squash 416.94 +/- 17.35 8.55 +/- 1.62 14.45 +/- 3.41  12.48 +/- 2.50 31.63 +/- 7.61 
Asparagus 232.02 +/- 14.50 7.32 +/- 1.46 11.04 +/- 5.21 8.10 +/- 1.06 565.37 +/- 6.57 
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Table 4-3.  (Continued).   
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed in ng/g wet weight.   
ND, Not Detected. 
 
 
 
Vegetable (R)SAL (S)SAL N-methyl-(R)SAL N-methyl-(S)SAL N-methyl-NorSAL
Potato 77.81 +/- 8.19 88.79 +/- 5.68 ND ND 67.11 +/- 5.71 
Iceberg Lettuce 16.85 +/- 6.10 18.35 +/- 3.89 22.56 +/- 3.02 19.06 +/- 6.87 101.22 +/- 3.01 
Tomato 54.84 +/- 6.38 56.55 +/- 3.69 311.58 +/- 16.11 300.83 +/- 11.50 80.16 +/- 7.73 
Onion 6.05 +/- 1.62 4.9 +/- 1.57 26.08 +/- 2.66 23.18 +/- 8.01 0.89 +/- 0.03 
Carrot 42.91 +/- 1.30 40.61 +/- 5.83 15.22 +/- 2.69 14.96 +/- 1.61 24.13 +/- 2.53 
Celery 1372.85 +/- 15.60 1382.01 +/- 12.03 232.83 +/- 9.20 239.64 +/- 7.48 1355.56 +/- 29.33
Yellow Corn 86.47 +/- 4.35 80.44 +/- 6.90 37.69 +/- 2.21 31.46 +/- 5.64 25.30 +/- 1.25 
Broccoli 44.84 +/- 2.31 49.56 +/- 6.93 2.44 +/- 0.20 6.94 +/- 0.63 35.24 +/- 2.04 
Green Cabbage 35.46 +/- 3.87 38.48 +/- 5.63 21.08 +/- 3.13 27.58 +/- 6.52 32.76 +/- 6.77 
Cucumber 12.87 +/- 1.52 13.66 +/- 0.98 11.10 +/- 2.61 9.81 +/- 1.74 17.09 +/- 2.25 
Bell Pepper 59.52 +/- 4.90 61.77 +/- 6.32 33.64 +/- 4.03 29.68 +/- 6.37 12.10 +/- 2.48 
Cauliflower 13.16 +/- 1.35 14.23 +/- 2.26 30.55 +/- 6.20 36.89 +/- 4.07 22.89 +/- 2.09 
Leaf Lettuce 2615.23 +/- 42.35 2660.49 +/- 33.55 627.63 +/- 8.33 631.56 +/- 11.95 2149.28 +/- 27.25
Sweet Potato 295.23 +/- 5.87 286.80 +/- 8.49 317.09 +/- 12.50 310.97 +/- 8.68 68.20 +/- 6.58 
Mushroom 3572.80 +/- 13.44 3557.40 +/- 17.48 5998.02 +/- 33.10 6026.26 +/- 25.6 595.29 +/- 18.39 
Green Onion 255.72 +/- 9.92 263.59 +/- 8.82 97.50 +/- 12.43 106.69 +/- 9.28 38.88 +/- 9.33 
Green Bean 195.17 +/- 9.31 215.58 +/- 6.89 322.34 +/- 4.22 330.41 +/- 6.57 277.47 +/- 3.93 
Radish 19.81 +/- 1.26 21.06 +/- 1.41 ND ND 22.11 +/- 0.36 
Yellow Squash 152.41 +/- 6.52 151.16 +/- 8.03 102.54 +/- 8.26 110.98 +/- 6.78 555.63 +/- 12.75 
Asparagus 104.82 +/- 18.44 101.43 +/- 12.83 177.03 +/- 16.21 169.63 +/- 13.43 47.95 +/- 3.05 
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Table 4-4.  Total neurotoxin load by fruit. 
 
Fruit TIQ Load Salsolinol Load Total Neurotoxin Load
Peach 228.75 +/- 11.45 14290.76 +/- 55.20 14519.51 +/- 66.65 
Cherry 630.76 +/- 25.54 12370.95 +/- 65.57 13001.71 +/- 91.11 
Banana 1673.46 +/- 72.33* 11224.17 +/- 49.20 12897.63 +/- 121.53 
Pear 16.11 +/- 5.22 9331.37 +/- 156.33 9347.48 +/- 161.55 
Grapefruit 499.34 +/- 18.32 2799.99 +/- 67.39 3299.33 +/- 85.71 
Lime 424.25 +/- 9.54 2826.09 +/- 66.20 3250.34 +/- 75.74 
Pineapple 135.34 +/- 52.47 3082.85 +/- 85.10 3218.19 +/- 137.57 
Tangerine 425.43 +/- 26.84 2569.80 +/- 71.40 2995.23 +/- 98.24 
Grape 257.06 +/- 9.16 2618.94 +/- 46.31 2876.00 +/- 55.47 
Avocado 556.75 +/- 23.51 1662.16 +/- 36.16 2218.91 +/- 59.67 
Kiwi Fruit 238.56 +/- 15.50 1767.80 +/- 122.59 2006.36 +/- 138.09 
Nectarine 86.37 +/- 8.47 1394.90 +/- 45.65 1481.27 +/- 54.12 
Strawberry 109.21 +/- 10.87 1238.33 +/- 47.38 1347.54 +/- 58.25 
Orange 84.06 +/- 7.11 1083.85 +/- 19.27 1167.91 +/- 26.38 
Lemon 361.20 +/- 10.30 753.91 +/- 42.54 1115.11 +/- 52.84 
Plum 162.89 +/- 14.19 798.21 +/- 19.19 961.10 +/- 33.38 
Apple 228.95 +/- 18.63 544.93 +/- 16.39 773.88 +/- 35.02 
Honeydew Melon 63.11 +/- 4.89 596.10 +/- 33.19 659.21 +/- 38.08 
Watermelon 70.25 +/- 3.55 266.63 +/- 15.70 336.88 +/- 19.25 
Cantaloupe 31.67 +/- 3.74 268.02 +/- 16.83 299.695 +/- 20.57 
 
  Values are expressed in ng/g wet weight.  
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Table 4-5.  Total neurotoxin load by vegetable. 
 
Vegetable TIQ Load Salsolinol Load Total Neurotoxin Load
Mushroom 1852.00 +/- 66.41 21924.35 +/- 135.93 23776.35 +/- 202.34 
Leaf Lettuce 528.97 +/- 23.02 8852.10 +/- 128.51 9381.07 +/- 151.53 
Celery 493.69 +/- 24.27 4592.55 +/- 74.36 5086.24 +/- 98.63 
Yellow Squash 452.42 +/- 24.88 1104.35 +/- 49.95 1556.77 +/- 74.83 
Green Bean 152.68 +/- 7.13 1392.89 +/- 40.52 1545.57 +/- 47.65 
Sweet Potato 156.60 +/- 9.54 1375.43 +/- 47.96 1532.03 +/- 57.50 
Asparagus 258.48 +/- 22.23 1166.23 +/- 70.53 1424.71 +/- 92.76 
Green Onion 89.48 +/- 6.86 909.93 +/- 59.49 999.41 +/- 66.35 
Tomato 143.74 +/- 6.72 832.43 +/- 49.11 976.17 +/- 55.83 
Potato 54.73 +/- 5.00 523.43 +/- 24.59 578.16 +/- 29.59 
Bell Pepper 181.93 +/- 12.92 384.38 +/- 28.20 566.31 +/- 41.12 
Iceberg Lettuce 97.46 +/- 8.72 292.22 +/- 32.23 389.68 +/- 40.95 
Yellow Corn 31.61 +/- 3.10 356.14 +/- 23.71 387.75 +/- 26.81 
Broccoli 50.99 +/- 4.99 239.24 +/- 15.21 290.23 +/- 20.20 
Green Cabbage 66.08 +/- 10.22 216.03 +/- 31.47 282.11 +/- 41.69 
Carrot 24.61 +/- 4.41 166.88 +/- 16.51 191.49 +/- 20.92 
Cauliflower 22.13 +/- 5.07 143.93 +/- 24.74 166.06 +/- 29.81 
Onion 21.29 +/- 4.33 111.53 +/- 20.35 132.82 +/- 24.68 
Radish 20.86 +/- 4.16 102.84 +/- 4.40 123.70 +/- 8.56 
Cucumber 18.26 +/- 2.62 92.09 +/- 14.35 110.35 +/- 16.97 
 
  Values are expressed in ng/g wet weight.  
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N-methyl-NorSAL) were detected in particularly high concentrations in peach, cherry, 
banana, pear, mushroom, leaf lettuce, celery and green bean.  In general, hydroxylated 
and methylated derivatives were present at higher concentrations than their parent TIQ. 
 
In contrast, TIQ was present at much higher concentrations than 1-benzyl-TIQ.  
N-methylated derivatives of salsolinol (N-methyl-(R/S)SAL and N-methyl-NorSAL) were 
typically found in much higher concentrations than their parent (R/S)SAL.  However, this 
effect was more pronounced in fruit species.  Interestingly, enantiomeric salsolinol 
derivatives were detected as racemic mixtures in all plant species, with no evidence of 
stereoselective synthesis.  In general, total toxin load was higher in fruits than in 
vegetables.  However, the plant with the highest total toxin load was button mushroom. 
 
 As shown in Table 4-6, the mushroom family (Agaricaceae) contained the 
highest average TIQ derivative load, salsolinol derivative load and total toxin load of all 
plant families subjected to analysis.  The banana family (Musaceae), rose family 
(Rosaceae), sunflower family (Asteraceae) and pineapple family (Bromeliaceae) also 
contained particularly high total average neurotoxin loads.  In general, plant families 
contained significantly higher levels of salsolinol derivatives than TIQ derivatives, most 
of which were an order of magnitude greater (rose, sunflower, pineapple, grape, carrot, 
rue, pea, morning glory, lily, amaryllis and grass families).  For most plants, total 
neurotoxin load was detected on the part per million scale (µg/g tissue).   
 
 The lowest average TIQ derivative, salsolinol derivative and total toxin loads 
were detected in plants from the mustard (Brassicaceae), grass (Poaceae), amaryllis 
(Amaryllidaceae) and gourd (Cucurbitaceae) families.  Plant families with intermediate 
average toxin levels included the nightshade (Solanaceae), lilly (Liliaceae), pea 
(Fabaceae), laurel (Lauraceae), rue (Rutaceae), carrot (Apiaceae) and grape 
(Vitaceae).      
 
 
4.3.2 Lifetime Intake of Fresh Fruits and Vegetables in PD Patients 
 
We received survey responses from 183 PD cases in men and 102 in women 
(mean age 66 +/- 10 years).  Of the normal human respondents, 137 were male and 148 
were female (mean age 68 +/- 11 years).  Major dietary factors were identified (Table  
4-7 and 4-8) in both PD and normal human respondents from principal components 
analysis of questionnaire data: the intake of 7 fruit items and 6 vegetable items.  One 
dietary pattern was characterized by high intakes of banana, apple, watermelon, orange, 
cantaloupe, grape and grapefruit (relative to other fruits); the other dietary pattern was 
characterized by high intakes potato, iceberg lettuce, tomato, onion, carrot and celery 
(relative to other vegetables).   
 
Examination of Table 4-9 reveals a trend in higher intake of apple, watermelon, 
orange, cantaloupe, grape and grapefruit in PD patients relative to controls.  However, 
only lifetime monthly intake or oranges reached statistical significance (P < 0.02).  A 
trend of higher intake of potato, iceberg lettuce, tomato and carrot in PD patients was 
also observed.  However, these differences did not reach statistical significance. 
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Table 4-6.  Average neurotoxin load by plant family. 
 
Family Common Name TIQ Load Salsolinol Load Total Neurotoxin Load
Agaricaceae Mushroom Family 1852.00 +/- 66.41 21924.35 +/- 135.93 23776.35 +/- 202.34 
Musaceae Banana Family 1673.46 +/- 72.33 11224.17 +/- 49.20 12897.63 +/- 121.53 
Rosaceae Rose Family 209.01 +/- 13.48 5709.92 +/- 57.96 5918.93 +/- 71.44 
Asteraceae Sunflower Family 313.22 +/- 15.87 4572.16 +/- 80.37 4885.38 +/- 96.24 
Bromeliaceae Pineapple Family 135.34 +/- 52.47 3082.85 +/- 85.10 3218.19 +/- 137.57 
Vitaceae Grape Family 257.06 +/- 9.16 2618.94 +/- 46.31 2876.00 +/- 55.47 
Apiaceae Carrot Family 259.15 +/- 14.34 2379.72 +/- 45.44 2638.87 +/- 59.78 
Rutaceae Rue Family 358.86 +/- 14.42 2006.73 +/- 53.36 2365.59 +/- 67.78 
Lauraceae Laurel Family 556.75 +/- 23.51 1662.16 +/- 36.16 2218.91 +/- 59.67 
Actinidiaceae Actinidia Family 238.56 +/- 15.50 1767.80 +/- 122.59 2006.36 +/- 138.09 
Fabaceae Pea Family 152.68 +/- 7.13 1392.89 +/- 40.52 1545.57 +/- 47.65 
Convolvulaceae Morning Glory Family 156.60 +/- 9.54 1375.43 +/- 47.96 1532.03 +/- 57.50 
Liliaceae Lily Family 258.48 +/- 22.23 1166.23 +/- 70.53 1424.71 +/- 92.76 
Solanaceae Nightshade Family 126.80 +/- 8.21 580.08 +/- 33.97 706.88 +/- 42.18 
Cucurbitaceae Gourd Family 127.14 +/- 7.94 465.44 +/- 26.00 592.58 +/- 33.94 
Amaryllidaceae Amaryllis Family 55.39 +/- 5.60 510.73 +/- 39.92 566.12 +/- 45.52 
Poaceae Grass Family 31.61 +/- 3.10 356.14 +/- 23.71 387.75 +/- 26.81 
Brassicaceae Mustard Family 40.02 +/- 6.11 175.51 +/- 18.96 215.53 +/- 25.07 
 
Values are expressed in ng/g wet weight. 
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Table 4-7.  Principal components analysis of fruit items.    
 
 
*  Eigenvalues > 1.000 considered principal components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fruit  Lifetime Mean (Servings/Month) Standard Error Eigenvalue* % of Variance
Banana 3.900 0.119 5.204 26.016 
Apple 5.286 0.145 2.071 10.356 
Watermelon 2.845 0.083 1.877 9.384 
Orange 5.020 0.132 1.563 7.816 
Cantaloupe 2.538 0.074 1.167 5.837 
Grape 2.993 0.090 1.071 5.355 
Grapefruit 2.369 0.064 1.010 5.052 
Strawberry 2.653 0.083 0.937 4.683 
Peach 2.574 0.072 0.761 3.806 
Pear 1.735 0.063 0.610 3.051 
Nectarine 0.619 0.020 0.594 2.972 
Honeydew Melon 1.254 0.030 0.518 2.592 
Plum 1.103 0.028 0.446 2.232 
Avocado 1.001 0.047 0.393 1.965 
Lemon 2.120 0.104 0.374 1.869 
Pineapple 1.496 0.051 0.328 1.642 
Tangerine 0.796 0.024 0.317 1.585 
Cherry 0.997 0.032 0.269 1.343 
Kiwi Fruit 0.417 0.031 0.252 1.260 
Lime 0.701 0.023 0.236 1.181 
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Table 4-8.  Principal components analysis of vegetable items. 
 
 
*  Eigenvalues > 1.000 considered principal components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vegetable  Lifetime Mean(Servings/Month) Standard Error Eigenvalue* % of Variance
Potato 10.386 0.176 4.915 24.573 
Iceberg Lettuce 9.437 0.197 1.909 9.546 
Tomato 6.469 0.156 1.708 8.538 
Onion 5.263 0.133 1.342 6.708 
Carrot 4.560 0.117 1.269 6.347 
Celery 4.518 0.106 1.055 5.275 
Yellow Corn 5.985 0.133 0.916 4.582 
Broccoli 2.994 0.085 0.880 4.402 
Green Cabbage 3.864 0.097 0.805 4.024 
Cucumber 3.731 0.088 0.722 3.611 
Bell Pepper 2.595 0.069 0.586 2.930 
Cauliflower 1.037 0.035 0.543 2.715 
Leaf Lettuce 3.818 0.123 0.528 2.638 
Sweet Potato 2.979 0.084 0.521 2.603 
Mushroom 1.310 0.080 0.479 2.395 
Green Onion 2.709 0.095 0.437 2.184 
Green Bean 6.168 0.135 0.416 2.081 
Radish 1.363 0.077 0.376 1.881 
Yellow Squash 2.094 0.063 0.342 1.709 
Asparagus 2.280 0.065 0.252 1.260 
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Table 4-9.  95% confidence intervals for principal components (mean lifetime 
monthly intake). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH, normal human controls. 
PD, Parkinson disease humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Food Item NH 95% CI PD 95% CI P Value 
Banana 3.71 – 4.50 2.57 – 4.10 0.12 
Apple 4.97 – 5.49 4.80 – 5.89 0.38 
Watermelon 2.59 – 3.00 2.64 – 3.13 0.54 
Orange 4.42 – 4.75 4.92 – 5.80 0.02* 
Cantaloupe 2.25 – 2.57 2.43 – 2.91 0.09 
Grape 2.76 – 3.22 2.72 – 3.27 0.80 
Grapefruit 2.15 – 2.52 2.33 – 2.67 0.62 
    
Potato 9.81 – 10.67 9.98 – 11.07 0.41 
Iceberg Lettuce 8.74 – 9.80 9.04 – 10.17 0.40 
Tomato 5.94 – 6.76 6.12 – 7.05 0.67 
Onion 4.96 – 5.78 4.82 – 5.48 0.43 
Carrot 4.12 – 4.73 4.35 – 5.04 0.29 
Celery 4.25 – 4.82 4.19 – 4.81 0.81 
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4.3.3 Reproducibility and Validity of the Survey Instrument 
 
On average, studies of reproducibility of the questionnaire revealed a 
correlation of 0.71 and a kappa score of 0.58 (Table 4-10).  This indicates average  
correlation and moderate agreement in regards to answers supplied on an initial 
questionnaire and the same questionnaire distributed 6 months later.  Based upon a  
simple one-month food diary, validity studies of the questionnaire revealed a mean 
correlation of 0.76 and a mean kappa score of 0.72 (Table 4-11), indicating average 
correlation and substantial agreement with current dietary habits.  No significant 
difference was noted within or between reproducibility and validity of the survey 
instrument.  
 
 
4.3.4 Accumulation of TIQ Derivatives in Rat Brain Over Time 
 
Using enantiomer selective HPLC-EC and LC-MS/MS, the contentrations of TIQ 
and salsolinol derivatives were determined in cerebral cortex, hippocampus, ventral 
midbrain, striatum and cerebellum in rats at age 1 day, 14 days, 30 days, 6 months, 1 
year, 1.5 years and 2 years.  Trends in TIQ derivative concentration by brain region are 
shown in Figure 4-1.   As observed in data presented in chapter 3, TIQ was found at 
higher concentrations than its methylated and benzylated derivatives (1-methyl-TIQ, N-
methyl-TIQ and 1-benzyl-TIQ) in all brain regions at virtually all time points.  
Furthermroe, TIQ and its methylated and benzylated derivatives were found at lower 
concentrations than (R/S)SAL and its derivatives at all ages.   
  
Once again, the regional concentrations of TIQ, 1-methyl-TIQ, N-methyl-TIQ, and 
1-benzyl-TIQ exhibited minimal variation across the brain.   The concentration of these 
derivatives appears to change very little over time, with roughly 90% of the total 
accumulating within the first one month of life.  The level of N-methylated salsolinol 
derivatives, however, tended to remain close to that of their parent salsolinol until later in 
life (1.5 yrs), when the concentration of salsolinol falls and that of the derivatives tend to 
rise.  The concentration of salsolinol and its derivatives experience a fast ascent within 
the first 6 months of life.  This effect was most pronounced in dopaminergic regions of 
the brain (ventral midbrain and striatum; Figure 4-1C and D).  Interestingly, levels of N-
methyl-NorSAL accumulate much more slowly in early life compared to (R/S)SAL or N-
methyl-(R/S)SAL, and continue to increase throughout life seemingly never reaching a 
plateau.  The total brain concentration of N-methyl-NorSAL was detected on the order of 
4 M at 2 years of age.  The steepest area of accumulation appears to be from 6 months 
to 1 year of life within dopaminergic regions.  Overall, the net level of TIQ and salsolinol 
derivatives rises and remains relatively constant over the life of the rat, with the 
exception of N-methyl-NorSAL (Figure 4-1F).   
 
 
4.4 DISCUSSION 
 
Using liquid chromatographic techniques, we have systematically determined the 
content of several potential neurotoxic TIQ derivatives in 40 of the most commonly 
consumed plant products in the US.  TIQ derivatives were detected in all foods 
subjected to analysis, revealing particularly high concentrations in banana, cherry, 
peach, grapefruit, avocado, button mushroom, leaf lettuce and celery.  Hydroxylated and 
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Table 4-10.  Reproducibility of food items. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  *  Kappa interpretation: 
0.00 – 0.20  Slight agreement; 
0.21 – 0.40  Fair agreement; 
0.41 – 0.60  Moderate agreement; 
0.61 – 0.80  Substantial agreement; 
0.81 – 1.00  Very good agreement.   
Vegetable Spearman Correlation Kappa* Fruit Spearman Correlation Kappa*
Potato 0.92 0.86 Banana 0.90 0.91 
Iceberg Lettuce 0.87 0.79 Apple 0.92 0.88 
Tomato 0.83 0.82 Watermelon 0.88 0.79 
Onion 0.79 0.76 Orange 0.88 0.82 
Carrot 0.73 0.60 Cantaloupe 0.87 0.77 
Celery 0.74 0.62 Grape 0.87 0.71 
Yellow Corn 0.91 0.87 Grapefruit 0.86 0.84 
Broccoli 0.82 0.60 Strawberry 0.85 0.73 
Green Cabbage 0.81 0.71 Peach 0.85 0.77 
Cucumber 0.79 0.79 Pear 0.79 0.71 
Bell Pepper 0.76 0.60 Nectarine 0.77 0.64 
Cauliflower 0.54 0.47 Honeydew Melon 0.73 0.64 
Leaf Lettuce 0.87 0.75 Plum 0.72 0.64 
Sweet Potato 0.72 0.81 Avocado 0.43 0.41 
Mushroom 0.55 0.47 Lemon 0.79 0.66 
Green Onion 0.69 0.55 Pineapple 0.69 0.62 
Green Bean 0.82 0.67 Tangerine 0.73 0.69 
Radish 0.48 0.44 Cherry 0.59 0.63 
Yellow Squash 0.56 0.38 Kiwi Fruit 0.46 0.44 
Asparagus 0.56 0.47 Lime 0.92 0.88 
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Table 4-11.  Validity of food items. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  Kappa interpretation: 
0.00 – 0.20  Slight agreement; 
0.21 – 0.40  Fair agreement; 
0.41 – 0.60  Moderate agreement; 
0.61 – 0.80  Substantial agreement; 
0.81 – 1.00  Very good agreement.
Vegetable Spearman Correlation Kappa* Fruit Spearman Correlation Kappa*
Potato 0.73 0.64 Banana 0.87 0.90 
Iceberg Lettuce 0.72 0.64 Apple 0.86 0.84 
Tomato 0.84 0.83 Watermelon 0.85 0.73 
Onion 0.79 0.66 Orange 0.85 0.77 
Carrot 0.69 0.62 Cantaloupe 0.79 0.71 
Celery 0.73 0.69 Grape 0.77 0.64 
Yellow Corn 0.59 0.63 Grapefruit 0.54 0.47 
Broccoli 0.65 0.72 Strawberry 0.87 0.75 
Green Cabbage 0.97 0.93 Peach 0.72 0.81 
Cucumber 0.92 0.88 Pear 0.55 0.47 
Bell Pepper 0.88 0.79 Nectarine 0.69 0.55 
Cauliflower 0.88 0.82 Honeydew Melon 0.82 0.67 
Leaf Lettuce 0.87 0.77 Plum 0.83 0.82 
Sweet Potato 0.87 0.71 Avocado 0.79 0.76 
Mushroom 0.86 0.84 Lemon 0.73 0.60 
Green Onion 0.85 0.73 Pineapple 0.74 0.62 
Green Bean 0.85 0.77 Tangerine 0.91 0.87 
Radish 0.79 0.71 Cherry 0.82 0.60 
Yellow Squash 0.75 0.68 Kiwi Fruit 0.81 0.71 
Asparagus 0.65 0.76 Lime 0.79 0.79 
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Figure 4-1.  TIQ derivative accumulation in the rat brain over time. 
The contrations of TIQ derivatives from (A) frontal cerebral cortex, (B) hippocampus, (C) 
ventral midbrain, (D) striatum and (E) cerebellum were determined in rat brain using 
HPLC-EC and LC-MS/MS over time.  Total brain concentrations are depicted in F.   
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methylated derivatives of TIQ were present at high concentrations relative to TIQ, as 
were the N-methylated derivatives of salsolinol.  Enantiomeric salsolinol derivatives were 
detected as racemic mixtures in all plants, with no evidence of stereoselective enzymatic 
synthesis.  The mushroom family (Agaricaceae) contained the highest average TIQ 
derivative load, salsolinol derivative load and total toxin load of all plant families.  The 
banana family (Musaceae), rose family (Rosaceae), sunflower family (Asteraceae) and 
pineapple family (Bromeliaceae) also contained particularly high total average 
neurotoxin loads.   
 
The first reports of TIQ derivative detection in foods utilized GC-MS techniques 
to quantify TIQ and 1-methyl-TIQ in white wine (1.7 ng/g and 354 ng/g, respectively), 
cheese (1.7 ng/g and 354 ng/g, respectively) and cocoa (1.1 ng/g and 12 ng/g, 
respectively) (Makino et al 1988; Makino et al 1990).  Niwa and co-workers later 
detected TIQ in meat (0.9 to 1.8 ng/g), cheese (5.2 ng/g), banana (2.2 ng/g), wine (0.6 
ng/g), beer (0.4 ng/g) and whiskey (0.7 ng/g) using GC-MS and concluded that TIQ 
concentrations were too low in foods to be revelant in PD (Niwa et al 1989).  Finally, 
using enantiomer selective HPLC-EC, Deng and colleagues detected (R) and (S)SAL 
in dried banana (65.34 ng/g and 61.63 ng/g, respectively), “German wine” (6.18 ng/g 
and 7.85 ng/g, respectively) and “French wine” (3.32 ng/g and 4.93 ng/g, respectively) 
(Deng et al 1997).  N-methyl-(R/S)SAL was not detected.  While tempting, direct 
comparison between the results of these studies and those of the present study 
becomes difficult when the ambiquity of sample ages, orgins and sizes in the above-
mentioned studies are taken into account.  Not to mention the sample derivitization and 
SPE involved in preparation for GC-MS, as detailed in chapter 3.  With this in mind, our 
observed detection of TIQ in fresh banana at 984 ng/g certainly does not compare with 
that of 2.2 ng/g in a single 20 g sample of unknown banana (Niwa et al 1989).  
However, consistent with our findings in banana, Deng and colleagues detected 
(R/S)SAL as a racemic mixture using HPLC-EC (Deng et al 1997).   
 
In aggregate, the present results of TIQ derivatives in plants suggest several 
conclusions: (1) that TIQ derivatives are readily formed within plants as suggested by 
Collins and co-workers (Collins 2002); (2) that derivatives of TIQ and salsolinol are 
formed via methylation or oxidation reactions, rather than de novo; (3) that amino 
acid/aldehyde condensation is the predominant synthetic pathway for (R/S)SAL, with 
very little to no input from enzymatic synthesis as found in dopaminergic regions of 
mammalian brain; (4) that plant families tend to have similar TIQ derivative profiles and 
overall content, suggesting a genetic component to isoquinoline and -carboline 
synthesis; and (5) that several TIQ derivatives known to cross the blood-brain barrier 
(TIQ, 1-methyl-TIQ, 1-benzyl-TIQ and N-methyl-NorSAL) are found at concentrations 
high enough for dietary accumulation in brain to be a feasible hypothesis. 
 
Utilizing a lifetime food-item intake questionnaire, our results demonstrate a trend 
of increased intake of several plants products (bananas, apples, watermelon, oranges, 
cantaloupe, grapes, grapefruit, potatoes, iceberg lettuce, tomatoes, onions, carrots and 
celery) in PD patients relative to age-matched controls.  However, only the lifetime intake 
of oranges reached statistical significance.  Interestingly, members of the rue 
(Rutaceae), banana (Musaceae), gourd (Cucurbitaceae), carrot (Apiaceae) and 
nightshade (Solanaceae) families are well represented in this list.  For instance, bananas 
are especially rich in both TIQ and salsolinol derivatives, particularly TIQ, 1-benzyl-TIQ, 
(R/S)SAL and N-methyl-NorSAL.  Members of the rue family (orange and grapefruit) 
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have particularly high concentrations of salsolinol derivatives such as (R/S)SAL and N-
methyl-(R/S)SAL.  Apples also appear to be rich in N-methyl-NorSAL.  Celery and carrot, 
members of the Apiaceae family, also concentrate (R/S)SAL and N-methyl-NorSAL.  
Potato and tomato, in contrast, do not seem to concentrate any particular TIQ derivative 
per se, but contain modest concentrations of many derivatives.  Thus, many of the food 
items with a tendency for heaver consumption by PD patients over their lifetime were 
found to concentrate one or several potentially neurotoxic TIQ derivatives. 
 
The risk of PD has been previously associated the intake of a small subset of 
whole food items and their nutrients or components.  For example, decreased potato 
and tree nut intake, icreased carbohydrate intake, increased iron intake or decreased 
intake of niacin and antoxidants (such as vitamine E) have been shown to be weakly 
associated with the development of PD (Anderson et al 1999; Davies et al 1994; Fall et 
al 1999; Golbe et al 1988; Hellenbrand et al 1996a; Hellenbrand et al 1996b; Johnson et 
al 1999; Logroscino et al 1996; Logroscino et al 1998).  In comparison with traditional 
single-food or nutrient methods, the dietary pattern approach to analysis is a more 
appropriate measure for several reasons.  In reality, humans eat combinations of food 
and its constituents (nutrients, toxins, etc.), which leads to a high collinearity among 
many of these compounds and foods.  It is therefore difficult to identify the effect of a 
single food or substance on a disease state.  Linear transformation using principal 
component analysis therefore represents a combination of food and their components 
and may be a more powerful predictor of health outcomes than a single measure alone 
(Hu 2002).  Furthermore, a dietary pattern analysis offers an approach for better 
understanding the complexities of eating behaviors of different population groups and 
subgroups and may be used to effectively develop dietary intervention strategies (Gao et 
al 2006; Millen et al 1996).  Ultimately, the development of idiopathic PD is multifactorial 
and no single aspect alone (such as consumption of a specific food item or substance) 
will likely ever demonstrate a direct cause-effect relationship in such a diverse 
background of risk factors associated with disease.  
            
Using common methods of analysis, the results of reproducibility and validity 
studies may be considered modest and on-par with several other dietary questionnaires 
(Block & Hartman 1989; Buzzard et al 2001; Matthys et al 2007; Nelson & Lytle 2009).  
However, due of the retrospective design of the survey instrument, our results are very 
likely to be affected by recall or selection bias to some extent.  For instance, our validity 
study is only revelant to the current decade of life and therefore cannot approximate the 
suitability of the instrument for any other years.  Furthermore, we could not and did not 
correct for any other known PD risk factors and thus cannot exclude the possibility of 
residual confounding by other unknown factors.  Finally, we cannot exclude the 
possibility that consumption of fruits and vegetables contaminated with pesticides or 
polychlorinated biphenyls may contribute to the observed results.  For instance, several 
of these compounds have been shown to have selective toxicity for nigrastriatal neurons 
in animal models (Mariussen & Fonnum 2001). 
 
The present study is also the first to demonstrate the accumulation of TIQ 
derivatives over time in rat brain.  Interestingly, the concentration of TIQ derivatives 
appears to change very little over time, with high accumulation within the first one month 
of life.  In contrast, salsolinol derivatives experience a fast ascent within the first 6 
months of life within dopaminergic regions, followed by another rise in concentration 
around 1.5 yrs in age.  Levels of N-methyl-NorSAL accumulate more slowly in early life, 
followed by rapid accumulation around 6 months to 1 year of age with continued 
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increases throughout life.  Overall, the net content of TIQ and salsolinol derivatives rises 
early and remains relatively constant over the life of the rat, with the exception of N-
methyl-NorSAL.  Interestingly, levels of dopamine and dopamine metabolites (DOPAC 
and HVA) rise throughout life in the ventral midbrain and striatum, and in effect mirror 
the rise in N-methyl-NorSAL (data not shown).  For instance, in the striatum DOPAC 
levels at 2 years reached 6 µM, while that of N-methyl-NorSAL was 1.8 µM.  Mean total 
brain content of DOPAC and HVA at 2 years of age was 8 µM and 1.5 µM, respectively.  
Mean total brain N-methyl-NorSAL content was determined to be 4 µM.  For reference, 
total brain N-methyl-(R)SAL and N-methyl-(S)SAL content was 2 µM and 1.5 µM, 
respectively at the 2 year time point.  The following conclusions can be drawn from these 
results: (1) TIQ derivatives can and do accumulate within regions of the rat brain from 
endogenous and/or exogenous sources; (2) metabolism of TIQ derivatives in rat brain 
appears to be either stable without net change in content or non-existant with gradual 
accumulation over time; and (3) the idea of salsolinol derivatives as metabolites of 
dopamine is strengthened, as their concentrations appear to mirror rises in dopamine 
content and to be intermediate to those of DOPAC and HVA.  Similar studies in human 
brain regions over time are necessary for extrapolation of these conclusions to humans 
and their implications for neurodegenerative disease.     
  
   
4.5 CONCLUSIONS 
 
Epidemiological studies suggest that environmental factors contribute to the 
pathogenesis of PD.  The discovery of MPTP confirmed that dopaminergic cell death 
could indeed be precipitated by environmental neurotoxins.  The TIQs are structurally 
similar to MPTP, inhibit complex I of the respiratory chain, and can initiate apoptosis in 
cultured dopaminergic neurons.  Using enantiomeric-selective HPLC-EC and LC-
MS/MS, the concentrations several TIQ derivatives were determined in those fruits (N = 
20) and vegetables (N = 20) most commonly consumed in the US.  TIQ derivatives were 
detected in all foods subjected to analysis, revealing particularly high concentrations in 
banana, cherry, peach, grapefruit, avocado, button mushroom, leaf lettuce and celery.  
Enantiomeric salsolinol derivatives were detected as racemic mixtures in all plants, with 
no evidence of stereoselective enzymatic synthesis.  The mushroom family 
(Agaricaceae) contained the highest average TIQ derivative load, salsolinol derivative 
load and total toxin load of all plant families.  The banana family (Musaceae), rose family 
(Rosaceae), sunflower family (Asteraceae) and pineapple family (Bromeliaceae) also 
contained particularly high total average neurotoxin loads.  Utilizing a lifetime food-item 
intake questionnaire, we demonstrate a trend of increased intake of several plants 
products (bananas, apples, watermelon, oranges, cantaloupe, grapes, grapefruit, 
potatoes, iceberg lettuce, tomatoes, onions, carrots and celery) in PD patients.  This 
finding was most significant for oranges.  These items include members of the rue 
(Rutaceae), banana (Musaceae), gourd (Cucurbitaceae), carrot (Apiaceae) and 
nightshade (Solanaceae) families, found to concentrate several potentially neurotoxic 
TIQ derivatives.  Finally, we demonstrate the time-dependent accumulation of TIQ 
derivatives in rat brain.  The concentration of TIQ derivatives appears to change very 
little over time, with high accumulation within the first one month of life.  Salsolinol 
derivatives experience a more rapid ascent within the first 6 months of life within 
dopaminergic regions, followed by another concentration increase later in life.  Levels of 
N-methyl-NorSAL accumulate more slowly, followed by rapid accumulation around 6 
months with sustained increases.  Overall, the net content of TIQ and salsolinol 
derivatives rises early and remains relatively constant over the life of the rat, with the 
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exception of N-methyl-NorSAL.  This data demonstrates the presence of potentially toxic 
TIQ derivatives in plants commonly utilized as food sources and provides evidence to 
support the accumulation of TIQs in the rodent brain over time.  Taken together, this 
may provide a link between dietary risk factors, the accumulation of toxic TIQ derivatives 
in the brain and the pathogenesis of PD. 
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CHAPTER 5.  IN VITRO TOXICITY OF METHYLATED TETRAHYDROSIOQUINOLINE 
DERIVATIVES 
 
 
5.1 INTRODUCTION 
 
A significant amount of research has been dedicated to the precise cause of 
nigral cell death in idiopathic PD.  One leading hypothesis is oxidative cell injury caused 
by mitochondrial respiratory failure with a defect in NADH–ubiquinone oxidoreductase 
(complex I, EC 1.6.5.3) (Mizuno et al 1998).  In support of this hypothesis, complex I 
activities in multiple brain regions of PD patients have been shown to be decreased 
relative to controls (Parker et al 1989; Schapira et al 1990).  Furthermore, of the 
potential cellular targets of MPP+, mitochondrial complex I is believed to be its most 
potent site of action (Tipton & Singer 1993).  Complex I is an extremely large and 
intricate enzyme system consisting of 41 different subunits in mammals.  Functionally, 
complex I serves as the entry point for electrons into the ETC and is located within the 
inner mitochondrial membrane, where it catalyzes electron transfer from NADH, 
generated from the tricarboxylic acid (TCA) cycle in the mitochondrial matrix, to 
ubiquinone (Lardy & Ferguson 1969).  Although some reports have suggested that a 
genetic defect in mitochondrial DNA causes complex I deficiency in familial PD patients, 
sporadic PD cannot be explained in terms of genetic predisposition alone, and unknown 
endogenous or exogenous factors contributing to complex I inhibition are a revelant 
possibility (Kotake & Ohta 2003).   
 
Salsolinol, an enantiomeric 6,7-dihydroxylated TIQ derivative formed by 
condensation of dopamine and formaldehyde, is found at higher concentrations within 
dopaminergic areas of the human brain and has been shown to inhibit complex 1 of the 
ETC (Musshoff et al 2003; Musshoff et al 2005; Musshoff et al 2000; Musshoff et al 
1999; Shavali et al 2003; Wanpen et al 2004).  Furthermore, (R/S)salsolinol and its N-
methylated derivatives have also been detected in the brain, CSF and urine of PD 
patients (Mravec 2006).  In addition to their ability to cross the blood-brain barrier, there 
is also evidence that N-methyl-6,7-dihydroxylated TIQs such as N-methyl-(R/S)salsolinol 
and N-methyl-norsalsolinol are more toxic than their parent salsolinol (Maruyama et al 
1993; Storch et al 2002).  These reports suggest that methylation at the N-position 
confers heightented toxicity and that these compounds could act as endogenous 
neurotoxins that contribute to the death of dopaminergic neurons.  However, little is 
known about their relative toxicity and the mechanism by which these compounds 
induce cell death.   
 
There is also data to suggest that another methylated TIQ derivative, 1-methyl-
TIQ, may prevent the neurotoxic effects of MPP+ (Makino et al 1990; Parrado et al 2000; 
Yamakawa et al 1999).  However, a protective effect of 1-methyl-TIQ may not be an 
accurate description, and instead may be due to a shielding effect of complex I from the 
much more potent toxin MPP+ (Parrado et al 2000).  For instance, a recent study of the 
cytotoxicity of several TIQ derivatives in dopaminergic SH-SY5Y cells demonstrated that 
1-methyl-TIQ exhibits cytotoxicity and complex I inhibition on par with other non-polar 
TIQ derivatives (Kotake et al 2007).  The possibility of a neuroprotective TIQ derivative is 
intriguing, but conflicting reports of its toxicity are troublesome and a more detailed 
account of its cellular activity is required before any definitive assertions can be made. 
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In the present study, human SH-SY5Y cells were utilized to quantify the 
reduction in mitochondrial membrane potential and resultant cytotoxicity of three 
methylated TIQ derivatives, N-methyl-norsalsolinol, N-methyl-(R/S)salsolinol and 1-
methyl-TIQ.  The human neuroblastoma cell line, SH-SY5Y, is a model for dopaminergic 
neurons.  These cells express several markers of dopaminergic neurons including TH, 
the vesicular monoamine transporter (VMAT), the DAT and -synuclein (Fountaine & 
Wade-Martins 2007; Takahashi et al 1994).  SH-SY5Y cells have also been widely used 
to study apoptosis of dopaminergic neurons by parkinsonism-inducing neurotoxins 
(Ouyang & Shen 2006; Valverde et al 2008).  Here, we quantify the direct toxicity of 
methylated TIQ derivatives by a reduction in overall cellular metabolism, a decrease in 
mitochondrial membrane potential and changes in nuclear morphology consistent with 
apoptosis.  We demonstrate that all three methylated derivatives destroy dopaminergic 
neurons in a dose-dependent manner.  Additionally, physical properties emparted by 
overall compound charge and structure are reported and related to membrane 
permeability and cytotoxicity. 
 
 
5.2 MATERIALS AND METHODS 
 
 
5.2.1 Chemicals 
 
Butanol, formaldehyde, dimethyl sulfoxide (DMSO), rotenone, sodium acetate 
and sodium cyanoborohydride were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  (R/S)saslolinol and norsalsolinol were purchased from Acros Organics (Geel, 
Belgium).  1-methyl-TIQ was purchased from AsisChem Inc. (Cambridge, MA, USA). 
 
 
5.2.2 Synthesis of N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol 
 
The tertiary amines N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol were 
prepared from their respective secondary amines norsalsolinol and (R/S)salsolinol by 
reductive methylation in the presence of formaldehyde and sodium cyanoborohydride.  
The reaction mixtures contained 0.5 M of the amine, 2.5 M formaldehyde, 0.2 M 
sodium acetate, and 1 M sodium cyanoborohydride at pH 5.  The reaction mixture was 
incubated at room temperature overnight under nitrogen in the dark.  The sample was 
clarified by centrifugation and the clear solution was acidified with HCl to pH 0.1 to 
decompose unreacted cyanoborohydride.  The solvent was evaporated and the 
product was extracted from the residue with isopropyl alcohol.  Evaporation of the 
solvent and extraction of the residue was repeated twice.  The final product was stored 
as a solution in isopropyl alcohol at -20 C. 
 
 
5.2.3 SH-SY5Y Cell Culture 
 
The human neuroblastoma cell line, SH-SY5Y, was obtained from the American 
Type Culture Collection (Manassas, VA, USA).  SH-SY5Y cells were grown in minimum 
essential medium: F-12 nutrient mixture (1:1) containing 15% fetal bovine serum and 1% 
non-essential amino acids (Gibco, Rockville, MD, USA) at 37 C under 5% CO2 in a 
humidified atmosphere. 
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5.2.4 Compound Handling and Dilution 
 
All compounds were stored in anhydrous form under vaccum at -80 C until the 
time of administration.  Stock solutions (1 mM) of all compounds were prepared in a 
laminar flow ventilation hood using DMSO and then diluted in culture medium to final 
concentrations.  DMSO concentration in the culture medium did not exceed 0.01%.  For 
each treatment, fresh solutions were used to avoid any possible breakdown by storage.   
 
 
5.2.5 MTT Assay 
 
Cell viability was measured using the MTT assay (Roche Applied Science, 
Indianapolis, IN, USA) (Molina-Jimenez et al 2003).  This colorimetric assay measures 
the metabolic activity of viable cells based on cleavage of the tetrazolium salt WST-1 to 
water-soluble formazan by mitochondrial dehydrogenase in living cells.  SH-SY5Y cells 
(5 x 103 cells/well) were seeded in 96-well plates and incubated with N-methyl-
norsalsolinol, N-methyl-(R/S)salsolinol or 1-methyl-TIQ at concentrations of 1 M, 10 
M, 20 M, 50 M, 200 M and 500 M at 37 C for 24 or 48 hrs.  Rotentone at 
concentrations of 0.01 M, 0.1 M, 1 M, 5 M and 20 M was used as a positive 
control.  After incubation, the medium was removed and 100 l of MTT reagent (0.5 
mg/ml MTT in complete medium) was added to each well.  Following an additional 4 hrs 
of incubation at 37 C, 100 l of DMSO was added to dissolve the formazan crystals, 
and the absorbance was then measured at 550 and 690 nm using a microplate reader 
(Bio-Rad Laboratories, Hercules, CA, USA).  Wells without cells were used as blanks 
and were subtracted as background from each sample.  Wells with cells but without 
toxins were used as negative control.  LC50 values were calculated with absorbance data 
using non-linear regression analysis.   
 
 
5.2.6 Measurement of Mitochondrial Membrane Potential (m) 
 
The collapse of the electrochemical gradient across the mitochondrial membrane 
is an early event in cellular apoptosis.  JC-1 dye localizes to the inner mitochondrial 
membrane where it forms either monomers or aggregates based on the mitochondrial 
membrane potential (m).  At high m (healthy cells), JC-1 accumulates sufficiently in 
the mitochondria to form aggregates (J-aggregates) that exhibit red fluorescence.  
Conversely, at lower m (dying cells) less dye enters mitochondria resulting in 
monomers that demonstrate green fluorescence withing the cell cytoplasm.  The JC-1 
aggregate:monomer ratio has been used as a tool to estimate changes in m (White & 
Reynolds 1996).  SH-SY5Y cells (5 x 103 cells/well) were seeded in 8-well glass slides 
and incubated with N-methyl-norsalsolinol, N-methyl-(R/S)salsolinol or 1-methyl-TIQ at 
concentrations of 100 M at 37 C for 15 min, 30 min and 1 hr.  Rotenone at a 
concentration of 1 M was utilized as a positive control.  JC-1 was dissolved in DMSO 
and further diluted in minimal essential medium (1 mg/ml final concentration).  After 
removal of the toxin-containing medium, cells were loaded with JC-1 for 15 min at 37 C, 
rinsed twice with phosphate buffered saline and immediately photographed on a Leica 
epifluorescent microscope using a rhodamine filter set (Leica Microsystems, 
Bannockburn, IL, USA).  Ten photos were taken randomly from each well.  The 
red/green ratio was determined densitometrically using ImageJ software (US National 
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Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/) from randomly 
selected micrographs in each experiment (10 photos per well).  Reported values 
represent percentages normalized to control cells. 
 
 
5.2.7 DAPI Histochemistry 
 
To assess nuclear morphology and apoptosis, SH-SY5Y cells were stained with 
4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. Louis, MO, USA), a fluorescent 
compound that binds to double-stranded DNA.  SH-SY5Y cells (5 x 103 cells/well) were 
seeded in 8-well glass slides and incubated with N-methyl-norsalsolinol, N-methyl-
(R/S)salsolinol or 1-methyl-TIQ at concentrations of 100 M at 37 C for 1 hr.  Rotenone 
at a concentration of 1 M was utilized as a positive control.  After exposure, cells were 
fixed in phosphate buffered saline containing 3.7% paraformaldehyde for 15 min.  After 
fixation, cells were washed twice with PBS for 5 min and then treated with DAPI (1 
mg/ml) in PBS.  After three 5 min wash cycles, slides were coverslipped with 1,3 diethyl-
8-phenylxanthine mounting compound (DPX; Sigma-Aldrich, St. Louis, MO, USA) and 
visualized under an epifluorescence microscope with ultraviolet excitation at 300-500 nm 
(Leica Microsystems, Bannockburn, IL, USA). 
 
 
5.2.8 Calculation of Molecular Properties 
 
The octanol/water partition coefficient (Log P), topological polar surface area 
(TPSA) and total molecular volume (Vm) were calculated for each compound using 
Mitools Toolkit software (http://www.molinspiration.com).   
 
 
5.2.9 Statistical Analyses 
 
Statistical analyses were based on median values derived from technical 
triplicates.  The results of experiments at the 24 hr time point were analyzed by means of 
one-way ANOVA using SAS software version 9.0 (SAS Institute Inc., Cary, NC, USA) for 
comparisons between compounds at each concentration.  The results of experiments at 
the 48 hr time point were analyzed by means of a student’s t test for comparisons of time 
(24 vs 48 hrs) for each concentration.  An alpha (α) of 0.05 was chosen for statistical 
significance.   
 
 
5.3 RESULTS 
 
 
5.3.1 Cytotoxicity of TIQ Derivatives 
 
Using the MTT assay to evaluate overall cell viability, SH-SY5Y cells were 
exposed to either N-methyl-(R/S)salsolinol, N-methyl-norsalsolinol or 1-methyl-TIQ for 
24 or 48 hrs.  The pesticide and known mitochondrial complex I inhibitor rotenone 
served as a positive control.  As shown in Figure 5-1, 24 hr treament of SY5Y cells with 
N-methyl-(R/S)salsolinol, N-methyl-norsalsolinol and 1-methyl-TIQ resulted in significant 
cytotoxicity.  Comapred to non-treated cells, N-methyl-norsalsolinol (LC50 = 0.305 mM), 
N-methyl-(R/S)salsolinol (LC50 = 0.377 mM) and 1-methyl-TIQ (LC50 = 2.153 mM)  
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Figure 5-1.  Viability of SH-SY5Y cells after 24 hour exposure to rotenone and TIQ 
derivatives. 
(A) Rotenone; (B) N-methyl-(R/S)salsolinol, N-methyl-norsalsolinol and 1-methyl-TIQ.   
* Indicates significant difference between N-methyl-norsalsolinol and others (P < 0.05).   
** Indicates significant difference between 1-methyl-TIQ and others (P < 0.05).  
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significantly reduced cell viability in a dose-dependent manner (Table 5-1).  However, N-
methyl-norsalsolinol was significantly more cytotoxic at 1 M (F (2, 27) = 5.77, P < 
0.008), 10 M (F (2, 27) = 7.27, P < 0.002) and 500 M (F = 8.29, P < 0.0001) 
concentrations relative to N-methyl-(R/S)salsolinol and 1-methyl-TIQ.  Conversely, a 
trend of decreased toxicity of 1-methyl-TIQ relative to N-methyl-(R/S)salsolinol and N-
methyl-norsalsolinol was observed, but only reached significance at the 200 M (F = 
8.29, P < 0.0001) concentration.  Overall, N-methyl-(R/S)salsolinol and N-methyl-
norsalsolinol exhibited similar toxicity (LC50 = 0.376 mM vs 0.305 mM), while 1-methly-
TIQ was much less potent (LC50 = 2.153 mM).  In aggregate, all methylated TIQ 
derivatives were much weaker toxins than rotentone (LC50 = 0.013 mM).    
 
The effect of exposure duration (24 vs 48 hrs) was most pronounced for 
rotentone, reaching significance at 1 M, 5 M and 20 M concentrations (Figure 5-2; P 
< 0.05).  In contrast, exposure duration in methylated TIQ derivatives was only evident at 
higher concentrations, reaching significance at 500 M for N-methyl-(R/S)salsolinol, and 
at 200 M and 500 M for N-methyl-norsalsolinol (P < 0.05). 
 
 
5.3.2 Decreased m after Acute Exposure to Methylated TIQ Derivatives 
 
The JC-1 dye was utilized to evaluate the m induced by exposure to TIQ 
derivatives and rotenone.  As shown in Figure 5-3, N-methyl-(R/S)salsolinol, N-methyl-
norsalsolinol and 1-methyl-TIQ all significantly decreased the red/green fluorescence 
ratio, and therefore decreased m, after 15 min exposure relative to untreated SY5Y 
cells (P < 0.05).  The decrease in m was time dependent, as the JC-1 red/green 
fluorescence ratio continued to decrease at the 30 min and 1 hr exposure time points for 
all compounds (Figure 5-4).  Emulating the results of cell viability experiments, the time-
dependent decrease in m was most pronounced for rotenone.  N-methyl-
(R/S)salsolinol and N-methyl-norsalsolinol exhibited almost identical changes in m, 
while 1-methyl-TIQ demonstrated the weakest decrease in m over time. 
 
 
5.3.3 Nuclear Morphology after Exposure to TIQ Derivatives 
 
Utilizing the DAPI staining protocol, nuclear morphology was evaluated after 
exposure to N-methyl-(R/S)salsolinol, N-methyl-norsalsolinol and 1-methyl-TIQ for 1 hr.  
As shown in Figure 5-5, typical apoptotic morphology such as chromatin condensation, 
nuclear fragmentation and pyknotic cellular contraction are visible after treatment with all 
methylated TIQ derivatives.  Once again, the most significant histochemical findings 
consistent with apoptosis were observed after exposure to rotenone. 
 
 
5.3.4 Molecular Properties of TIQ Derivatives 
 
The calculated molecular properties of N-methyl-(R/S)salsolinol, N-methyl-
norsalsolinol, 1-methyl-TIQ and rotenone are listed in Table 5-1 (a complete listing of 
molecular properties of all TIQ derivatives found in this document can be found in 
Appendix A, Table A-2).  The log P, a standard measure of solubility, was highest for 
rotenone and 1-methyl-TIQ (3.585 and 2.048, respectively).  A high log P value indicates 
a predilection for sequestration in non-polar or hydrophobic environments.  As a direct  
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Table 5-1.  Cytotoxicity and physical properties of study compounds. 
 
  
*  LC50 24 hrs = Median Lethal Concentration at 24 hrs 
 
 
 
 
 
 
Figure 5-2.  Viability of SH-SY5Y cells after 48 hour exposure to rotenone and TIQ 
derivatives. 
(A) Rotenone; (B) 1-methyl-TIQ; (C) N-methyl-(R/S)salsolinol; (D) N-methyl-
norsalsolinol.   
* Indicates a significant difference between the 24 and 48 hr exposure period (P < 0.05).   
Compound LC50 24 hrs* (mM) Log P TPSA (Å2) Vm (cm3/mol) 
Rotenone 0.013 3.585 63.241 348.335 
N-Methyl-Norsalsolinol 0.305 0.741 43.694 168.988 
N-Methyl-(R/S)Salsolinol 0.377 1.301 43.694 185.575 
1-Methyl-TIQ 2.153 2.048 12.027 152.596 
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Figure 5-3.  Decreased mitochondrial membrane potential (m) after acute 
exposure to TIQ derivatives.   
JC-1 staining of SH-SY5Y cells after 15 min exposure to mitochondrial toxins.  (A) 
Compound-free control; (B) 100 µM 1-Methyl-TIQ; (C) 100 µM N-Methyl-(R/S)Salsolinol; 
(D) 100 µM N-Methyl-Norsalsolinol; (E) 1 µM Rotenone. (F) Normalized red:green 
fluorescence ratios of compounds after 15 min exposure.  Values represent the mean +/- 
SEM of three experiments with four wells in each treatment.  Scale bar=25 µm.  
* Indicates significant difference between compounds and control (P < 0.05).   
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Figure 5-4.  Red/Green fluorescence ratios of study compounds over 1 hour. 
Time-dependent decrease in m in SH-SY5Y cells treated with 100 µM 1-methyl-TIQ, 
N-methyl-(R/S)salsolinol or N-methyl-norsalsolinol.  1 µM rotenone was utilized as 
positive control.  Values represent the mean +/- SEM of three independent experiments.   
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Figure 5-5.  TIQ derivative-induced apoptosis of SH-SY5Y cells.   
DAPI-stained nuclei are shown from (A) control cells and cells treated with (B) 100 µM 1-
methyl-TIQ, (C) 100 µM N-methyl-(R/S)salsolinol, (D) 100 µM N-methyl-norsalsolinol 
and (E) 1 µM rotenone for 1 hr.  Small, pyknotic cells undergoing apoptosis are visible 
after exposure to all study compounds.  Cells treated with 1 µM rotenone (F) depict the 
early and late stages of chromatin condensation and fragmentation characteristic of 
apoptosis. 
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function of their polar oxygen molecules, rotenone, N-methyl-(R/S)salsolinol and N-
methyl-norsalsolinol exhibited higher TPSA than 1-methyl-TIQ.  TPSA is commonly used 
in medicinal chemistry for the optimisation of cell permeability.  Molecules with a polar 
surface area of greater than 140 Å2 are believed to be poor at permeating cell 
membranes.  For penetration of the blood-brain-barrier, TPSA values should typically be 
less than 60 Å2 (Ertl et al 2000).  A significant positive correlation was observed 
between cytotoxicity (LC50 value) and TPSA (correlation coefficient r2 = 0.92), but not 
between cytotoxicity and log P value (r2 = 0.06) or Vm (r2 = 0.34).  
 
 
5.4 DISCUSSION 
 
The present study demonstrates that N-methyl-(R/S)salsolinol, N-methyl-
norsalsolinol and 1-methyl-TIQ induce cell death in human SH-SY5Y dopaminergic 
neuroblastoma cells in a dose-dependent manner.  Although the relative toxicity of N-
methyl-(R/S)salsolinol and N-methyl-norsalsolinol were very similar, N-methyl-
norsalsolinol was slightly more cytotoxic to SY5Y cells (LC50 0.377 mM and 0.305 mM, 
respectively).  1-methyl-TIQ, however, was almost an order of magnitude less toxic to 
SY5Y cells (LC50 2.153 mM).  Overall, rotenone (LC50 0.013 mM) was over 20 times 
more cytotoxic relative to either of the the N-methylated salsolinols.  Cytotoxicity was 
positively correlated to TPSA, a measure of cell membrane permeability, for all study 
compounds.  Studies of mitochondrial function indicate that these methylated TIQ 
derivatives induce an acute, time-dependent decrease in m, with potencies that 
closely mirror those of overall cellular viability.  A collapse of m is very likely 
accompanied by an impairment of overall cellular energy production without generation 
of reactive oxygen species.  Finally, analysis of nuclear morphology indicates that cell 
death is likely apoptotic in nature.  
 
N-methyl-(R)salsolinol is arguably the best-studied of the TIQ derivatives in terms 
of cell death mechanisms.  To date, several reports document the cytotoxicity of N-
methyl-(R)salsolinol in SH-SY5Y cells (Akao et al 2002; Akao et al 1999; Maruyama et al 
2001; Maruyama et al 1997a; Maruyama et al 1997b; Maruyama et al 2004; Naoi et al 
2000; Yi et al 2006a; Yi et al 2006b).  Interestingly, at concentrations of 1 mM, the S-
enantiomer of N-methyl-salsolinol was determined to be significantly less toxic than the 
R-enantiomer in SY5Y cells using single-cell gel electrophoresis (the “comet assay”) for 
detection of DNA fragmentation (Maruyama et al 1997a; Maruyama et al 1997b).  Based 
on the results of these studies alone, the role of N-methyl-(S)salsolinol in dopaminergic 
cell death has been largely ignored.  A later study by Akao and colleagues utilized 500 
M N-methyl-(R)salsolinol exposure to SY5Y cells for 72 hrs to confirm apoptotic cell 
death using DNA ladder electrophoresis and detection of activated caspase 3 (Akao et al 
1999).  These results were later confirmed in a separate experiment demonstrating the 
loss of m, activation of caspase 3 and DNA fragmentation after 250 M N-methyl-
(R)salsolinol exposure to SY5Y cells for 24 hrs (Naoi et al 2000).  Maruyama and 
colleagues demonstrated that 24 hr exposure to 200 M N-methyl-(R)salsolinol induced 
an acute decrease in m (at 3 hrs) activation of caspases and fragmentation of DNA 
(Maruyama et al 2001).  Akao and co-workers have also demonstrated that 500 M N-
methyl-(R)salsolinol reduced m in the early phase of apoptosis and was inhibited by 
both Bcl-2 (a pan-caspase inhibitor) and cyclosporin A (an inhibitor or mitochondrial pore 
opening) independently, suggesting the dependence of the caspase cascade and the 
mitochondrial permeability transition in N-methyl-(R)salsolinol-induced apoptosis (Akao 
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et al 2002).  This was also the first report to demonstrate that rasagiline (N-propargyl-
1(R)-aminoindan), an irreversible MAO-B inhibitor, suppressed m reduction, release of 
cytochrome c from mitochondria and apoptosis induced by N-methyl-(R)salsolinol in SH-
SY5Y cells (Akao et al 2002).  The compound benzofuranylpropylaminopentane (BPAP; 
a catecholaminergic enhancer) was also shown to inhibit apoptosis by direct stabilization 
of m and the induction of the anti-apoptotic protein Bcl-2 in SY5Y cells exoposed to N-
methyl-(R)salsolinol (Maruyama et al 2004).  A recent study by Yi and colleagues 
demonstrated that the binding of N-methyl-(R)salsolinol to mitochondria was inhibited by 
clorgyline, a MOA-A inhibitor (Yi et al 2006a).  However, MAO-A inhibition does not 
apprear to be a prerequisite for the protective function of propargylamine derivatives, 
such as rasagiline, towards N-methyl-(R)salsolinol-mediated toxicity (Yi et al 2006b).  In 
aggregate, these studies suggest that N-methyl-(R)salsolinol enters mitochondria via a 
MAO dependent mechanism and there induces apoptotic cell death by complex 1 
inhibition with resultant destabilization of m, the release of cytochrome c from the 
mitochondrial matirx and induction of the caspase cascade. 
 
Unfortunately, none of the above-mentioned reports utilized an array of N-methyl-
(R)salsolinol dosages or an overall measure of cell viability, such as the MTT assay, to 
determine a standard convention of toxicity such as the LC50 or median lethal 
concentration.  Without such a measure, a comparison between compounds or between 
reports becomes virtually impossible.  However, our results, obtained using racemic N-
methyl-(R/S)salsolinol are largely consistent with previous reports in respect to the acute 
collapse of m.  It should be mentioned, however, that the results of Maruyama, Naoi 
and colleagues should be interpreted with caution.  For instance, all of the above-
metioned reports utilize the synthetic methods of Teitel and colleagues for synthesis of 
racemic N-methyl-(R/S)salsolinol (Teitel et al 1972).  However, no explanation or 
procedure for the difficult and expensive separation and purification of R- and S-
enantiomers is provided.  Furthermore, to date, no publication has provided any physical 
data (such as NMR or mass spectra) to prove successful yield.  With this in mind, the 
dominant toxicity of the R-enantiomer may be suspect. 
 
N-methyl-norsalsolinol, a compound known to inhibit MAO and TH in vitro, has 
received much less attention in terms of cytotoxity (Moser et al 1996a; Scholz et al 
1997).  The present study represents the first to quantify the definitive cytotoxicity of N-
methyl-norsalsolinol in dopaminergic neurons.  Furthermore, our data suggests that the 
induced decrease in m and overall toxicity of N-methyl-norsalsolinol is on par with that 
of N-methyl-(R/S)salsolinol in SY5Y cells.  In agreement with our findings, N-methyl-
norsalsolinol was shown to be equally as toxic to cultured PC12 cells as N-methyl-
(R)salsolinol (Maruyama et al 1993; Naoi et al 1995).  However, it should mentioned that 
that PC12 cells are well known to rely far more upon glycolysis than the tricarboxylic acid 
cycle for their energy supply, and may thus be less sensitive to complex 1 inhibitor-
mediated cytotoxicity (Basma et al 1992).  Nevertheless, both N-methyl-(R/S)salsolinol 
and N-methyl-norsalsolinol appear to be at least twice as cytotoxic as their parent 
(R/S)salsolinol in SY5Y cells (LC50 0.704 mM) (Storch et al 2000).  This finding suggests 
that methylation at the N-position does confer heightened toxicity to salsolinol 
derivatives.       
 
 The observed cytotoxicity of 1-methyl-TIQ in SH-SY5Y cells (LC50 2.153 mM) is 
consistent with a recent study by Kotake and colleagues (LC50 2.81 mM) (Kotake et al 
2007).  In this report, the complex I inhibiton and resultant cytotoxicity of several TIQ 
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derivatives were determined in SH-SY5Y cells.  Overall, N-methyl-TIQ and 1-methyl-TIQ 
were the least cytotoxic of all direct TIQ derivatives under study (LC50 2.63 mM and 2.81 
mM, respectively).  For reference, the reported LC50 of TIQ in SY5Y cells was 1.19 mM.  
These results may explain the finding that the inhibitory effect on mitochondrial 
respiration induced by MPP+ in isolated rat liver mitochondria is prevented by the 
addition of 1-methyl-TIQ (Parrado et al 2000).  As suggested by the authors, 1-methyl-
TIQ may bind to complex 1 of mitochondria and effectively shield the enzyme system 
from compounds with orders of magnitude higher toxicity such as MPP+ (LC50 
approaching 0.001 mM in SY5Y cells).  However, based on its relatively weak toxicity, it 
may still induce a decrease in m and initiate cell death on much longer time scales.  
Thus, 1-methyl-TIQ does not necessarily appear to be neuroprotective, but rather less 
deadly. 
 
Another mechanism which may contribute to the strong effects of N-methyl-
norsalsolinol and N-methyl-(R/S)salsolinol on mitochondrial indices of cellular energy 
might be their mild inhibitory effect on the -ketoglutarate dehydrogenase complex (-
KGDH) of the TCA cycle (McNaught et al 1995a).  Since -KGDH catalyses the 
oxidation of -ketoglutarate to succinate, which is a substrate for mitochondrial complex 
II, the blockade of -KGDH would additionally inhibit electron transfer via complex II.  
Since the metabolism of -ketoglutarate by -KGDH produces NADH, reduction of -
KGDH activity would partially inhibit complex I by decreasing NADH and, in addition, 
inhibition of the rate-limiting enzyme -KGDH would lead to impairment of the general 
function of the TCA cycle.  Interestingly, a decrease in -KGDH activity has been 
demonstrated in the SN of PD patients (Mizuno et al 1994). 
 
It should also be mentioned that the presented data do not rule out the possibility 
that free radical formation is involved in the impairment of cellular energy production 
induced by N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol.  Production of hydroxyl 
radicals through oxidation of N-methylated salsolinols has been reported under in vitro 
conditions (Naoi et al 1998a; Nappi et al 1999).  On the other hand, N-methyl-
(R)salsolinol has been shown to scavenge hydroxyl radicals produced by oxidation of 
dopamine in vitro and in vivo (Naoi et al 1998a).  However, by using the same cell line 
and similar experimental conditions, Willets and colleagues demonstrated that 
antioxidative substances, such as ascorbic acid and atocopherol, failed to protect SH-
SY5Y cells against (R/S)salsolinol-induced toxicity, suggesting that free radical formation 
does not play a major role in salsolinol derivative-induced toxicity in this cell system 
(Willets et al 1995).   
 
The results presented herein also demonstrate a significant positive correlation 
between cytotoxicity and TPSA for all compounds under study.  TPSA, defined simply as 
the molecular surface corresponding to oxygen and nitrogen, is one of the most 
important parameters used to characterize the transport properties of molecules.  TPSA 
values have shown very good correlations with intestinal absorption, cell membrane 
solubility and blood-brain barrier penetration (Clark 1999a;b).  Based on TPSA 
calculations, all study compounds have a polar area less than 140 Å2, making all 
compounds good candidates for permeating cell membranes.  This observation may 
suggest that TIQ derivatives may induce cellular apoptosis independent of active 
membrane transport.  However, TIQ derivatives with very high TPSA and very low log P 
values may be too hydrophilic for passive membrane transport and may require 
transporters such as the DAT for toxicity.       
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5.5 CONCLUSIONS 
 
The endogenous neurotoxins N-methyl-norsalsolinol and N-methyl-
(R/S)salsolinol, which are structurally similar to MPTP, have been reported to inhibit 
mitochondrial complex I (NADH-Q reductase) activity as does the MPTP metabolite 
MPP+.  However, the mechanism of N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol 
leading to neuronal cell death is largely unknown.  Our results demonstrate that these N-
methylated salsolinols are toxic to dopaminergic neuroblastoma SH-SY5Y cells by 
impairment of mitochondrial function.  This impairment is most likely caused by inhibition 
of mitochondrial complex I activity, and possibly enhanced by blocking the general 
function of the TCA cycle.  N-methyl-norsalsolinol and N-methyl-(R/S)salsolinol induce a 
dose-dependent decrease in cell survival with LC50 values of 0.305 mM and 0.377 mM 
after 24 hrs, respectively.  Another methylated TIQ derivative with suspected 
neuroprotective properties, 1-methyl-TIQ, was shown to be an order of magnitude less 
toxic to SY5Y cells (LC50 2.153 mM).  Rotenone, a potent inhibitor of mitochondrial 
complex I, was over 20 times more cytotoxic relative to either of the the N-methylated 
salsolinols (LC50 0.013 mM).  Using the JC-1 dye, it was determined that these 
methylated TIQ derivatives induce an acute, time-dependent collapse of m, likely 
accompanied by an impairment of overall cellular energy production.  Analysis of nuclear 
morphology confirmed that cell death is likely apoptotic in nature.  This data confirms 
that N-methylated salolinol derivatives are indeed toxic to human dopaminergic neurons.  
Their synthesis within dopaminergic regions of the brain coupled with the potential for 
accumulation from exogenous sources make them strong candidates for a 
neurotoxicological component to the pathobiology of PD. 
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CHAPTER 6.  SUMMARY AND DISCUSSION 
 
 
6.1 SUMMARY 
 
 The research presented herein represents a comprehensive and systematic 
evaluation of TIQ accumulation in the brain via endogenous and/or exogenous sources 
and their relationship to neurodegenerative disease.  First, using liquid chromatographic 
and immunocytochemical techniques the regional distribution of several TIQs were 
determined in mouse, rat, normal human and PD human brain.  The cellular localization 
of an important and relatively unknown TIQ, N-methyl-NorSAL, was determined in rodent 
brain using a novel monoclonal antibody.  Second, the content of several TIQs were 
determined in 40 commonly consumed plants using liquid chromatography.  The intake 
of these foods and their toxin profiles were then explored in relation to PD using a 
lifetime food-serving intake questionnaire.  Using rat brain samples from several age 
groups, the accumulation of TIQs over time was demonstrated in several brain regions.  
Finally, using a model for human dopaminergic neurons, the dose-dependent cytotoxicity 
of select N-methylated TIQs was demonstrated and associated with mitochondrial 
dysfunction.  Presented as a supplement to the primary studies, the thermal stability and 
molecular physical properties of TIQs were determined. 
 
Several members of the TIQ family of monoamine alkaloids can be formed from 
dopamine or its oxidized metabolites and may be involved in the pathogenesis of 
monoaminergic cell death in PD.  Many salsolinol derivatives were detected at higher 
concentrations in regions of increased dopamine synthesis and turnover such as the 
ventral midbrain and striatum, respectively.  Furthermore, salsolinols were present at 
higher concentrations than TIQ and its benzyl and methyl derivatives, especially in 
human brain.  Both enantiomers of SAL were found in all brain regions, with noticeable 
correlations identified between stereoselective synthesis of (R)SAL and dopamine 
concentration.  A possible consequence of nigrostriatal dopaminergic cell death, 
significantly lower levels of (R)SAL, (S)SAL, N-methyl-(R)SAL and N-methyl-(S)SAL 
were detected in the caudate nuclei of PD in comparison with normal human brain.  
Overall, the methylated and benzylated derivatives of TIQ were present at lower 
concentrations than their parent compound.  In the brain, topological trends in derivative 
concentration suggest regionally distinct methylation patterns.  Finally, stability 
experiments revealed high thermal tolerance for all TIQs.   
 
The TIQ derivative N-methyl-NorSAL is present in normal human brain, has been 
identified in the CSF of PD patients and can be derived from dopamine by condensation 
with aldehydes or α-ketoacids.  Using HPLC-EC, N-methyl-NorSAL was detected in all 
regions of rodent and human brain.  In rodent brain, N-methyl-NorSAL concentrations 
were similar among frontal cortex, ventral midbrain, striatum, hippocampus and 
cerebellum.  Conversely, in normal human brain, N-methyl-NorSAL was concentrated in 
dopaminergic regions (SN and striatum).  N-methyl-NorSAL levels were significantly 
lower in the SN and caudate nuclei from PD patients, a finding possibly related to the 
death of nigrostriatal neurons.  Furthermore, N-methyl-NorSAL-IR co-localized with a 
general neuronal marker and a monoaminergic marker.  The widespread neuronal 
localization of N-methyl-NorSAL in several mammalian species suggests that this 
compound acts as a relatively weak neurotoxin. 
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Epidemiological studies suggest that environmental factors contribute to the 
pathogenesis of PD.  Several TIQs have been shown to inhibit complex I of the ETC, 
initiate apoptosis in cultured dopaminergic neurons and are recognized as latent 
substances in plants.  High concentrations of TIQ derivatives were detected in banana, 
cherry, peach, grapefruit, avocado, button mushroom, leaf lettuce and celery.  
Enantiomeric salsolinol derivatives were detected as racemic mixtures, indicating that 
stereoselective enzymatic synthesis does not occur in plants.  The mushroom family 
(Agaricaceae) contained the highest average TIQ derivative load, salsolinol derivative 
load and total toxin load of all plant families analyzed.  The banana family (Musaceae), 
rose family (Rosaceae), sunflower family (Asteraceae) and pineapple family 
(Bromeliaceae) also contained particularly high average neurotoxin loads.  Utilizing a 
lifetime food-item intake questionnaire, a trend of increased intake of several plants 
products (bananas, apples, watermelon, oranges, cantaloupe, grapes, grapefruit, 
potatoes, iceberg lettuce, tomatoes, onions, carrots and celery) was observed in PD 
patients.  However, this finding only reached significance in oranges.  Members of the 
rue (Rutaceae), banana (Musaceae), gourd (Cucurbitaceae), carrot (Apiaceae) and 
nightshade (Solanaceae) families were found to be highly consumed by both normal and 
PD humans, and to concentrate several potentially neurotoxic TIQ derivatives. 
 
Using HPLC-EC and LC-MS/MS, the accumulation of TIQ derivatives in rat brain 
was demonstrated over time.  The concentration of TIQ derivatives appears to change 
very little over time, with high accumulation within the first several weeks of life.  
Salsolinol derivatives experience a more rapid ascent within the first 6 months of life 
within dopaminergic regions, followed by another rise in concentration in late life.  Levels 
of N-methyl-NorSAL accumulate more slowly, followed by rapid accumulation around 6 
months with sustained increases over time.  Overall, the net content of TIQ and 
salsolinol derivatives rises early and remains relatively constant over the life of the rat, 
with the exception of N-methyl-NorSAL. 
 
Finally, we demonstrate that the endogenous TIQs N-methyl-NorSAL and N-
methyl-(R/S)SAL are toxic to dopaminergic neuroblastoma SH-SY5Y cells by impairment 
of mitochondrial function.  N-methyl-NorSAL and N-methyl-(R/S)SAL induce a dose-
dependent decrease in cell survival with LC50 values of 0.305 mM and 0.377 mM after 
24 hrs, respectively.  1-methyl-TIQ, was shown to be an order of magnitude less toxic to 
SY5Y cells (LC50 2.153 mM), potentially explaining its suggested relative neuroprotective 
properties.  Rotenone, a potent inhibitor of mitochondrial complex I, was over 20 times 
more cytotoxic relative to either of the N-methylated salsolinols (LC50 0.013 mM).   
A significant positive correlation between cytotoxicity and polar surface area, a measure 
of membrane permeability, was also observed for these compounds.  All of the 
methylated TIQ derivatives examined induce an acute, time-dependent collapse of m, 
suggesting an impairment of overall cellular energy production.  Analysis of nuclear 
morphology confirmed that cell death is apoptotic in nature.  
 
 Several important issues regarding the toxicity of TIQs in the brain are 
specifically addressed by our results.  First, our studies of TIQ detection in animal and 
plant tissues are of the highest standard and are unparalleled in comparison to the 
published literature.  Our experiments represent a fundamental and thorough analysis in 
a controversial and poorly understood realm of neurobiology.  We demonstrate that TIQs 
are found within neurons of many brain regions in both rodents and humans, suggesting 
that glial cells may not be necessary for toxicity and that these toxins may cause cell 
death throughout the brain.  We demonstrate that (R/S)SAL and its derivatives are found 
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at higher levels in dopaminergic regions of human brain and that these compounds 
increase as the content of dopamine increases in the rat brain, both of which support the 
hypothesis that salsolinol derivatives may be synthesized from dopamine within neurons 
(Cohen & Collins 1970; Schöpf & Bayerle 1934).  Second, our quantative data in plants 
is the first to truly establish that TIQs are indeed natural substances found in the 
environment at sufficient concentrations to allow for accumulation in the brain after 
intake.  Furthermore, data obtained from our food-intake questionnaire suggests that PD 
patients may ingest higher quantities of select fruits and vegetables that contain 
relatively high levels of several TIQ derivatives.  These results provide evidence to 
support a pragmatic exogenous means of neurotoxin exposure.  Examination of the 
physical properties presented in Appendix A, in conjunction with previous data 
concerning the blood-brain barrier permeability of select TIQ derivatives (Abe et al 2001; 
Origitano et al 1981; Song et al 2006; Thumen et al 2002) suggests that most TIQs are 
good candidates for penetration of the gastrointestinal mucosa after oral ingestion and 
subsequent penetration into the brain.  These findings definitively place potentially 
cytotoxic TIQ derivatives within dopaminergic regions of the brain essential to the 
pathophyisology of PD.  Finally, our experiments demonstrating the in vitro toxicity of N-
methylated salsolinols in dopaminergic neurons definitively confirms the findings of other 
groups (Akao et al 2002; Akao et al 1999; Maruyama et al 2001; Maruyama et al 1997a; 
Maruyama et al 1997b; Maruyama et al 2004; Naoi et al 2000; Yi et al 2006a; Yi et al 
2006b) and establishes a relative measure of their toxicity.  They also demonstrate, for 
the first time, that the toxicity of N-methyl-NorSAL is higher than that of N-methyl-
(R/S)SAL in dopaminergic neurons.  In conclusion, these results provide strong support 
for our global hypothesis of TIQ accumulation and concentration in dopaminergic regions 
of human brain over time via both endogenous and exogenous means, leading to 
gradual mitochondrial dysfunction and ultimate neuronal cell death with subsequent 
development of parkinsonian symptomatology.    
 
 
6.2 DISCUSSION    
 
The potential role of TIQs in the pathobiology of PD places the mitochondrion in 
a centralized role in initiating cell death and provides an avenue for the interaction of 
several genes known to be associated with the development of disease.  As such, the 
function of the mitochondrion in apoptosis and the role of neurotoxins (such as the TIQs) 
superimposed on genetic susceptibility warrants further discussion.    
 
Over the past three decades, two fundamentally different forms of cell death, 
apoptosis and necrosis, have been defined.  Necrosis is a passive process that occurs 
when a major environmental damaging event causes irreversible cellular dysfunction.  
This results in cell swelling with cell membrane breakdown and release of cellular 
contents and is usually associated with an inflammatory response.  Apoptosis, on the 
other hand, is a well defined active process that involves shrinkage of the cell, 
breakdown of cellular proteins, condensation of the nucleus, and cleavage of nuclear 
DNA, and typically does not cause inflammation (Cummings et al 1997; Honig & 
Rosenberg 2000).  Apoptosis research has undergone a change from a paradigm in 
which the nucleus determines the apoptotic process to one in which mitochondria are a 
major center of death control (Aizenman et al 2000; Brenner & Kroemer 2000; Joza et al 
2001).  It is now clear that many different apoptotic signals converge on mitochondria.  A 
variety of key events in apoptosis focus on mitochondria, including changes in electron 
transport, loss of mitochondrial transmembrane potential, altered cellular oxidation-
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reduction potential, release of caspase regulators, and participation of pro- and 
antiapoptotic Bcl-2 family proteins (Aizenman et al 2000; Bernardi et al 1999; Brenner & 
Kroemer 2000; Kroemer 1999). 
 
In the three-step model of apoptosis proposed by Kroemer and colleagues ,three 
phases can be distinguished during apoptosis, an initiation phase, which is extremely 
heterogeneous, during which signal transduction cascades or damage pathways are 
activated, a decision phase, during which the cell decides to die, and a degeneration 
phase, during which proteins released from mitochondria cause the activation of 
programmed cell death through the activation of caspases and nucleases (Brenner & 
Kroemer 2000; Kroemer 1999; Marzo et al 1998).  During the decision phase 
mitochondria integrate different death signals and trigger the decision to die by releasing 
proapoptotic proteins.  The mitochondrial intermembrane space contains a number of 
cell death-promoting factors, including cytochrome c, second mitochondria derived 
activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), apoptosis-
inducing factor (AIF) and procaspases (Aizenman et al 2000; Chai et al 2000; Joza et al 
2001).  The released cytochrome c interacts with procaspase 9, apoptotic peptidase 
activating factor 1 (Apaf-1), and ATP to trigger the assembly of the apoptosome which 
proteolytically activates caspase-9 and other “executioner phase” caspases (Skulachev 
1998; Yuan & Yankner 2000).  When the caspases are activated they cleave a wide 
variety of proteins in the cell, which results in cell death via apoptosis.  The caspase-
9/caspase-3 pathway is also regulated by proteins of the IAP (inhibitor of apoptosis 
proteins) family.  One of these, X-linked inhibitor of apoptosis protein (XIAP), binds to 
caspase-9 and inhibits its proteolytic activity. The caspase-inhibiting effects of XIAP are 
antagonized by another intermembrane protein, Smac/DIABLO (Chai et al 2000; Meier 
et al 2000).  AIF is a flavoprotein normally confined to the mitochondrial intermembrane 
space.  Once released to the cytosol, AIF translocates to the nucleus and induces 
nuclear chromatin condensation, as well as large scale DNA fragmentation in a caspase-
independent fashion (Joza et al 2001; Marzo et al 1998). 
 
Direct evidence of mitochondrial dysfunction leading to disease is gleaned from 
clinical manifestations caused by mitochondrial DNA (mtDNA) mutations.  Mitochondrial 
dysfunction due to defects in oxidative phosphorylation, such as those induced by 
complex I inhibitors, increases reactive oxygen species production and leads to 
accumulated mitochondrial oxidative damage, energy insufficiency, cell dysfunction and 
progressive physiological dysfunction in tissues requiring a large supply of energy 
(Esposito et al 1999; James et al 1996).  Several particular mtDNA polymorphisms and 
haplotypes have been reported to be associated with the risk of PD, and mutations in 
mtDNA or in the nuclear-encoded mtDNA polymerase-G (POLG) cause PD-like 
symptoms (Autere et al 2004; Luoma et al 2007).  Recently, the finding that the electron 
acceptor coenzyme Q10, also a potent antioxidant, can slow the progressive deterioration 
of function in PD provides a further clue that decreasing mitochondrial oxidative stress 
may alter the progression of this disease.  Therefore, mitochondrial dysfunction, 
resulting from genetic defects, endogenous/environmental toxins, or a combination of 
the two, may cause oxidative modification of -synuclein that leads to selective 
neurodegeneration by means of oxidative stress (Sherer et al 2003). 
 
Only a small fraction of PD cases are caused by single-gene mutations.  
However, the identification of these rare, inherited mutations causing familial forms of 
PD have provided much insight into the discovery of novel proteins and pathways that 
are likely to be relevant in the pathogenesis of both the genetic and sporadic forms of 
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PD.  These genes include -synuclein, parkin, PINK1, DJ-1 and LRRK2.  The 
demonstration that -synuclein is the main constituent of LBs leads to the suggestion 
that cell degeneration may arise through the -synuclein-related pathway, protein 
misfolding and aggregation.  These proteins are ubiquitinated and initially degraded by 
the UPS, in which parkin acting as an E3 ligase in the UPS system has a crucial role.  
The identification of mutations in DJ-1 as a possible redox sensor, and phosphatase and 
tensin homologue PINK1, a mitochondrial kinase, provided further evidence that 
mitochondrial dysfunction and oxidative stress might have a primary role in the 
pathogenesis of PD (Bonifati et al 2003; Valente et al 2004).  PINK1 encodes a putative 
serine/threonine kinase with a mitochondrial targeting sequence.  Studies have revealed 
that PINK1 is associated with the inner mitochondrial membrane and is exposed to the 
intermembrane space (Gandhi et al 2006; Silvestri et al 2005).  Parkin localizes 
predominantly to the cytosol but also associates with the mitochondrial outer membrane.  
PINK1 might modulate the activity or stability of parkin either within the mitochondrion or 
in the cytosol, as it might be released from mitochondria under certain conditions 
(Dodson & Guo 2007).  Moreover, in Drosophila, it has been shown that PINK1 and 
parkin function, at least in part, in the same pathway.  These studies suggest a role for 
PINK1 in normal mitochondrial function and imply that parkin is downstream of PINK1 
(Clark et al 2006; Gautier et al 2008).  The findings that the PINK1/parkin pathway 
promotes mitochondrial fission and/or inhibits fusion in Drosophila and that the loss of 
mitochondrial integrity in PINK1 and parkin mutants derives from reduced mitochondrial 
fission further support the possibility that PINK1 and parkin might regulate mitochondrial 
dynamics (Deng et al 2008; Poole et al 2008).  Obviously, neurotoxins causing 
dysfunction of existing mitochondria in the setting of these mutations would be 
disastrous for the cell.  
 
 Mitochondrial functions are performed in concert with other cell compartments 
and are regulated by various extracellular and intracellular signals.  A host of nuclear 
receptors and other nuclear transcription factors, such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-B), activator protein-l (AP-1), cAMP response 
element binding protein (CREB) and protein 53 (p53), involved in growth, metabolic and 
developmental processes, have been detected in mitochondria (Psarra & Sekeris 2008).  
Recently, the idea that these mitochondrially localized transcription factors can act not 
only on the nucleus but also on mitochondrial transcription has gained support.  To 
adapt to a changing environment, it is necessary for cells to be able to regulate 
transcription of genes serving a common function by way of interaction with common 
binding sites in the two genomes including nuclei and mitochondria.  Oxidative stress 
and the redox state are also involved in the survival signaling pathway of stressed cells 
(Reddehase et al 2009).  In response to increased oxidative stress, there may be some 
alteration in dopaminergic neurons in terms of mitochondrial abundance, copy number 
and integrity of mtDNA under these pathological conditions.  Within its tolerable 
threshold, reactive oxygen species, induced by neurotoxin exposure, may activate 
protective responses through expression of specific genes to aid cells in coping with 
hazardous environments.  Once beyond this threshold, these reactive oxygen species 
may cause damage to mtDNA and other biomolecules of the affected dopaminergic 
neurons and elicit an apoptotic cascade induction of mitochondrial membrane 
permeability transition and release of proapoptotic proteins such as cytochrome c, which 
eventually leads to dopaminergic neuron degeneration.  Being the major supplier of 
energy in mammalian cells, mitochondria are necessary to provide more energy for 
damage repair and cellular survival during disease processes with excessive oxidative 
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stress.  In order to meet the demand for energy supply, signals transmitted to the 
nucleus may induce mitochondrial proliferation and mtDNA amplification to produce 
more functional mitochondria.  The abundance of mitochondria in a cell is determined by 
the biogenesis and division of the organelles and tightly controlled by the activation of 
specific transcription factors encoded by nuclear genes (Attardi & Schatz 1988).  Nuclear 
respiratory factors 1 and 2 (NRF-1 and NRF-2) are transcriptional regulators that act on 
the nuclear genes coding for peptides necessary for the mitochondrial ETC.  They also 
regulate the expression of many other genes involved in mtDNA replication (Evans & 
Scarpulla 1990; Virbasius et al 1993).  Mitochondrial transcription factor A (Tfam) acts 
on promoters within mtDNA and regulates the replication and transcription of the 
mitochondrial genome (Virbasius & Scarpulla 1994).  Both NRF-1 and NRF-2 can 
regulate the expression of the Tfam gene by binding to consensus-binding sites.  This 
provides a unique mechanism for the cell to integrate the expression of nuclear DNA-
encoded proteins with the transcription of genes encoded by mtDNA.  Recently, 
evidence has emerged that peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1) is a major regulator of mitochondrial biogenesis (Puigserver et 
al 2003).  PGC-1 regulates the expression of transcription factors involved in the 
coordinated expression of mitochondrial genes, such as NRF-1 and NRF-2, which in turn 
trigger the expression of nuclear genes coding for polypeptides of the ETC and proteins 
involved in transcription and replication of mtDNA (Puigserver et al 2003).  Recently, the 
production of a Tfam knockout mouse model of PD, and the reduced mtDNA expression 
and ETC deficiency in the midbrain dopaminergic neurons of these animals further 
support this hypothesis (Ekstrand et al 2007).  It thus becomes evident that in neurons 
stressed by mitochondrial toxins, a thorough understanding of pro-survival pathways of 
nigrostriatal neurons is crucial for the prevention of disease progression. 
 
 
6.3 FUTURE DIRECTIONS 
 
In conclusion, the body of work included in this dissertation provides important 
new insights into the role of TIQ derivatives in PD and points out clear avenues for future 
studies.  One apparent starting point would be confirmation of TIQ-induced apoptosis in 
5Y cells using western blot analysis for detection of a subset of the above-mentioned 
mitochondrial proteins.  Although apoptosis and necrosis may not be mutually exclusive 
in the setting of TIQ-mediated cell death, mechanistically related toxins such as rotenone 
tend to exclusively initiate apoptosis in dopaminergic cells. 
 
Subsequent studies would involve a more precise determination of mechanisms 
involved in TIQ accumulation.  By obtaining a more expansive collection of normal 
human brain samples from all decades of life, a TIQ derivative accumulation profile 
could be obtained and compared to that of the rodent.  This data would be central to our 
hypothesis of time-dependent accumulation of TIQs in the human brain.   
 
A logical experimental progression would then lead towards exploring our 
hypothesis of cytosolic dopamine and its relation to TIQ derivative 
production/accumulation.  This would involve the utilization of mouse strains harboring 
mutations in proteins which contribute to the regulation of vesicular and cytosolic 
dopamine concentrations.  VMAT2 is a transmembrane protein responsible for uptake of 
cytosolic monoamines within neurons.  Based upon our hypothesis, VMAT2 may play a 
role in neuroprotection by sequestering dopamine into vesicles and away from TIQ 
derivative biosynthesis.  Previous neurochemical analysis of VMAT2-deficient mice 
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shows general age-dependent reductions in brain tissue levels of dopamine, 
norepinephrine, epinephrine and serotonin by approximately 80–90%, which is 
accompanied by increased dopamine and serotonin turnover in multiple regions of the 
brain (Caudle et al 2007; Colebrooke et al 2006; Mooslehner et al 2001).  Furthermore, 
loss of VMAT2 function causes gradual neurodegeneration in the SNpc and locus 
ceruleus of aged VMAT2-deficient mice.  To date, TIQ derivative concentrations have 
not been measured in these mice.  A very interesting experiment would involve 
chromatographic analysis of multiple brain regions of these animals over various ages.   
 
Another presynaptic protein involved in the pathophysiology of PD is -synuclein, 
whose overexpression causes PD in humans.  Interestingly, -synuclein knockdown has 
been shown to increase the density of VMAT2 molecules, and VMAT2 has been shown 
to co-immunoprecipitate with -synuclein (Fountaine et al 2008).  Mice overexpressing 
wild-type human -synuclein have excellent construct validity as models of sporadic PD.  
These mice reproduce pathological findings in early PD, demonstrate regionally 
selective accumulation of insoluble -synuclein and exhibit multiple deficits observed in 
early PD, including olfactory deficits and autonomic dysfunction (Fleming et al 2006).  
Therefore, they may represent very early stages of the disease and provide information 
on mechanisms that initiate the pathophysiological cascades in PD.  Chromatographic 
analysis of TIQ derivatives in the brain of these mice at various time points would 
provide insight into the potentially toxic consequences of -synuclein overexpression.  
Comparison of these values with those of VMAT2-deficient mice may also shed light on 
the interaction of these proteins within neurons.  Based upon our hypotheses, -
synuclein overexpression would reduce VMAT2 levels and lead to increased production 
of TIQ derivatives and eventually cell death.   
 
  Ultimately, analysis of TIQ derivatives in these mutant strains could provide 
valuable information on accumulation in human brain and allow for the formulation of 
new hypotheses concerning intracellular trafficking and production/storage or interaction 
with additional intracellular systems.   
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Table A-1.  Limits of detection and quantification. 
 
Compound LOD* (ng/ml) LOQ* (ng/ml) LOD / LOQ Ratio 
TIQ 0.0288 0.30 10.417 
1-Methyl-TIQ 0.0254 0.30 11.811 
N-Methyl-TIQ 0.0294 0.30 10.204 
1-Benzyl-TIQ 0.0219 0.30 13.699 
(R)SAL 0.0629 0.70 11.129 
(S)SAL 0.0634 0.70 11.041 
N-Methyl-(R)SAL 0.0643 0.70 10.886 
N-Methyl-(S)SAL 0.0651 0.70 10.753 
NorSAL 0.0549 0.70 12.750 
Dopamine 0.0365 0.70 19.178 
DOPAC 0.0392 0.70 17.857 
HVA 0.0406 0.70 17.241 
 
*  LOD = limit of detection.  
*  LOQ = limit of quantification. 
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Figure A-1.  1H NMR spectra of TIQ.    
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Figure A-2.  1H NMR spectra of N-methyl-TIQ.   
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Figure A-3.  1H NMR spectra of 1-methyl-TIQ. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Figure A-4.  1H NMR spectra of 1-benzyl-TIQ. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Figure A-5.  1H NMR spectra of (R/S)salsolinol. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Figure A-6.  1H NMR spectra of norsalsolinol. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
  154
 
Figure A-7.  1H NMR spectra of N-methyl-(R/S)salsolinol. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge.  
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Figure A-8.  1H NMR spectra of N-methyl-norsalsolinol. 
Comparison of chemical shift (lower bracketed values) and peak integration (upper 
values) at baseline (A) and after 28 days of heat exposure at 60 C (B) reveals no 
significant structural changes after thermal challenge. 
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Table A-2.  Molecular properties of TIQ derivatives and related compounds. 
 
 
Log P = Octanol/Water Partition Coefficient. 
TPSA = Topological Polar Surface Area. 
MW = Molecular Weight. 
Vm = Molecular Volume. 
 
Compound Log P TPSA (Å2) MW (g/mol) Vm (cm3/mol) 
TIQ 1.489 12.027 133.194 136.010 
1-Methyl-TIQ 2.048 12.027 147.221 152.596 
N-Methyl-TIQ 1.734 3.238 147.221 152.952 
1-Benzyl-TIQ 3.476 12.027 223.319 224.246 
(R/S)Salsolinol 1.056 52.483 179.219 168.632 
N-Methyl-(R/S)Salsolinol 1.301 43.694 193.246 185.575 
Norsalsolinol 0.496 52.483 165.192 152.045 
N-Methyl-Norsalsolinol 0.741 43.694 179.219 168.988 
Rotenone 3.585 63.241 394.423 348.335 
MPTP 2.330 3.238 173.259 180.369 
MPP+ -2.726 3.885 170.235 171.089 
Reticuline 2.375 62.162 329.396 308.315 
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APPENDIX B.  PARKINSON DISEASE LIFETIME FRUIT AND VEGETABLE INTAKE 
QUESTIONNAIRE 
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Dear Research Subject, 
 
Thank you for taking the time to fill out this survey, which is part of a research study.  
With growing evidence that the development of Parkinson disease (PD) may be 
influenced by environmental factors, we are interested in the role that dietary habits may 
play in the progression of this disease.  This survey will present a number of questions 
about your lifetime intake of various foods and should take about 30 minutes to 
complete.  Although you will not be asked any sensitive questions, you may become 
tired while completing the survey.  If so, please feel free to take a break and return the 
survey in the envelope provided.  This survey is voluntary and if you do not wish to 
participate your medical care will not be affected in any way.  If you have any questions 
or concerns at any time, please feel free to contact your questionnaire administrator.  
You willingness to complete this questionnaire will indicate that you freely consent to 
participate.  It is with high hopes that information gained from this study can be used in 
the future for the prevention and/or treatment of PD.  Again, thank you for taking the time 
to participate in this study. 
 
Sincerely, 
Mark S. LeDoux, M.D., Ph.D. and Ronald F. Pfeiffer, M.D. 
University of Tennessee Health Science Center 
Department of Neurology 
855 Monroe Avenue, Link Building Suite 415 
Memphis, Tennessee 38163 
Phone: 901-448-1662 
 
General Instructions: 
Please estimate, on average, how many servings of the following foods you ate every 
month during the indicated age ranges of your life.  Please do not skip any foods.  
Please use the following symbols when answering questions: 
 
Never A few times per year (< once per month) 
One serving per 
month 
If > one serving per month, write 
the number 
Ø + 1 2, 3, 4, etc. 
 
For example, if you never ate a food, write “Ø” in the box.  If you ate a serving of food 
greater than (>) once per month, write the number of servings you ate of that food per 
month.  If you only ate a serving of food a few times per year or less than (<) one serving 
per month, write “+” in the box.  Your study administrator will show you pictures and cup 
sizes to help you estimate serving sizes.   
 
Age (Years): __________     Weight (lbs.): __________                            
Gender (Male or Female): __________  Height (ft.): __________ 
Race: ________                                                  Survey Date: __________ 
 
 
Please place a check mark next to ONE of the following: 
 
I have been diagnosed with Parkinson disease _____  
 
I have NOT been diagnosed with Parkinson disease (control subject) _____ 
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Part 1. Using the symbols in the answer key above, write the number of servings of 
fresh fruits you consumed every month in the box under the indicated age ranges.  One 
serving equals approximately one medium sized fresh fruit, one half cup of cut fruit, or 
six ounces of fruit juice. 
 
Fruit 0-20 Years 21-40 Years 41-60 Years >60 Years 
Banana     
Apple     
Watermelon     
Orange     
Cantaloupe     
Grape     
Grapefruit     
Strawberry     
Peach     
Pear     
Nectarine     
Honeydew 
(melon) 
    
Plum     
Avocado     
Lemon     
Pineapple     
Tangerine     
Cherry     
Kiwi fruit     
Lime     
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Part 2. Using the symbols in the answer key above, write the number of servings of 
fresh or cooked vegetables you consumed every month in the box under the indicated 
age ranges.  One serving equals approximately one cup leafy vegetables or one half cup 
of other vegetables. 
 
Vegetable 0-20 Years 21-40 Years 41-60 Years >60 Years 
Potato     
Lettuce 
(iceberg) 
    
Tomato     
Onion (yellow)     
Carrot     
Celery     
Corn     
Broccoli     
Cabbage     
Cucumber     
Bell Pepper      
Cauliflower     
Lettuce (leaf)     
Sweet potato     
Mushroom     
Green onion     
Green bean     
Radish     
Squash      
Asparagus     
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